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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
relative benefits and risks of those procedures and therapies
can produce helpful guidelines that improve the effectiveness
of care, optimize patient outcomes, and favorably affect the
overall cost of care by focusing resources on the most
effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of such guidelines in the area of cardiovascu-
lar disease since 1980. This effort is directed by the ACC/
AHA Task Force on Practice Guidelines, whose charge is to
develop and revise practice guidelines for important cardio-
vascular diseases and procedures. The Task Force is pleased
to have this guideline cosponsored by the Society for Car-
diovascular Angiography and Interventions (SCAI). Experts
in the subject under consideration have been selected from all
three organizations to examine subject-specific data and write
guidelines. The process includes additional representatives
from other medical practitioner and specialty groups where
appropriate. Writing groups are specifically charged to per-
form a formal literature review, weigh the strength of evi-
dence for or against a particular treatment or procedure, and
include estimates of expected health outcomes where data
exist. Patient-specific modifiers, comorbidities, and issues of
patient preference that might influence the choice of partic-
ular tests or therapies are considered, as well as frequency of
follow-up and cost-effectiveness. When available, informa-
tion from studies on cost will be considered; however, review
of data on efficacy and clinical outcomes will be the primary
basis for preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived
conflicts of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest. These statements are reviewed by the parent task
force, reported orally to all members of the writing panel at
each meeting, and updated and reviewed by the writing
committee as changes occur.
The practice guidelines produced are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the
diagnosis, management, or prevention of specific diseases or
conditions. These guidelines attempt to define practices that
meet the needs of most patients in most circumstances. These
guideline recommendations reflect a consensus of expert
opinion after a thorough review of the available, current
scientific evidence and are intended to improve patient care.
If these guidelines are used as the basis for regulatory/payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and patient in light of all of the circumstances
presented by that patient.
These guidelines were approved for publication by the
governing bodies of the ACCF, AHA, and SCAI. The
guidelines will be reviewed annually by the ACC/AHA Task
Force on Practice Guidelines and will be considered current
unless they are revised or withdrawn from distribution. The
summary article and recommendations are published in the
January 3, 2006, issue of the Journal of the American College
of Cardiology, the January 3/10, 2006, issue of Circulation,
and the January 2006 issue of Catheterization and Cardio-
vascular Interventions. The full-text guideline is posted on
the World Wide Web sites of the ACC (www.acc.org), the
AHA (www.americanheart.org), and the SCAI (www.
scai.org). Copies of the full text and the executive summary
are available from the ACC, AHA, and the SCAI.
Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
The ACC/AHA Task Force on Practice Guidelines was
formed to gather information and make recommendations
about appropriate use of technology for the diagnosis and
treatment of patients with cardiovascular disease. Percutane-
ous coronary interventions (PCIs) are an important group of
technologies in this regard. Although initially limited to
balloon angioplasty and termed percutaneous transluminal
coronary angioplasty (PTCA), PCI now includes other new
techniques capable of relieving coronary narrowing. Accord-
ingly, in this document, implantation of intracoronary stents
and other catheter-based interventions for treating coronary
atherosclerosis are considered components of PCI. In this
context, PTCA will be used to refer to those studies using
only balloon angioplasty, whereas PCI will refer to the
broader group of percutaneous techniques. These new tech-
nologies have impacted the effectiveness and safety profile
initially established for balloon angioplasty. Moreover, addi-
tional experience has been gained in the use of adjunctive
pharmacological treatment with glycoprotein (GP) IIb/IIIa
receptor antagonists and the use of bivalirudin, thienopyri-
dines, and drug-eluting stents (DES). In addition, since
publication of the guidelines in 2001, greater experience in the
performance of PCI in patients with acute coronary syn-
dromes and in community hospital settings has been gained.
In view of these developments, an update of these guidelines
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is warranted. This document reflects the opinion of the
ACC/AHA/SCAI writing committee charged with updating
the 2001 guidelines for PCI (1). 
Several issues relevant to the Writing Committee’s process
and the interpretation of the guidelines have been noted pre-
viously and are worthy of restatement. First, PCI is a tech-
nique that has been continually refined and modified; hence,
continued, periodic guideline revision is anticipated. Second,
these guidelines are to be viewed as broad recommendations
to aid in the appropriate application of PCI. Under unique
circumstances, exceptions may exist. These guidelines are
intended to complement, not replace, sound medical judg-
ment and knowledge. They are intended for operators who
possess the cognitive and technical skills for performing PCI
and assume that facilities and resources required to properly
perform PCI are available. As in the past, the indications are
categorized as class I, II, or III on the basis of a multifactor-
ial assessment of risk and expected efficacy viewed in the
context of current knowledge and the relative strength of this
knowledge. 
These classes summarize the recommendations for proce-
dures or treatments as follows: 
Class I: Conditions for which there is evidence for
and/or general agreement that a given proce-
dure or treatment is beneficial, useful, and
effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or
treatment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
In addition, the weight of evidence in support of the rec-
ommendation is listed as follows: 
• Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
• Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
A recommendation with level of evidence B or C does not
imply that the recommendation is weak. Many important
clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Even though randomized trials
e169
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are not available, there may be a very clear clinical consen-
sus that a particular test or therapy is useful and effective.
In instances where recommendations of class III, level of
evidence C, occur, it is recognized that the bases of these rec-
ommendations are opinion and the consensus of the writing
group. In this setting, it is not unreasonable for clinical trials
to be conducted to further investigate the validity of this con-
sensus opinion. The schema for classification of recommen-
dations and level of evidence is summarized in Table 1,
which also illustrates how the grading system provides an
estimate of the size of the treatment effect and an estimate of
the certainty of the treatment effect.
The committee conducted comprehensive searching of the
scientific and medical literature on PCI, with special empha-
sis on randomized controlled trials and meta-analyses pub-
lished since 2001. In addition to broad-based searching on
PCI, specific targeted searches were performed on the fol-
lowing subtopics: catheter-based intervention, stents (drug-
eluting and bare-metal), cardiac biomarkers (e.g., creatine
kinase and troponins), pharmacological therapy (aspirin,
thienopyridines, GP IIb/IIIa inhibitors, heparin, and direct
thrombin inhibitors), special populations (women, patients
with diabetes, elderly), coronary artery bypass grafting
(CABG), high-risk PCI, quality, outcomes, volume, left main
PCI (protected and unprotected), distal embolic protection,
intravascular ultrasound (IVUS), fractional flow reserve
(FFR), vascular closure, and secondary prevention/risk fac-
tor modification. The complete list of keywords is beyond
the scope of this section. The committee reviewed all com-
piled reports from computerized searches and conducted
additional searching by hand. Literature citations were gen-
erally restricted to published manuscripts appearing in jour-
nals listed in Index Medicus. Because of the scope and
importance of certain ongoing clinical trials and other emerg-
ing information, published abstracts were cited when they
were the only published information available. Additionally,
the Committee reviewed and incorporated recommendations
and/or text from published ACC/AHA or SCAI documents to
maintain consistency, as appropriate.
Initially, this document describes the background informa-
tion that forms the foundation for specific recommendations.
Topics fundamental to coronary intervention are reviewed,
followed by separate discussions relating to unique technical
and operational issues. This format is designed to enhance
the usefulness of this document for the assessment and care
of patients with coronary artery disease (CAD). Formal rec-
ommendations for the use of PCI according to clinical pres-
entation are included in Section 5. A clear distinction is
drawn between the emergency use of PCI for patients with
ST-segment elevation myocardial infarction (STEMI),
termed “primary PCI,” and all other procedures, which are
included under the term “elective PCI” (see Section 4.2 for
further discussion).
This committee includes cardiologists with and without
involvement in interventional procedures, and a cardiac sur-
geon. This document was reviewed by 2 official reviewers
nominated by ACC; 2 official reviewers nominated by AHA;
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The value of coronary angioplasty was further defined by
comparing its results to those of alternative methods of treat-
ment. Randomized clinical trials have assessed the outcomes
of patients treated by a strategy of initial angioplasty to one
of medical therapy alone or to coronary artery bypass surgery
(10-14). The results of these trials have clarified the utility of
angioplasty in terms of effectiveness, complications, and
patient selection. The technique of coronary angioplasty has
also been expanded by the development of devices that
replace or serve as adjuncts to the balloon catheter. These
“new devices” have been evaluated and have had a variable
impact in enhancing the immediate- and long-term efficacy
and safety of coronary angioplasty. The following section of
this report expands on this background and describes the
practice of PCI as it is applied today. 
Advances in coronary-based interventions, especially the
use of bare-metal stents (BMS) and drug-eluting stents
(DES), have improved the efficacy and safety profile of per-
cutaneous revascularization observed for patients undergo-
ing PTCA. For example, stents reduce both the acute risk of
major complications and late-term restenosis. The success of
new coronary devices in meeting these goals is reflected in
part by the rapid transition from the use of PTCA alone (less
than 30%) to the high use of PCI with stenting, which was
greater than 70% by the late 1990s (Figure 1) (15).
Atherectomy devices and stenting, associated with improved
acute angiographic and clinical outcomes compared with
PTCA alone in specific subsets, continue to be applied to a
wider patient domain that includes multivessel disease and
complex coronary anatomy. However, strong evidence (level
A data from multiple randomized clinical trials) is primarily
available for stenting over PTCA in selected patients under-
going single-vessel PCI. 
2 official reviewers nominated by SCAI; 1 official reviewer
from the ACC/AHA Task Force on Practice Guidelines; and
8 content reviewers, including members from the AHA
Committee on Diagnostic and Interventional Cardiac
Catheterization and the ACCF Cardiac Catheterization and
Intervention Committee. 
2. GENERAL CONSIDERATIONS AND
BACKGROUND
Coronary angioplasty was first introduced by Andreas
Gruentzig in 1977 (2) as a nonsurgical method for coronary
arterial revascularization. Fundamentally, the technique
involved advancing a balloon-tipped catheter to an area of
coronary narrowing, inflating the balloon, and then removing
the catheter after deflation. Early reports demonstrated that
balloon angioplasty could reduce the severity of coronary
stenosis and diminish or eliminate objective and subjective
manifestations of ischemia (3-5). Although angioplasty was
clearly feasible and effective, the scope of coronary disease
to be treated was quite narrow. Also, because angioplasty
could result in sudden arterial occlusion and subsequent
myocardial infarction (MI), immediate access to coronary
bypass surgery was essential (6). With experience and time,
however, the cognitive and technical aspects as much as the
equipment used to perform angioplasty became more
refined. Observational reports of large numbers of patients
confirmed that coronary angioplasty could be applied to
broad groups of coronary patients with higher rates of suc-
cess and lower rates of complications than seen in initial
experiences (7,8). More than 1 000 000 PCI procedures are
performed yearly in the United States (9), and it has been
estimated that nearly 2 000 000 procedures are performed
annually worldwide. 
Figure 1. Frequency of device use in the SCAI registry. Source data from Laskey et al. Catheter Cardiovasc Interv 2000;49:19-22
(15).
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The range of non-balloon revascularization technology
approved by the Food and Drug Administration (FDA) for
use in native and/or graft coronary arteries includes balloon
expandable stents, DES, extraction atherectomy, directional
coronary atherectomy, rotational atherectomy, rheolytic
thrombectomy catheter, proximal and distal embolic protec-
tion devices, excimer laser coronary atherectomy, and local
radiation devices to reduce in-stent restenosis (ISR) (16,17).
A variety of devices are under investigation, including new
designs of balloon or self-expanding stents and mechanical
thrombectomy devices. This guideline update will focus on
the FDA-approved balloon-related and non-balloon coronary
revascularization devices.
3. OUTCOMES
The outcomes of PCI are measured in terms of success and
complications and are related to the mechanisms of the
employed devices, as well as the clinical and anatomic
patient-related factors. Complications can be divided into 2
categories: (a) those common to all arterial catheterization
procedures and (b) those related to the specific technology
used for the coronary procedure. Specific definitions of suc-
cess and complications exist, and where appropriate, the def-
initions used herein are consistent with the ACC-National
Cardiovascular Data Registry (NCDR®) Catheterization
Laboratory Module version 3.0 (18). The committee recom-
mends such standards whenever feasible in order to accom-
modate the common database for the assessment of out-
comes. With increased operator experience, new technology,
and adjunctive pharmacotherapy, the overall success and
complication rates of angioplasty have improved.
3.1. Definitions of PCI Success
The success of a PCI procedure may be defined by angio-
graphic, procedural, and clinical criteria.
3.1.1. Angiographic Success
A successful PCI produces substantial enlargement of the
lumen at the target site. The consensus definition before the
widespread use of stents was the achievement of a minimum
stenosis diameter reduction to less than 50% in the presence
of grade 3 Thrombolysis In Myocardial Infarction (TIMI)
flow (assessed by angiography) (1). However, with the
advent of advanced adjunct technology, including coronary
stents, a minimum stenosis diameter reduction to less than
20% has been the clinical benchmark of an optimal angio-
graphic result. Frequently, there is a disparity between the
visual assessment and computer-aided quantitative stenosis
measurement (19,20), and, thus, the determination of success
may be problematic when success rates are self-reported. 
3.1.2. Procedural Success
A successful PCI should achieve angiographic success with-
out major clinical complications (e.g., death, MI, emergency
coronary artery bypass surgery) during hospitalization (1,3).
Although the occurrence of emergency coronary artery
bypass surgery and death are easily identified end points, the
definition of procedure-related MI has been debated. The
development of Q waves in addition to a threshold value of
creatine kinase (CK) elevation has been commonly used.
Most agree that the definition of MI as put forth by the
ACC/European Society of Cardiology document on the rede-
finition of MI (21) should be the accepted standard.
However, the clinical significance and definition of cardiac
biomarker elevations in the absence of Q waves remains the
subject of investigation and debate (21a). Several reports
have identified non–Q-wave MIs with CK-MB elevations 3
to 5 times the upper limit of normal as having clinical sig-
nificance (22,23). One report suggests that a greater than 5
times increase in CK-MB is associated with worsened out-
come (24). Thus, this degree of increase in CK-MB without
Q waves is considered by most to qualify as an associated
complication of PCI. Troponin T or I elevation occurs fre-
quently after PCI. The timing of the peak elevation after PCI
is unclear (25). Minor elevations do not appear to have prog-
nostic value, whereas marked (greater than 5 times) eleva-
tions are associated with worsened 1-year outcome (Table 2)
(26-40). Troponin T or I elevation occurs more frequently
than CK-MB increase after PCI (34).
3.1.3. Clinical Success
In the short term, a clinically successful PCI includes
anatomic and procedural success with relief of signs and/or
symptoms of myocardial ischemia after the patient recovers
from the procedure. The long-term clinical success requires
that the short-term clinical success remain durable and that
the patient have persistent relief of signs and symptoms of
myocardial ischemia for more than 6 months after the proce-
dure. Restenosis is the principal cause of lack of long-term
clinical success when a short-term clinical success has been
achieved. Restenosis is not considered a complication but
rather an associated response to vascular injury. The inci-
dence of clinically important restenosis may be judged by the
frequency with which subsequent revascularization proce-
dures are performed on target vessels after the index proce-
dure. 
3.2. Acute Outcome: Procedural Complications
Class I
All patients who have signs or symptoms suggestive of
MI during or after PCI and those with complicated
procedures should have CK-MB and troponin I or T
measured after the procedure. (Level of Evidence: B)
Class IIa
Routine measurement of cardiac biomarkers (CK-
MB and/or troponin I or T) in all patients undergoing
PCI is reasonable 8 to 12 hours after the procedure.
(Level of Evidence: C)
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Another study indicated that more extensive stent expan-
sion resulted in CK release but did not increase adverse car-
diac events (59). Accordingly, it is important to acknowledge
that the significance of mild biomarker rises after clinically
successful PCI should be distinguished from situations
wherein patients experience an unequivocal “clinical” infarc-
tion manifested by chest pain and diagnostic ECG findings
(60).
Routine measurement of CK-MB is advocated by some
(21) and actually mandated by certain healthcare systems. In
this regard, the current Committee supports the recommen-
dations of the 2001 Guidelines and recommends that all
patients who have signs or symptoms suggestive of MI dur-
ing or after PCI and those with complicated procedures
should have CK-MB and troponin I or T measured after the
procedure. In addition, the Committee recommends that rou-
tine measurement of cardiac biomarkers (CK-MB and/or tro-
ponin I or T) in every patient undergoing PCI is reasonable 8
to 12 h after the procedure. In such patients, a new CK-MB
or troponin I or T rise greater than 5 times the upper limit of
normal would constitute a clinically significant periproce-
dural MI. 
The need to perform emergency coronary artery bypass
surgery (CABG) has been considered as a potential compli-
cation of PCI. Typically, CABG is performed as a rescue
revascularization procedure to treat acute ischemia or infarc-
tion resulting from PCI-induced acute coronary occlusion. In
the era of balloon angioplasty, the rate of emergency CABG
was 3.7% (49). In a more contemporary time period, with the
availability of stents, the reported rate was 0.4% among a
similar cohort of patients. 
Various definitions have been proposed for stroke. A com-
mon feature to definitions has been a loss of neurologic func-
tion of vascular cause that lasts more than 24 h. More recent-
ly, attention has been directed to refining the definition of
transient ischemic attack (TIA), which indirectly broadens
that of stroke (61). The time-based definition of a TIA is a
sudden, focal neurologic deficit that lasts less than 24 h that
is of presumed vascular origin and confined to an area of the
brain or eye perfused by a specific artery. The new definition
of TIA is a brief episode of neurologic dysfunction caused by
brain or retinal ischemia, with clinical symptoms typically
lasting less than 1 hour and without evidence of infarction.
Presence of cerebral infarction by imaging techniques con-
stitutes evidence of stroke regardless of the duration of
symptoms.
Bleeding is a complication of increasing concern with the
more frequent use of potent antithrombin and antiplatelet
agents. A frequently used definition for bleeding developed
by the TIMI group includes classification as major, moder-
ate, or minor. Major bleeding is defined as intracranial,
intraocular, or retroperitoneal hemorrhage or any hemor-
rhage requiring a transfusion or surgical intervention or that
results in a hematocrit decrease of greater than 15% or hemo-
globin decrease of greater than 5 g per dL (62). Episodes of
hemorrhage of lesser magnitude would fall into the moder-
Complications associated with PCI are similar to those
resulting from diagnostic cardiac catheterization, but their
prevalence is more frequent. Complications have been cate-
gorized as major (death, MI, and stroke) or minor (transient
ischemic attack, access site complications, renal insufficien-
cy, or adverse reactions to radiographic contrast). Additional
specific complications include intracoronary thrombosis,
coronary perforation, tamponade, and arrhythmias.
Reported rates for death after diagnostic catheterization
range from 0.08% to 0.14%, whereas analyses of large reg-
istries indicate overall unadjusted in-hospital rates for PCI of
0.4% to 1.9% (Table 3) (41-52). This range is greatly influ-
enced by the clinical indication for which PCI is performed,
with the highest mortality rates occurring among patients
with STEMI and cardiogenic shock. Death in such patients
may not be a direct result of the PCI procedure but rather a
consequence of the patient’s underlying illness. For example,
in a combined analysis of PCI as primary reperfusion thera-
py for STEMI, the short-term mortality rate was 7% (53).
Even after exclusion of patients with cardiogenic shock, in-
hospital mortality was 5%. 
Myocardial infarction can be a direct result of PCI, most
commonly due to abrupt coronary occlusion or intracoronary
embolization of obstructive debris. Determining and com-
paring the incidence of MI after PCI is difficult because the
definition of MI as a result of PCI is controversial. The con-
ventional definition requires 2 of the following: a) prolonged
chest discomfort or its equivalent; b) development of patho-
logic Q waves; and c) rise in serum cardiac biomarkers above
a critical level. Rates of periprocedural MI using this defini-
tion have ranged from 0.4% to 4.9%. Using a consistent def-
inition for MI, the incidence of this complication has
declined approximately 50% with the routine use of intra-
coronary stents (21,21a,50).
More recently, an isolated rise and fall in either CK-MB or
troponin is considered to be a marker of myocardial necrosis
(21). The relationship between cardiac biomarker elevation
and myocardial cell death and evidence of subendocardial
infarction on magnetic resonance imaging (MRI) support
this position (54,55). Furthermore, large rises in cardiac bio-
markers are associated with an increased risk for late death
(26,56,57). Whether death in such patients is a consequence
of the myonecrosis or a marker of patients who are at
increased risk for death because of more advanced coronary
disease is unclear. Complicating our understanding of the
implications of this definition is the very frequently observed
mild to modest elevation of serum CK-MB among patients
with apparently uncomplicated PCI. When troponin is meas-
ured after PCI, more than 70% of patients exhibit elevated
values after an otherwise successful intervention (58). Such
patients may have no symptoms or electrocardiographic
(ECG) abnormalities to suggest ischemia yet are “enzyme
positive.” One study has suggested a postprocedural increase
in troponin T of 5 times normal is predictive for adverse
events at 6 years. The long-term prognostic significance of
smaller postprocedural troponin T elevations awaits further
investigation (27) (Table 2) (26-40).
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In addition to multivessel disease, other clinical factors
adversely impact late mortality. In randomized patients with
treated diabetes undergoing PTCA in BARI, the 5-year sur-
vival was 65.5%, and the cardiac mortality rate was 20.6%
compared with 5.8% in patients without treated diabetes
(67), although among eligible but not randomized diabetic
patients treated with PTCA, the 5-year cardiac mortality rate
was 7.5% (68). In the 1985-1986 NHLBI PTCA Registry, 4-
year survival was significantly lower in women (89.2%) than
in men (93.4%) (69). In addition, although LV dysfunction
was not associated with an increase in in-hospital mortality
or nonfatal MI in patients undergoing PTCA in the same reg-
istry, it was an independent predictor of a higher long-term
mortality (70). 
A major determinant of event-free survival after coronary
intervention is the incidence of restenosis, which had, until
the development of stents, remained fairly constant despite
multiple pharmacologic and mechanical approaches to limit
this process (Table 4) (71-95). The incidence of restenosis
after coronary intervention varies depending on the defini-
tion, i.e., whether clinical or angiographic restenosis or tar-
get-vessel revascularization is measured (96). Data from
multiple randomized clinical trials and prospective registries
suggest that DES incorporating either rapamycin or paclitax-
el with a timed-release polymer are associated with a reduc-
tion in restenosis rates to less than 10% across a wide spec-
trum of clinical and angiographic subsets.
The pathogenesis of the response to mechanical coronary
injury is thought to relate to a combination of growth factor
stimulation, smooth muscle cell migration and proliferation,
organization of thrombus, platelet deposition, and elastic
recoil (97,98). In addition, change in vessel size (or lack of
compensatory enlargement) has been implicated (99). It has
been suggested that attempts to reduce restenosis have failed
in part because of lack of recognition of the importance of
this factor (100). Although numerous definitions of resteno-
sis have been proposed, greater than 50% diameter stenosis
at follow-up angiography has been most frequently used
because it was thought to correlate best with maximal flow
and therefore ischemia. However, it is now recognized that
the response to arterial injury is a continuous rather than a
dichotomous process, occurring to some degree in all
patients (101). Therefore, cumulative frequency distributions
of the continuous variables of minimal lumen diameter or
percent diameter stenosis are frequently used to evaluate
restenosis in large patient populations (102) (Figure 2) (80). 
Although multiple clinical factors (diabetes, unstable angi-
na [UA]/NSTEMI, STEMI, and prior restenosis) (103,104),
angiographic factors (proximal left anterior descending
artery [LAD], small vessel diameters, total occlusion, long
lesion length, and saphenous vein grafts [SVGs]) (105), and
procedural factors (higher postprocedure percent diameter
stenosis, smaller minimal lumen diameter, and smaller acute
gain) (102) have been associated with an increased incidence
of restenosis, the ability to integrate these factors and predict
the risk of restenosis in individual patients after the proce-
dure remains difficult. The most promising potential
ate/minor categories. A listing of other bleeding classifica-
tions has been developed for use by the ACC-NCDR® (18).
3.3. Acute Outcome: Success Rates
Success has been described on both a lesion and patient
basis. In early studies of PTCA, lesion success is defined as
an absolute 20% reduction in lesion severity with final steno-
sis less than 50%. When describing the results of multiple
attempted lesions, success is classified as either partial (some
but not all attempted lesions successfully treated) or total
(each attempted lesion successfully treated). Procedural suc-
cess is defined as the achievement of either partial or total
angiographic success without death, MI, or emergency
CABG (49).
Reported rates of angiographic success now range between
82% and 98% depending on the device used and the types of
lesions attempted. Formal comparisons demonstrate that suc-
cess rates are now higher (91% to 92%) in the era of new
technology, which includes stents and contemporary drug
therapies, than in the era of conventional balloon angioplas-
ty (72% to 74%) (49). The types of lesions attempted strong-
ly influence success rates. The chance of dilating a chronic
total occlusion averages 65%, and specific clinical and
anatomic factors have been identified that affect this rate
(63). Quite different are the success rates for total occlusions
associated with STEMI. Success rates over 90% can be
expected in this subgroup (64).
With an increase in angiographic success rates and a
decline in periprocedural MI and the need for emergency
CABG, procedural success rates have risen from a range of
80% to 85% to a range of 90% to 95% (Table 3) (41-52).
3.4. Long-Term Outcome and Restenosis
Although improvements in technology, such as stents, have
resulted in an improved acute outcome of the procedure, the
impact of these changes on long-term (5 to 10 years) out-
come may be less dramatic because factors such as advanced
age, reduced left ventricular (LV) function, and progression
of complex multivessel disease in patients currently under-
going PCI may have a more important influence. In addition,
available data on long-term outcome are mostly limited to
patients undergoing PTCA. Ten-year follow-up of the initial
cohort of patients treated with PTCA revealed an 89.5% sur-
vival rate (95% in patients with single-vessel disease, 81% in
patients with multivessel disease) (65). In patients undergo-
ing PTCA within the 1985-1986 National Heart, Lung, and
Blood Institute (NHLBI) PTCA Registry (66), 5-year sur-
vival was 92.9% for patients with single-vessel disease,
88.5% for those with 2-vessel disease, and 86.5% for those
with 3-vessel disease. In patients with multivessel disease
undergoing PTCA in the Bypass Angioplasty
Revascularization Investigation (BARI) (10), 5-year survival
was 86.3%, and infarct-free survival was 78.7%.
Specifically, 5-year survival was 84.7% in patients with 3-
vessel disease and 87.6% in patients with 2-vessel disease. 
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approaches to favorably impact the restenosis process are
stents and, more recently, DES and catheter-based radiation.
More than 6300 patients have been studied in 12 randomized
clinical trials to assess the efficacy of PTCA versus stents to
reduce restenosis (Table 5) (80,83,88,106-114). 
The pivotal BENESTENT (BElgian NEtherlands STENT
study) (80) and STRESS (STent REStenosis Study) trials
(83) documented that stents significantly reduce angiograph-
ic restenosis compared with balloon angioplasty (BENES-
TENT: 22% vs 32%; STRESS: 32% vs 42%, respectively).
These results were further corroborated in the BENESTENT
II trial, in which the angiographic restenosis rate was reduced
by almost half (from 31% to 16% in patients treated with bal-
loon angioplasty versus heparin-coated stents, respectively)
(88). 
In addition, randomized studies in patients with ISR have
shown that both intracoronary gamma and beta radiation sig-
nificantly reduced the rate of subsequent angiographic and
clinical restenosis by 30% to 50% (92,115-117). Late suba-
cute thrombosis was observed in some of these series (117),
but this syndrome has resolved with judicious use of stents
and extended adjunct antiplatelet therapy with ticlopidine or
clopidogrel. The development of DES has significantly
reduced the rate of ISR (see Section 7.3.6 for full discus-
sion).
3.5. Predictors of Success/Complications
3.5.1. Lesion Morphology and Classification
Target lesion anatomic factors related to adverse outcomes
have been widely examined. Lesion morphology and
absolute stenosis severity were identified as the prominent
predictors of immediate outcome during PTCA in the
prestent era (118,119). Abrupt vessel closure, due primarily
to thrombus or dissection, was reported in 3% to 8% of
patients and was associated with certain lesion characteris-
tics (120-122). The risk of PTCA in the prestent era relative
to anatomic subsets has been identified in previous NHLBI
PTCA Registry data (7) and by the ACC/AHA Task Force on
Practice Guidelines (1,123). The lesion classification based
on severity of characteristics proposed in the past (123-125)
has been principally altered using the present PCI tech-
niques, which capitalize on the ability of stents to manage
initial and subsequent complications of coronary interven-
Table 4. Selected Trials of Pharmacological and Mechanical Approaches to Limit Restenosis
Restenosis Rate, %
Study Year Reference n Agent Placebo or Control Agent
Schwartz 1988 (71) 376 Aspirin and dipyridamole 39 38
Ellis 1989 (72) 416 Heparin 37 41
Pepine 1990 (73) 915 Methylprednisolone 39 40
CARPORT 1991 (74) 649 Vapiprost 19 21
O’Keefe 1992 (75) 197 Colchicine 22 22
MERCATOR 1992 (76) 735 Cilazapril 28 28
CAVEAT* 1993 (77) 500 DCA versus PTCA 57 50
CCAT 1993 (78) 136 DCA versus PTCA 43 46
Serruys 1993 (79) 658 Ketanserin 32 32
BENESTENT* 1994 (80) 520 Stent versus PTCA 32 22
ERA 1994 (81) 458 Enoxaparin 51 52
Leaf 1994 (82) 551 Fish oil 46 52
STRESS* 1994 (83) 410 Stent versus PTCA 42 32
Weintraub 1994 (84) 404 Lovastatin 42 39
BOAT* 1998 (85) 492 DCA versus PTCA 40 31
Wantanabe* 1996 (86) 118 Probucol 40 20
Tardif* 1997 (87) 317 Probucol 39 21
BENESTENT II* 1998 (88) 823 Stent versus PTCA 31 17
TREAT* 1999 (89) 255 Tranilast 39 18
PRESTO* 2000 (90) 192 DCA and Tranilast 26 11
ARTIST* 2002 (91) 298 Rotablation (in-stent) 51 65
versus PTCA
START* 2002 (92) 476 Radiation (in-stent) 45 29
SIRIUS* 2003 (93) 1058 Sirolimus-coated stent versus 36 9
bare stent
TAXUS-IV* 2004 (94) 1314 Paclitaxel-coated stent versus 27 8
bare stent
RESCUT 2004 (95) 428 Cutting balloon (in-stent) 31 30
versus PTCA
DCA indicates directional coronary atherectomy; n, number of patients; and PTCA, percutaneous transluminal coronary angioplasty.
*P less than 0.05.
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Figure 2. Balloon stent vs balloon angioplasty in coronary artery disease. Cumulative frequency distribution curves for the 2 study
groups, showing minimum lumen diameters measured before and after intervention and follow-up (B), the percentage of stenosis at
follow-up, and the percentage of patients with clinical end points. Significant differences were apparent that consistently favored the
stent group over the angioplasty group with respect to the increased minimal lumen diameter at intervention (A) and follow-up (B),
the percentage of stenosis at follow-up (C), and the incidence of major clinical events (D). The vertical dashed line in D indicated the
end of the study. Reprinted with permission from Serruys et al. N Engl J Med 1994;331:489-95 (80). Copyright 2004 Massachusetts
Medical Society. All rights reserved.
the operator classified the lesion after finishing the case and
knowing whether the case was successful or had complica-
tions. No prospective studies using core laboratory analysis
have validated this system. Nonetheless, the SCAI classifi-
cation system utilizing vessel patency in addition to C and
non-C class appears promising to categorize the risk of suc-
cess and complications with PCI.
3.5.1.1. Clinical Factors
Coexistent clinical conditions can increase the complication
rates for any given anatomic risk factor. For example, com-
plications occurred in 15.4% of patients with diabetes versus
5.8% of patients without diabetes undergoing balloon angio-
plasty in a multicenter experience (119,122). Several studies
have reported specific factors associated with increased risk
of adverse outcome after PTCA. These factors include
advanced age, female gender, UA, congestive heart failure
(HF), diabetes, and multivessel CAD (10,118,119,127-
130,134,135). Elevated baseline C-reactive protein (CRP)
has recently also been shown to be predictive of 30-day death
and MI (128,136). Other markers of inflammation, such as
tions (126). As a result, the Committee has revised the previ-
ous ACC/AHA lesion classification system to reflect high-
risk (at least 1 type C lesion characteristic) and non–high-
risk (no type C lesion characteristic) lesions (Table 6) in
accordance with the PCI Clinical Data Standards from the
ACC-NCDR® (18). Studies (127-130) have confirmed that
complex coronary lesions remain predictive of adverse
events after PCI. However, although the risk of restenosis
and technical failure remains high for chronic total occlu-
sions, the risk of acute complications is not increased.
The SCAI proposed a new lesion classification using 7
lesion characteristics (131). This system dichotomizes
lesions by the presence or absence of a type C characteristic
and vessel patency versus total occlusion, yielding 4 lesion
classes (Table 7) (132). Utilizing data from the voluntary
ACC-NCDR®, the SCAI group presented analyses that
showed that the more simplified SCAI lesion classification
provided better discrimination for success and complications
than the ACC/AHA lesion classification system (132,133).
The SCAI lesion classification system was validated from
a voluntary registry, which imposes a potential bias because
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Table 6. Lesion Classification System
Descriptions of a High-Risk Lesion (Type C Lesion)
Diffuse (length greater than 2 cm)
Excessive tortuosity of proximal segment
Extremely angulated segments, greater than 90°
Total occlusions more than 3 months old and/or bridging collaterals*
Inability to protect major side branches
Degenerated vein grafts with friable lesions*
*The high risk with these criteria is for technical failure and increased restenosis, not for acute complications.
Table 7. SCAI Lesion Classification System: Characteristics of Class
I-IV Lesions
Type I lesions (highest success expected, lowest risk)
(1) Does not meet criteria for C lesion
(2) Patent
Type II lesions
(1) Meets any of these criteria for ACC/AHA C lesion
Diffuse (greater than 2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, greater than 90°
Inability to protect major side branches
Degenerated vein grafts with friable lesions
(2) Patent
Type III lesions
(1) Does not meet criteria for C lesion
(2) Occluded
Type IV lesions
(1) Meets any of the criteria for ACC/AHA C lesion
Diffuse (greater than 2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, greater than 90°
Inability to protect major side branches
Degenerated vein grafts with friable lesions
Occluded for more than 3 months
(2) Occluded
Reprinted from Krone et al. Evaluation of the American College of Cardiology/American
Heart Association and the Society for Coronary Angiography and Interventions lesion clas-
sification system in the current “stent era” of coronary interventions (from the ACC-
National Cardiovascular Data Registry®). Am J Cardiol 2003;92:394 (Appendix B) (132).
interleukin-6 and other cytokines, have also been shown to
be predictive of outcome (137). The BARI trial found that
patients with diabetes and multivessel CAD had an increased
periprocedural risk of ischemic complications and increased
5-year mortality compared with patients without diabetes or
patients with diabetes undergoing bypass surgery using inter-
nal mammary artery (IMA) grafts (10,42). Patients with
impaired renal function, especially those with diabetes, are at
increased risk for contrast nephropathy (138) and increased
30-day and 1-year mortality (139,140). Renal insufficiency
is a strong predictor of outcome in both primary and elective
PCI (141-143). Increased risk for death or severe compro-
mise in LV function may occur in association with a compli-
cation involving a vessel that also supplies collateral flow to
viable myocardium. Certain variables were used to prospec-
tively identify patients at risk for significant cardiovascular
compromise during PTCA (144,145). These resulted in a
composite 4-variable scoring system, prospectively validated
to be both sensitive and specific in predicting cardiovascular
collapse for failed PTCA, which includes: 1) percentage of
myocardium at risk (e.g., greater than 50% viable myocardi-
um at risk and LV ejection fraction of less than 25%), 2) pre-
angioplasty percent diameter stenosis, 3) multivessel CAD,
and 4) diffuse disease in the dilated segment (124) or a high
myocardial jeopardy score (125). Patients with higher pre-
procedural jeopardy scores were shown to have a greater
likelihood of cardiovascular collapse when abrupt vessel clo-
sure occurred during PTCA (144).
3.5.1.2. Left Main CAD
CABG has long been considered the “gold standard” for
revascularization of lesions in the unprotected left main
(ULM) coronary artery (146). With the advent of newer tech-
nology utilizing BMS and DES, experience has been gained
in performing PCI in ULM coronary artery lesions. Some
studies have demonstrated that stenting of the ULM is feasi-
ble and appears to be a promising strategy in selected
patients (147-152). Patients treated for ULM disease have
varied from those presenting with stable angina to those with
MI and shock. However, despite the feasibility and high pro-
cedural success rate of ULM PCI in the pre-DES era, there
are reports of an unacceptably high incidence of long-term
adverse events (153-155). This may be attributed to the
inclusion of high-risk patients, such as those not considered
good surgical candidates. The experience with BMS for
ULM PCI in the multicenter ULTIMA (Unprotected Left
Main Trunk Intervention Multicenter Assessment) registry
suggested a high early mortality (2% per month among hos-
pital survivors over the first 6 months after hospital dis-
charge), and careful surveillance with coronary angiography
was recommended (153) (see Section 6.3.4). Patients pre-
senting with MI, ULM occlusion, and cardiogenic shock
have lower successful PCI rates (69.7% vs 100%, P equals
0.040), higher in-hospital mortality (71.4% vs 10%, P equals
0.0008), and higher 1-year mortality rates (P equals 0.0064)
than stable MI patients regardless of performance of primary
PCI with stents (155). 
More recently, published studies of left main PCI using
DES have reported 6-month or 1-year death rates ranging
from 0% to 14% (Table 8) (147-150,152-161). Furthermore,
ISR appears to be improved with the use of DES versus
BMS. One of the larger studies performed to date showed
that the 6-month angiographic restenosis rate was signifi-
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3.5.3. Women
An estimated 33% of the more than 1 million PCIs per-
formed in the United States annually are in women. The need
for more data concerning outcomes from PCI in women has
led the AHA to issue a scientific statement summarizing
available studies (169). Compared with men, women under-
going PCI are older and have a higher incidence of hyper-
tension, diabetes mellitus, hypercholesterolemia, and comor-
bid disease (69,170-174). Women also have more UA and a
higher functional class of stable angina (Canadian
Cardiovascular Society [CCS] class III and IV) for a given
extent of disease (175). Yet, despite the higher-risk profile in
women, the extent of epicardial coronary disease is similar to
(or less than) that in men. In addition, although women pre-
senting for revascularization have less multivessel disease
and better LV systolic function, the incidence of HF is high-
er in women than in men. The reason for this gender paradox
is unclear, but it has been postulated that women have more
diastolic dysfunction than men (176). 
Early reports of patients undergoing PTCA revealed a
lower procedural success rate in women (172); however,
subsequent studies have noted similar angiographic outcome
and incidence of MI and emergency CABG in women and
men (69). Although reports have been inconsistent, in sever-
al large-scale registries, in-hospital mortality is significantly
higher in women (177), and an independent effect of gender
on acute mortality after PTCA persists after adjustments for
the baseline higher-risk profile in women (69,178). The rea-
son for the increase in mortality is unknown, but small ves-
sel size (179) and hypertensive heart disease in women have
been thought to play a role. Although a few studies have
noted that gender is not an independent predictor of mortali-
ty when body surface area (a surrogate for vessel size) is
accounted for (171), the impact of body size on outcome has
not been thoroughly evaluated. The higher incidence of vas-
cular complications, coronary dissection, and perforation in
women undergoing coronary intervention has been attributed
to the smaller vasculature in women than in men. In addition,
diagnostic IVUS studies have not detected any gender-spe-
cific differences in plaque morphology or luminal dimen-
sions once differences in body surface area were corrected,
which suggests that differences in vessel size account for
some of the apparent early and late outcome differences pre-
viously noted in women (180). It has also been postulated
that the volume shifts and periods of transient ischemia dur-
ing PTCA are less well tolerated by the hypertrophied ven-
tricle in women, and HF has shown to be an independent pre-
dictor of mortality in both women and men undergoing
PTCA (181). 
Women continue to have increased bleeding and vascular
complications compared with men, but these rates have
decreased with the use of smaller sheath sizes and early
sheath removal, weight-adjusted heparin dosing, and less
aggressive anticoagulation regimens (169). Use of IIb/IIIa
platelet receptor antagonists during PCI is not associated
with an increased risk of major bleeding in women
cantly lower in the ULM group receiving DES than in those
who received BMS (7.0% vs 30.3%, P less than 0.001)
(160). The lower rate of restenosis of DES compared with
BMS has been confirmed in other studies of ULM PCI (159). 
There have been some attempts to predict success of ULM
PCI using customary risk factors such as age, renal failure,
coronary calcification, and location of the lesion in the left
main coronary artery. In general, younger patients with pre-
served LV function, noncalcified coronary arteries, and com-
plete delivery of stent,  fare better. Maintenance of
antiplatelet therapy after the procedure is critical, as is the
implementation of secondary prevention therapies. Careful
postprocedure surveillance with coronary angiography is
needed to prevent fatal MI or sudden death that may be asso-
ciated with ISR with a large area of myocardium in jeopardy;
however, the frequency and best method of follow-up are
unknown (162). One study’s authors from the BMS era sug-
gested routine surveillance angiography at 2 and 4 months
after PCI (153). Others advocate routine stress testing or car-
diac catheterization at 3 and 6 months even in asymptomatic
patients (148,150). Studies from the DES era have reported
performing routine angiography 4 to 8 months after PCI or
earlier if clinically indicated by symptoms or documented
myocardial ischemia (159,160). Other issues that remain to
be resolved are technical issues (e.g., optimal bifurcation
stenting technique, stent size), degree of revascularization
necessary, cost-effectiveness, and the selection of patients
best suited for DES. 
In conclusion, CABG using IMA grafting is the “gold stan-
dard” for treatment of ULM disease and has proven benefit
on long-term outcomes. The use of DES has shown encour-
aging short-term outcomes, but long-term follow-up is need-
ed. Nevertheless, the use of PCI for patients with significant
ULM stenosis who are candidates for revascularization but
not suitable for CABG can improve cardiovascular outcomes
and is a reasonable revascularization strategy in carefully
selected patients. Recommendations for ULM PCI in specif-
ic angina subsets can be found in Sections 5.1, 5.2, 5.3, and
5.4 and in Section 6.3.4 for post-PCI follow-up.
3.5.2. Risk of Death
In the majority of patients undergoing elective PCI, death as
a result of PCI is directly related to the occurrence of coro-
nary artery occlusion and is most frequently associated with
pronounced LV failure (144,145). The clinical and angio-
graphic variables associated with increased mortality include
advanced age, female gender, diabetes, prior MI, multivessel
disease, left main or equivalent coronary disease, a large area
of myocardium at risk, pre-existing impairment of LV or
renal function, post-PCI worsening of renal function, and
collateral vessels supplying significant areas of myocardium
that originate distal to the segment to be dilated
(10,118,120,122,134,135,138,139,140,144,163-167). Peri-
procedural stroke also increases in-hospital and 1-year mor-
tality (168). PCI in the setting of STEMI is associated with a
significantly higher death rate than is seen in elective PCI.
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(182,183), and the direct thrombin inhibitor bivalirudin dur-
ing elective PCI appears to reduce the risk of bleeding (com-
bined major and moderate bleeding) in both women and men
compared with unfractionated heparin (184).
Improved outcomes have been reported in more recently
treated women undergoing both PTCA and PCI, despite the
fact that the women are older and have more complex disease
than women treated previously (Table 9) (69,170,185-189).
In fact, in the 1993-1994 NHLBI PTCA Registry (open to
women only), procedural success was higher and major com-
plications lower than in women treated in the 1985-1986 reg-
istry (190). Additionally, in patients undergoing PTCA in
BARI, in-hospital mortality, MI, emergency coronary artery
bypass surgery rates, and 5-year mortality were similar in
women and men, although women had a higher incidence of
periprocedural HF and pulmonary edema (188). 
The widespread use of stents and adjunctive pharmacolog-
ic therapy has improved outcomes in patients undergoing
contemporary PCI (80,83,112,191-202). Early studies of
drug-eluting stents in small vessels (less than or equal to 2.75
mm), of particular importance in women, report favorable
long-term results in both women and men (203). The hope
that stents would eliminate the difference in outcomes
between women and men has not been realized. Gender dif-
ferences in mortality have persisted for patients treated with
stents both in the setting of acute and nonacute MI (204). In
a meta-analysis of invasive versus conservative therapy of
patients with UA/NSTEMI, men demonstrated a clear sur-
vival advantage using routine invasive therapy with GP
IIb/IIIa inhibitors and intracoronary stents; however, using
similar therapy, the results for women were not significantly
improved (205), although it has been shown that the benefits
of an invasive strategy have been limited to high-risk women
(206).
In women with STEMI, the relative benefit of primary PCI
compared with fibrinolytic therapy is similar to that in men,
but there is a larger absolute benefit in women owing to their
higher event rate (207). In patients with shock complicating
acute MI, the benefit of revascularization is similar in
women and men (208).
In general, the risks and benefits of adjunctive pharma-
cotherapy in women are similar to those in men, although an
increased rate of minor bleeding has been reported in women
treated with abciximab (183). When IIb/IIIa platelet receptor
antagonists are used with unfractionated heparin, a lower
dose of the latter should be considered to decrease the risk of
bleeding in women (Table 9) (69,170,185-189).
Few gender-specific data are available on the outcomes of
other percutaneous coronary devices. Although directional
coronary atherectomy has been associated with lower proce-
dural success and higher bleeding complications in women
(209), similar benefit to that in men has been reported from
embolic protection devices used in saphenous vein PCI (210)
and from vascular brachytherapy (169).
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(18.0% vs 6.7%), and 3-year (21.6% vs 9.6%) mortality rates
than nondiabetic patients (226). Patients with diabetes with a
first MI who were randomly assigned to the early invasive
strategy faired worse than those managed conservatively
(42-day mortality: death or MI, or death alone, 14.8% vs
4.2%; P less than 0.001) (227). An early catheterization and
intervention strategy after fibrinolysis was of little benefit in
these patients with diabetes. Although adjusted in-hospital
mortality was not different in diabetic and nondiabetic
patients, data from the NHLBI registry showed that at 1 year,
adjusted mortality and repeat revascularization were signifi-
cantly higher in diabetics (228). Thus, routine catheterization
and PCI in this patient subgroup should be based on clinical
need and ischemic risk stratification. 
Stenting decreases the need for target-vessel revasculariza-
tion procedures  in diabetic patients compared with PTCA
(229). The efficacy of stenting with GP IIb/IIIa inhibitors
was assessed in the diabetic population compared with those
without diabetes in a substudy of the EPISTENT (Evaluation
of IIb/IIIa Platelet Inhibitor for Stenting) trial (230). One
hundred seventy-three diabetic patients were randomized to
stent/placebo combination, 162 patients to stent/abciximab
combination, and 156 patients to PTCA/abciximab combina-
tion. For the composite end point of death, MI, or target-ves-
sel revascularization, the rates were as follows: 25%, 23%,
and 13% for the stent/placebo, PTCA/abciximab, and
stent/abciximab groups (P equals 0.005). Irrespective of
revascularization strategy, abciximab significantly reduced
6-month death and MI rate in patients with diabetes for all
strategies. Likewise, 6-month target-vessel revascularization
was reduced in the stent/abciximab group approach. One-
year mortality for diabetics was 4.1% for the stent/placebo
group and 1.2% for the stent/abciximab group. Although this
difference was not significant, the combination of stenting
and abciximab among diabetics resulted in a significant
reduction in 6-month rates of death and target-vessel revas-
cularization compared with stent/placebo or PTCA/abcix-
imab therapy (230). Similar results in 1-year target-vessel
revascularization and mortality have been reported with
abciximab and the small-molecule GP IIb/IIIa inhibitor
tirofiban (231). (See Section 6.2.2 Glycoprotein IIb/IIIa
Inhibitors.) The BARI trial, in which stents and abciximab
were not used, showed that survival was better for patients
with treated diabetes undergoing CABG with an arterial con-
duit than for those undergoing PTCA (232). The benefit of
CABG in patients with diabetes may be related to lessened
mortality after subsequent Q-wave MI among patients with
diabetes. In the BARI trial, the benefit of bypass surgery in
diabetic patients was greater in those patients with more
extensive disease (e.g., more than 4 lesions). This advantage
was largely due to a lower mortality for subsequent MI
(233).
Since the BARI trial was completed, several studies have
assessed the use of PCI with stenting versus CABG in
patients with multivessel disease. Patients with diabetes were
assessed specifically in studies from the ARTS (Arterial
Revascularization Therapies Study) and AWESOME (Angina
3.5.4. The Elderly Patient
Age greater than 75 years is one of the major clinical vari-
ables associated with increased risk of complications (211-
214). In the elderly population, the morphologic and clinical
variables are compounded by advanced years, with the very
elderly having the highest risk of adverse outcomes (215). In
octogenarians, although feasibility has been established for
most interventional procedures, the risks associated with
both percutaneous and nonpercutaneous revascularization
are increased (216-218). Octogenarians undergoing PCI have
a higher incidence of prior MI, lower LV ejection fraction,
and more frequent HF (219,220). In the stent era, procedural
success and restenosis rates are comparable to those for
nonoctogenarians, albeit with higher incidences being
reported for in-hospital and long-term mortality and for vas-
cular and bleeding complications (221). A multicenter study
compared an early invasive strategy versus an early conser-
vative strategy in 2220 patients hospitalized for UA/NSTE-
MI. Among patients 65 years or older, the early invasive
strategy conferred a 4.8% absolute risk reduction (39%
Relative Risk Reduction [RRR]) in death or MI at 6 months.
In a post hoc analysis, patients aged 75 years or older expe-
rienced a 10.8% reduction (56% RRR) in 6-month death or
MI with an early invasive strategy. However, there was a sig-
nificant major bleeding rate in patients aged 75 years or older
assigned to an invasive versus a conservative strategy
(16.6% vs 6.5%, P equals 0.009) (222). For patients enrolled
in the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC) trial
of PCI for STEMI using routine stenting versus balloon
angioplasty, with or without abciximab administration in
both revascularization strategies, 1-year mortality increased
exponentially for each decile of age after 65 years (1.6% for
patients less than 55 years, 2.1% for 55 to 65 years, 7.1% for
65 to 75 years, 11% for greater than 75 years; P less than
0.0001). The incidence of stroke and major bleeding was also
increased in the elderly at 1 year. Abciximab administration
did not confer a benefit in elderly patients but was deemed
safe. In contrast, routine stent implantation in elderly patients
reduced 1-year rates of ischemic target-vessel revasculariza-
tion (7.0% vs 17.6%, P less than 0.0001) and subacute or late
thrombosis (0% vs 2.2%, P equals 0.005) compared with bal-
loon angioplasty. The authors acknowledged that additional
risks/benefits of stent or IIb/IIIa inhibitor use in elderly
patients with STEMI might have become evident had more
patients been enrolled in this study (223). Thus, with rare
exception (primary PCI for cardiogenic shock in patients
greater than 75 years of age), a separate category has not
been created in these guidelines for the elderly (224).
However, their higher incidence of comorbidities and risk for
bleeding complications should be taken into account when
considering the need for PCI (218,225).
3.5.5. Diabetes Mellitus
In the TIMI-IIB study of MI, patients with diabetes mellitus
had significantly higher 6-week (11.6% vs 4.7%), 1-year
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embolic protection devices (Percusurge and GuideWire)
(253-255) are associated with promising results (254,255)
(see Section 5.5.2, Late Ischemia After CABG). The native
vessels should be treated with PCI if feasible. Patients with
older and/or severely diseased SVGs may benefit from elec-
tive repeat CABG surgery rather than PCI (256,257). 
In some circumstances, PCI of a protected left main coro-
nary artery stenosis with a patent and functional LAD or left
circumflex coronary conduit can be considered. PCI should
be recognized as a palliative procedure with the potential to
delay the ultimate application of repeat CABG surgery.
3.5.7. Specific Technical Considerations
Certain outcomes of PCI may be specifically related to the
technology utilized for coronary recanalization.
Periprocedural CK-MB elevation appears to occur more fre-
quently after use of ablative technology such as rotational or
directional atherectomy (23,77,85,243,258). Antecedent UA
appears to be a clinical predictor of slow flow and peripro-
cedural infarction after ablative technologies (259), and
direct platelet activation has been demonstrated to occur with
both directional and rotational atherectomy (260). In support
of the premise that platelets play a pathophysiologic role in
periprocedural MI are observations that the presence and
magnitude of CK-MB elevation after ablative technologies
can be reduced to levels observed after PTCA by the admin-
istration of prophylactic platelet GP IIb/IIIa receptor block-
ade (261,262). 
Coronary perforation may occur more commonly after the
use of atheroablative devices, including rotational, direction-
al, or extraction atherectomy, and excimer laser coronary
angioplasty. However, the incidence of perforation has been
reported variably to be 0.10% to 1.14% with balloon angio-
plasty, 0.25% to 0.70% with directional coronary atherecto-
my, 0.0% to 1.3% with rotational atherectomy, 1.3% to 2.1%
with extraction atherectomy, and 1.9% to 2.0% after excimer
laser coronary angioplasty (263,264). Coronary perforation
complicates PCI more frequently in the elderly and in
women. Although 20% of perforations may be secondary to
the coronary guidewire, most are related to the specific tech-
nology used. Perforation is usually (80% to 90%) evident at
the time of the interventional procedure and should be a pri-
mary consideration in the differential diagnosis for cardiac
tamponade manifest within 24 h of the procedure. Perfor-
ations may be classified on the basis of angiographic appear-
ance as type I (extraluminal crater without extravasation),
type II (pericardial and myocardial blush without contrast jet
With Extremely Serious Operative Mortality Evaluation)
groups. Glycoprotein IIb/IIIa inhibitors were used in approx-
imately 11% of AWESOME PCI patients and were not incor-
porated into the ARTS protocol. At 3 years of follow-up, the
survival rates of the diabetic subsets treated with CABG and
PCI were not significantly different in either ARTS or AWE-
SOME. Repeat revascularization was higher with PCI in the
subsets of patients with diabetes in both trials. 
Randomized trials, meta-analysis of trials, and epidemio-
logical studies have shown the superiority of DES over BMS
in terms of reducing late repeat revascularization (234-236).
There are, as yet, inadequate data from which to infer impact
on long-term survival after PCI for patients with diabetes.
The sum effect of DES and GP IIb/IIIa inhibitors will be
assessed against contemporary CABG in multivessel-disease
patients with diabetes in the upcoming National Institutes of
Health (NIH)–sponsored Future Revascularization
Evaluation in Patients With Diabetes Mellitus: Optimal
Management of Multivessel Disease (FREEDOM trial)
(237). A discussion about the selection of patients with dia-
betes for surgical revascularization or PCI may be found in
Section 3.6, Comparison With Bypass Surgery. Preliminary
data suggest late outcomes in diabetic patients after PCI are
similar to nondiabetics if the hemoglobin A1C can be main-
tained less than 7.0% (238). Management of other risk fac-
tors, particularly lipid abnormalities, in patients with dia-
betes has also been shown to have a very significant effect on
long-term outcome (239-242). These observations empha-
size the importance of diabetes management and secondary
prevention therapies after PCI.
3.5.6. PCI After Coronary Artery Bypass Surgery
Although speculated to be at higher risk, patients having PCI
of native vessels after prior coronary bypass surgery have, in
recent years, nearly equivalent interventional outcomes and
complication rates compared with patients having similar
interventions without prior surgery. For PCI of SVG, studies
indicate that the rate of successful angioplasty exceeds 90%,
the death rate is less than 1.2%, and the rate of Q-wave MI is
less than 2.5% (Table 10) (243-248). The incidence of
non–Q-wave MI may be higher than that associated with
native coronary arteries (249-251). 
In consideration of PCI for SVG, the age of the SVG and
duration and severity of myocardial ischemia should be
taken into consideration. Use of GP IIb/IIIa blockers has not
been shown to improve results of angioplasty in vein grafts
(252). However, preliminary studies of 2 different distal
Table 10. Probability of Success, Complications, and Restenosis After Balloon Angioplasty or Stenting in Patients After Coronary Bypass Surgery
Conduit Site Reference Success Rate Death Rate MI Rate* Restenosis Rate†
Saphenous vein graft (243-246) Greater than 92% Less than 2% 15% 20% to 35%
Internal mammary artery (247) 97% Less than 1% 12.5% 7% anastomotic, 
25% ostial site
Left main (248) 95% Less than 2% 10% 25%
MI indicates myocardial infarction.
*Greater than 3 times normal CK-MB on serial determinations after intervention..
†Restenosis measured as target-vessel revascularization.
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extravasation), and type III (extravasation through a frank [1
mm] perforation) (263). In the absence of extravasation (type
III), the majority of perforations may be effectively managed
without urgent surgical intervention. Type III perforations
have been successfully managed nonoperatively with peri-
cardiocentesis, reversal of anticoagulation, and either pro-
longed perfusion balloon inflation at the site of perforation or
deployment of a covered stent. Perforations caused by
atheroablative devices usually require surgical repair.
3.5.8. Issues of Hemodynamic Support in 
High-Risk PCI
Controversy exists about the ability to predict hemodynamic
compromise during PCI. Hemodynamic compromise,
defined as a decrease in systolic blood pressure to an
absolute level less than 90 mm Hg during balloon inflation,
was often associated with LV ejection fraction less than 35%,
greater than 50% of myocardium at risk, and PTCA per-
formed on the last remaining vessel (120,163). 
Early feasibility studies of high-risk PTCA using percuta-
neous cardiopulmonary support (CPS) indicated that
although initial likelihood of success was high, vascular mor-
bidity was also high, with an incidence of 43% (265,266).
However, no study has published data to validate commonly
used high-risk categorizations. 
Elective high-risk PCI can be performed safely without
intra-aortic balloon pump (IABP) or CPS in most circum-
stances. Emergency high-risk PCI such as primary PCI for
STEMI can usually be performed without IABP or CPS. CPS
for high-risk PCI should be reserved only for patients at the
extreme end of the spectrum of hemodynamic compromise,
such as those patients with extremely depressed LV function
and patients in cardiogenic shock. However, in patients with
borderline hemodynamics, ongoing ischemia, or cardiogenic
shock, insertion of an intra-aortic balloon just before coro-
nary instrumentation has been associated with improved out-
comes (267,268). Furthermore, it is reasonable to obtain vas-
cular access in the contralateral femoral artery before the
procedure in patients in whom the risk of hemodynamic
compromise is high, thereby facilitating intra-aortic balloon
insertion, if necessary. 
For high-risk patients, clinical and anatomic variables
influencing complications and outcome should be assessed
before the performance of PCI to determine procedural risk,
the risk of abrupt vessel closure, and potential for cardiovas-
cular collapse. In patients having a higher-risk profile (such
as those with LV dysfunction, single patent vessel or ULM,
degenerated SVG, or high thrombus burden in the obstructed
vessel), consideration of alternative therapies, particularly
coronary bypass surgery, formalized surgical standby, or
periprocedural hemodynamic support should be addressed
before proceeding with PCI. Several small retrospective
studies have evaluated the use of elective balloon pump sup-
port before high-risk PCI. These studies generally reveal suc-
cessful reperfusion by PCI, with improved procedural or in-
hospital morbidity and mortality (267,269,270). An alterna-
tive approach is to use standby IABP, which results in slight-
ly greater complications for patients undergoing standby
IABP than for those in whom the IABP was in place before
the procedure (271). Available data for the use of IABP in
high-risk patients involve retrospective analyses of relative-
ly small numbers of patients; therefore, no formal recom-
mendations are suggested. The decision to proceed with
IABP before PCI remains a clinical judgment made by the
physician based on the high-risk characteristics of coronary
anatomy and overall status of the patient.
3.6. Comparison With Bypass Surgery
The major advantage of PCI is its relative ease of use and
avoidance of general anesthesia, thoracotomy, extracorpore-
al circulation, central nervous system complications, and
prolonged convalescence. Repeat PCI can be performed
more easily than repeat bypass surgery, and revascularization
can be achieved more quickly in emergency situations. The
disadvantages of PCI are early restenosis and the inability to
relieve many totally occluded arteries and/or those vessels
with extensive atherosclerotic disease. 
Coronary artery bypass surgery has the advantages of
greater durability (graft patency rates exceeding 90% at 10
years with arterial conduits) (272) and more complete revas-
cularization regardless of the morphology of the obstructing
atherosclerotic lesion. Generally speaking, the greater the
extent of coronary atherosclerosis and its diffuseness, the
more compelling the choice of coronary artery bypass sur-
gery, particularly if LV function is depressed. Patients with a
lesser extent of disease and localized lesions are good candi-
dates for endovascular approaches. 
PTCA and coronary artery bypass surgery have been com-
pared in many nonrandomized and randomized studies.
Whereas randomized controlled trials are the only way to
completely eliminate bias between comparative therapies,
large prospective registries can best extend observations to
broad segments of the population who might be excluded
from randomized trials. Through risk-adjustment methodolo-
gies, large groups of patients can be evaluated between ther-
apies to attempt to eliminate the impact of baseline differ-
ences. A number of registries have compared coronary
bypass graft surgery with PCI (52). New York State man-
dates a registry of all patients undergoing PCI and CABG
that is monitored by audit and provides survival data on all
New York State residents. Patients with multivessel disease
treated between January 1, 1997, and December 31, 2000,
were followed up for 3 years (52). During this period when
stent utilization was common, the adjusted hazard ratio
favored surgery for all subsets of multivessel disease
patients. The surgical advantage was greatest for patients
with 3-vessel disease with involvement of the proximal LAD
and least for patients with 2-vessel disease without anterior
descending involvement. One important factor differentiat-
ing the techniques was significantly more complete revascu-
larization in the surgery group. By identifying trends such as
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low-up results indicated that freedom from combined cardiac
events was significantly greater for bypass surgery than for
the PTCA group (77% vs 47%; P less than 0.001). However,
there were no differences in overall and cardiac mortality or
in the frequency of MI between the 2 groups. Patients who
had bypass surgery were more frequently free of angina
(79% vs 57%) and had fewer additional reinterventions
(6.3% vs 37%) than patients who had PTCA. This study indi-
cated that freedom from combined cardiac events at 3-year
follow-up was greater in bypass patients than in those who
had PTCA and that the PTCA group had a higher incidence
of recurrence of angina and need for repeat procedures.
Cumulative cost at 3 years was greater for surgery than for
the PTCA group. 
In the ARTS trial, the first trial to compare stenting with
surgery, there was no significant difference in mortality
between PCI and surgical groups at 1 and 3 years (281,282).
The main difference compared with previous PTCA and
CABG trials was an approximate 50% reduction in the need
for repeat revascularization in a group randomized to PCI
with stent placement (281). 
Similar results were reported by the Stent or Surgery (SoS)
trial. In this trial, 988 patients with multivessel disease were
randomized to PCI (78% received stents) or CABG. At a
median follow-up of 2 years, 21% of the PCI group required
repeat revascularization compared with 6% of the CABG
group (hazard ratio 3.85, 95% confidence interval [CI] 2.56-
5.79, P less than 0.0001). The incidence of death or Q-wave
MI was similar in both groups (hazard ratio 0.95, 95% CI
0.63-1.42, P equals 0.80). Mortality was higher in the PCI
group, but this was influenced by a particularly low surgical
mortality and a high rate of noncardiovascular deaths in the
PCI group (283).
The ERACI II study randomized 450 patients with multi-
vessel disease (91% UA) to PCI or CABG. At a mean follow-
up of 18.5 months, survival was 96.9% in PCI group versus
92.5% in the CABG group (P less than 0.017). Freedom
from MI was also better in the PCI group than in the CABG
group (97.7% vs 93.4%, P less than 0.017). Similar to other
studies, the need for repeat revascularization was higher in
the PCI group (16.8% vs 4.8%, P less than 0.002) (284).
In the AWESOME study, 454 patients with medically
refractory myocardial ischemia and high-risk features for
adverse outcomes with surgery were randomized to either
PCI (54% received stents) or CABG. High-risk features
included: prior open heart surgery, age greater than 70 years,
LV ejection fraction less than 0.35, MI within 7 days, or
IABP required. Comparable survival was observed between
the PCI and CABG groups at 3 years (80% vs 79%), with
more frequent repeat revascularization in the PCI group.
Additionally, survival free of UA in the PCI group was with-
in 90% of that in the CABG group (285).
Direct comparison of initial strategies of PCI or CABG in
patients with multivessel coronary disease is possible only
by randomized trials because of selection criteria of patients
for PCI. There have been 5 large (more than 300 patients)
randomized trials of PTCA versus CABG and 2 smaller stud-
these, registries can provide important insight for clinical
improvement.
The most accurate comparisons of outcomes are best made
from prospective randomized trials of patients suitable for
either treatment. Although results of these trials provide use-
ful information for selection of therapy in several patient
subgroups, prior studies of PTCA may not reflect outcome of
current PCI practice, which includes frequent use of stents
and antiplatelet drugs. Similarly, many previous studies of
CABG may not reflect outcome of current surgical practice,
in which arterial conduits are used whenever practicable.
Beating heart bypass operations are also employed for select-
ed patients with single-vessel disease with reduced morbidi-
ty (273). In addition, patients are selected for PCI (with or
without stenting) because of certain lesion characteristics,
and these anatomic criteria are not required for CABG. 
Randomized trials also must be interpreted carefully. It is
unethical to withhold subsequent PCI or CABG from
patients solely because they fail an earlier treatment; thus,
comparative prospective studies can only compare initial
strategies of revascularization. This critically important point
is frequently overlooked by those who claim that a random-
ized study proves equally good outcome of one method of
revascularization over the other. 
Despite these limitations, some generalizations can be
made from comparative trials of PTCA and CABG. First, for
most patients with single-vessel disease, late survival is sim-
ilar with either revascularization strategy, and this might be
expected given the generally good prognosis of most patients
with single-vessel disease managed medically (274-276). 
Two prospective clinical trials have evaluated PTCA and
CABG for revascularization of isolated disease of the LAD.
Investigators in the Medicine, Angioplasty or Surgery Study
(MASS) used a combined end point of cardiac death, MI, or
refractory angina requiring repeat revascularization by sur-
gery; at 3 years of follow-up, this combined end point
occurred in 24% of PTCA patients, 17% of medical patients,
and 3% of surgical patients (277). Importantly, there was no
difference in overall survival in the 3 groups. In the
Lausanne trial of 134 patients with isolated LAD disease
treated by either PTCA (68 patients) or bypass with an IMA,
survival was similar in the 2 groups, and 94% of PTCA
patients and 95% of CABG patients were free of limiting
symptoms (278). However, patients in the PTCA group took
more antianginal drugs than surgical patients, and at median
follow-up of 2.5 years, 86% of CABG-treated versus 43% of
PTCA-treated patients were free from late events (P less than
0.01); this difference was primarily due to restenosis (32%)
requiring subsequent CABG (16%) or PTCA (15%). Neither
of the 2 aforementioned trials included stenting, a technique
that would be expected to reduce rates of early restenosis by
as much as 50% in appropriately selected lesions
(108,279,280). 
In a similar manner, the 3-year follow-up of the Argentine
randomized trial of PTCA versus CABG multivessel disease
(ERACI study) (279) demonstrated that in patients random-
ized to PTCA or bypass surgery, the 1-, 3-, and 5-year fol-
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236) (see also Section 7.3.5 on DES). At this writing, no pub-
lished studies are available comparing PCI with DES to
CABG; thus, the impact of contemporary therapy with DES
compared with CABG requires further evaluation. The
ARTS II study compared outcomes for 600 surgically treat-
ed patients in ARTS II with 600 similar patients prospective-
ly treated with multistent, sirolimus-eluting stent (SES)
implantation [P.W. Serruys, oral presentation, American
College of Cardiology Scientific Session, Orlando, Fla,
March 2005]. Preliminary data from that study showed a
lower rate of perioperative MI for the stent group. The sur-
gery group still had fewer repeat revascularization proce-
dures; however, the difference was markedly attenuated
compared with the ARTS I BMS group. Furthermore, med-
ical management of atherosclerosis, both before and after
revascularization, has continued to evolve with the increased
use of beta-blockers, inhibitors of the renin-angiotensin-
aldosterone system, and lipid-lowering agents. Other
changes in patient management that may influence these
conclusions are the use of GP IIb/IIIa inhibitors, as men-
tioned above, and the use of direct thrombin inhibitors dur-
ing PCI, the more frequent use of IMA grafts, and the emer-
gence of less invasive surgical approaches. It is likely that
during the progress of their disease, many patients will ben-
efit from a combined application of percutaneous and surgi-
cal techniques, taking advantage of the low morbidity of per-
cutaneous methods and the established long-term benefit of
surgical revascularization with arterial conduits.
Recommendations for revascularization in various patient
subsets are presented in Section 5.
3.7. Comparison With Medicine
There has been a considerable effort made to evaluate the rel-
ative effectiveness of bypass surgery compared with PCI for
coronary artery revascularization. In contrast to this, very lit-
tle effort has been directed toward comparing medical thera-
py with PCI for the management of stable and UA. Several
randomized trials are currently available comparing PCI with
the medical management of angina (Table 12) (289,296-
302). Most trials comparing PCI with medical therapy have
utilized PTCA, not stents, in comparison with medical ther-
apy, and no major trials are available comparing DES with
medical therapy. The ACME (Angioplasty Compared to
Medicine) investigators randomized 212 patients with sin-
gle-vessel disease, stable angina pectoris, and ischemia on
treadmill testing to PTCA or medical therapy. This trial
demonstrated superior control of symptoms and better exer-
cise capacity in patients managed with PTCA than in those
given medical therapy. Death and MI were infrequent occur-
rences, and their incidence was similar in both groups. The
Veterans Administration ACME trial investigators provided
long-term results in an additional 101 randomized patients
with double-vessel disease not previously reported (300) that
indicated that patients randomized to medical therapy or
PTCA had similar improvement in exercise duration, free-
dom from angina, and improvement in quality of life at the
ies and 5 large trials of PCI using stents versus CABG (10-
12,279,281,283-289). Characteristics of the studies are sum-
marized in Table 11 (11,12,279,282-290). These trials
demonstrate that in appropriately selected patients with mul-
tivessel coronary disease, an initial strategy of standard PCI
with BMS yields similar overall outcomes (e.g., death, MI)
to initial revascularization with coronary artery bypass. 
An important exception to the conclusion of the relative
safety of PCI in multivessel disease is the subgroup of
patients with treated diabetes mellitus. In BARI, the only
trial with a sufficiently large patient enrollment to examine
survival alone, the data showed that among treated diabetic
patients assigned to PTCA, 7-year survival was 55.7% com-
pared with 76.4% for patients having CABG (P equals
0.0011); the improved outcome with CABG was due to
reduced cardiac mortality (5.8% vs 20.6%, P equals 0.0003),
which was confined to those receiving at least 1 IMA graft
(10,67,290). There was no mortality difference at 7 years in
the remainder of the patients, those without diabetes and
patients with diabetes not undergoing medical treatment
(290). Better survival of diabetic patients with multivessel
disease treated initially with CABG has also been observed
in a large retrospective study from Emory (291) and in the 8-
year results of Emory Angioplasty Surgery Trial (EAST)
(292). In the BARI trial, the benefit of bypass surgery in dia-
betic patients was greater in those patients with more exten-
sive disease (e.g., more than 4 lesions). This advantage was
largely due to a lower mortality for subsequent MI (233,293).
As compelling as these reports may be, it is of interest that
treated diabetic patients enrolled in the BARI registry did not
show a similar advantage for CABG over PCI, which sug-
gests that physician judgment in the selection of diabetic
patients for PCI may be an important factor (42,68). 
Patients with diabetes have been evaluated specifically in
studies from the ARTS and AWESOME groups, which
included the use of stents (294,295). GP IIb/IIIa inhibitors
were used in approximately 11% of AWESOME PCI patients
and were not incorporated into the ARTS protocol. After 3
years of follow-up, the survival rates of the diabetic subsets
treated with CABG and PCI were not significantly different
in either ARTS or AWESOME. Repeat revascularization was
higher with PCI in the subsets of patients with diabetes in
both trials. The sum effect of DES and GP IIb/IIIa inhibitors
will be assessed against contemporary CABG in multivessel
disease patients with diabetes in the upcoming NIH-spon-
sored FREEDOM trial.
Overall, 6 trials have been published comparing PCI using
stents with CABG in single-vessel or multivessel disease.
Both revascularization techniques relieve angina. In aggre-
gate, these trials have not shown a difference between CABG
and PCI in terms of mortality or procedural MI among the
populations studied, which have mostly included low-risk
patients. Stents appear to have narrowed the late repeat
revascularization difference that favored CABG in the bal-
loon era. Randomized trials, meta-analysis of trials, and epi-
demiological studies have shown the superiority of DES over
BMS in terms of reducing late repeat revascularization (234-
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The Atorvastatin Versus Revascularization Treatment
(AVERT) trial (298) randomly assigned 341 patients with
stable CAD, normal LV function, and class I and/or II angi-
na to PTCA or medical therapy with 80 mg of atorvastatin
daily (mean low-density lipoprotein cholesterol equals 77
mg per dL). At 18 months of follow-up, 13% of the medical-
ly treated group had ischemic events compared with 21% of
the PTCA group (P equals 0.048). Angina relief was greater
in those treated with PTCA. Although not statistically differ-
ent when adjusted for interim analysis, these data suggest
that in low-risk patients with stable CAD, aggressive lipid-
lowering therapy can be as effective as PTCA in reducing
ischemic events. 
During the MASS-II trial (289), 611 patients with stable
angina, multivessel disease, and preserved LV function were
randomized to 3 treatment groups: medical therapy, CABG,
or PCI (medical therapy n equals 203, CABG n equals 203,
and PCI n equals 205). One-year survival was similar in the
3 groups at 98.5%, 96.0%, and 95.6%, respectively. At 1 year
of follow-up, a Q-wave MI had occurred in 2% of CABG
patients, 8% of the PCI patients, and 3% of the medical ther-
apy patients. By 1 year, additional revascularization proce-
dures were performed in 8.3% of medical therapy patients,
13.3% of PCI patients, and only 0.5% of CABG patients.
More patients were free of angina at 1 year in the CABG and
PCI groups (88% and 79%, respectively) than in the medical
therapy groups, in which only 46% were free of angina. This
small contemporary trial utilizing aggressive medical man-
agement demonstrated that medical therapy for multivessel
disease has a low incidence of early events including death
and Q-wave MI but is inferior to PCI and CABG for the con-
trol of angina.
Given the limited data available from randomized trials
comparing medical therapy with PCI, it seems prudent to
consider medical therapy for the initial management of most
patients with CCS classification class I and II stable angina
and to reserve PCI and CABG for those patients with more
severe symptoms and ischemia. The symptomatic patient
who wishes to remain physically active, regardless of age,
will usually require PCI or CABG to accomplish this.
The Clinical Outcomes Utilization Revascularization and
Aggressive Drug Evaluation (COURAGE) trial was
designed to compare intensive medical therapy with PCI plus
intensive medical therapy. Enrollment has been completed,
and results are expected to be available in the next few years.
This trial will provide further valuable information about the
relative merits of medical treatment plus PCI versus medical
treatment alone and will also give us a detailed assessment of
outcomes relative to quality of life and economic cost (303).
The Bypass Angioplasty Revascularization trial in patients
with diabetes (BARI 2d) was designed to compare revascu-
larization in addition to aggressive medical therapy in
patients with diabetes compared with aggressive medical
therapy alone. Enrollment was completed in the first quarter
of 2005. 
Patients with UA and NSTEMI have been randomized to
medical therapy or PCI in the FRagmin and Fast
time of 6-month follow-up. Thus, these patients with double-
vessel PTCA did not demonstrate superior control of their
symptoms as compared with medical therapy, as was experi-
enced by the ACME patients with single-vessel disease. This
small study suggests that PTCA is less effective in control-
ling symptoms in patients with double-vessel disease and
stable angina than in those with single-vessel disease. 
The Randomized Intervention Treatment of Angina
(RITA)-2 investigators randomized 1018 patients with stable
angina to PTCA or conservative (medical) therapy
(297,299). Patients who had inadequate control of their
symptoms with optimal medical therapy were allowed to
cross over to myocardial revascularization. The combined
end point of the trial was all-cause mortality and nonfatal MI.
The 504 PTCA and 514 medically treated patients were fol-
lowed up for a mean of 7 years. Death due to all causes
occurred in 43 (8.5%) of the PTCA patients and 43 (8.4%) of
the medical patients. Of the 86 deaths, only 8 were due to
heart disease. Angina improved in both groups, but there was
a 16.5% absolute excess of grade 2 or worse angina in the
medical group at 3 months after randomization (P less than
0.001). These differences in angina narrowed over time, with
the PTCA group always having less angina than the med-
ically treated patients. Thus, RITA-2 demonstrated that
PTCA results in better control of symptoms of ischemia and
improves exercise capacity compared with medical therapy
but is associated with a higher combined end point of death
and periprocedural MI. It is important to remember that
although the patients in this trial were asymptomatic or had
only mild angina, 62% of them had multivessel CAD, and
34% had significant disease in the proximal segment of the
LAD (301). Thus, most of these patients had severe anatom-
ic CAD. 
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study
provides additional information comparing medical therapy
with PTCA or CABG revascularization in patients with doc-
umented CAD and asymptomatic ischemia by both stress
testing and ambulatory ECG monitoring (301). This trial ran-
domized 558 patients suitable for revascularization by PTCA
or CABG to 3 treatment strategies: angina-guided drug ther-
apy (n equals 183), angina- plus ischemia-guided drug ther-
apy (n equals 183), and revascularization by PTCA or CABG
surgery (n equals 192). Of the 192 patients who were ran-
domized to revascularization, 102 were selected for PTCA
and 90 for CABG. At 2 years of follow-up, death or MI had
occurred in 4.7% of the revascularization patients compared
with 8.8% of the ischemia-guided group and 12.1% of the
angina-guided group (P less than 0.01). Because a large por-
tion of the patients underwent CABG surgery instead of
PTCA to achieve complete revascularization, it is not appro-
priate to directly compare these results with RITA-2.
Nonetheless, the ACIP study suggests that outcomes of
revascularization with CABG surgery and PTCA are very
favorable compared with medical therapy in patients with
asymptomatic ischemia with or without mild angina. It
should be emphasized that aggressive lipid-lowering therapy
was not widely employed in either treatment arm of ACIP. 
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Revascularisation during InStability in Coronary artery dis-
ease (FRISC) II and Treat Angina with Aggrastat and deter-
mine the Cost of Therapy with an Invasive or Conservative
Strategy (TACTICS) TIMI 18 trials, as well as in RITA-3.
These trials utilizing stenting as the primary therapy have
favored the invasive approach (206,302,304). They are dis-
cussed in Section 5.3.
4. INSTITUTIONAL AND OPERATOR
COMPETENCY
4.1. Quality Assurance
Class I
1. An institution that performs PCI should establish an
ongoing mechanism for valid peer review of its quali-
ty and outcomes. Review should be conducted both at
the level of the entire program and at the level of the
individual practitioner. Quality-assessment reviews
should take risk adjustment, statistical power, and
national benchmark statistics into consideration.
Quality-assessment reviews should include both tabu-
lation of adverse event rates for comparison with
benchmark values and case review of complicated
procedures and some uncomplicated procedures.
(Level of Evidence: C)
2. An institution that performs PCI should participate in
a recognized PCI data registry for the purpose of
benchmarking its outcomes against current national
norms. (Level of Evidence: C)
Definition of Quality in PCI
Satisfactory quality in PCI may be defined as the appropriate
selection of patients for the procedure and the achievement
of risk-adjusted outcomes that are comparable to national
benchmark standards in terms of procedure success and
adverse event rates. To achieve optimal quality and outcomes
in PCI, it is necessary that both the physician operator and
the supporting institution be appropriately skilled and expe-
rienced. 
Institutional Quality-Assurance Requirement
PCI is a demanding, technically complex procedure. The
potential exists for substantial quality variation among both
operators and institutions. 
In the United States, responsibility for quality assurance is
vested in the healthcare institution, which is responsible to
the public to ensure that patient care conducted under its
jurisdiction is of acceptable quality. Thus, the institution has
the responsibility to monitor its PCI program’s quality with
respect to process, appropriateness, and outcomes in order to
identify and correct any circumstances in which quality falls
below accepted norms. Quality-assessment review should be
conducted both at the level of the entire program and at the
level of the individual practitioner.
Each institution that performs PCI must establish an ongo-
ing mechanism for valid peer review of its quality and out-
comes. The program should provide an opportunity for inter-
ventionalists, as well as for physicians who do not perform
angioplasty but are knowledgeable about it, to review its
overall results on a regular basis. The review process should
tabulate the results achieved both by individual physician
operators and by the overall program and compare them with
national benchmark standards with appropriate risk adjust-
ment. Valid quality assessment requires that the institution
maintain meticulous records that include the patient demo-
graphic and clinical characteristics necessary to assess
appropriateness and to conduct risk adjustment.
Role of Risk Adjustment in Assessing Quality
A raw adverse event rate that is not appropriately risk adjust-
ed has little meaning. Data compiled from large registries of
procedures performed in recent years have generated multi-
variate risk-adjustment models for adverse event rates for
PCI in the current era. Six multivariate models of the risk of
mortality after PCI have been published (43,47,305-308). 
Although these models differ somewhat, they are consis-
tent in identifying acute MI, shock, and age as important
risk-stratification variables for mortality. The ACC-NCDR
reported a univariate mortality rate of 0.5% for patients
undergoing elective PCI, a mortality rate of 5.1% for patients
undergoing primary PCI within 6 h of the onset of STEMI,
and a mortality rate of 28% for patients undergoing PCI for
cardiogenic shock (305). Thus, it is clear that to assess PCI
mortality rates, patients should be stratified by whether they
are undergoing elective PCI, primary PCI for acute STEMI
without shock, or primary PCI for STEMI with shock.
Challenges in Determining Quality
As discussed above, given the complexity of case selection
and procedure conduct, quality is difficult to measure in PCI
and is not determined solely by adverse event rates even
when properly adjusted for risk. Accurate assessment of
quality becomes more problematic for low-volume operators
and institutions, because absolute event rates are expected to
be small. Thus, particularly in low-volume circumstances,
quality may be better assessed by an intensive case review
process conducted by recognized experts who can properly
judge all of the facets of the conduct of a case. Case review
also has merit in high-volume situations, because it can iden-
tify subtleties of case selection and procedure conduct that
may not be reflected in pooled statistical data.
Requirement for Institutional Resources and Support
A high-quality PCI program requires appropriately trained
and experienced skilled physician operators. However, the
operator does not work in a vacuum. An operator needs a
well-maintained, high-quality cardiac catheterization facility
to practice effectively. In addition, the operator depends on a
multidisciplinary institutional infrastructure for support and
response to emergencies. Thus, to provide quality PCI serv-
ices, the institution must ensure that its catheterization facil-
ity is properly equipped and managed and that all of its nec-
essary support services are of high quality and are readily
available.
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tional techniques such as rotational atherectomy, balloon
valvuloplasty, and closure of patent foramen ovale and atrial
septal defect. 
It is recommended that an interventional cardiology opera-
tor be certified by the American Board of Internal Medicine
in interventional cardiology. Ideally, board certification in
interventional cardiology should be required for credential-
ing. The American Board of Internal Medicine certifying
examination in interventional cardiology has been adminis-
tered annually since 1999. As of the 2004 administration, a
total of 4718 individuals have been certified.
Privilege Renewal
Criteria for practitioner privilege renewal should be based on
both activity level and outcomes. The assessment process
should ascertain whether a physician operator’s activity level
is sufficient to maintain competence. In addition, the assess-
ment process should assess the appropriateness of the opera-
tor’s case selection and compare the operator’s risk-adjusted
outcomes with established national benchmark standards
(310). This is discussed in depth in Section 4.2. Current
benchmark standards for mortality, complication rates, and
risk adjustment will be subject to future revision as proce-
dure technique is refined and newer data emerge. It is impor-
tant that institutions assist with these efforts by participating
in active database efforts to track clinical and procedural
information for individual operators and their institutions.
Outcome Data Tabulation and Reporting
Institutions performing PCI should gather data needed to
monitor their outcomes and should submit their data to a
national registry for benchmarking purposes. Institutions
should conduct meticulous record keeping that details the
cases performed-patient demographics and comorbidities,
The Quality-Assessment Process
Quality assessment is a complex process that includes more
than mere tabulation of success and complication rates.
Components of quality in coronary interventional procedures
include appropriateness of case selection, quality of proce-
dure execution, proper response to intraprocedural problems,
accurate assessment of procedure outcome, and appropriate-
ness of postprocedure management. It is important to con-
sider each of these parameters when conducting a quality-
assessment review. A quality program performs appropriate-
ly selected procedures that achieve risk-adjusted outcomes,
in terms of procedure success and complication rates, that are
comparable to national benchmark standards. Patient charac-
teristics that determine appropriateness are discussed else-
where in this document. Multivariate models that predict risk
have been published previously (43,47,305-308). 
It is accepted that quality-assurance monitoring is best con-
ducted through the peer review process despite the political
challenges associated with colleagues evaluating each other.
There has been a considerable controversy surrounding
efforts to define standards, criteria, and methodologies for
conducting quality assessment. There are many challenges to
conducting this process in a fair and valid manner. 
The cornerstone of quality-assurance monitoring is the
assessment of procedural outcomes in terms of success and
adverse event rates. Other components of quality-assurance
monitoring include establishment of criteria for assessing
procedure appropriateness and application of proper risk
adjustment to interpret adverse event rates. Because adverse
events should be rare, a valid estimate of a properly risk-
adjusted adverse event rate generally requires tabulation of
the results of a large number of procedures. This adds an
additional challenge to the valid assessment of low-volume
operators and institutions. The responsible supervising
authority should monitor the issues outlined in Table 13
(309).
Initial Physician Operator Credentialing Criteria
The institutional credentialing committee should document
that an interventionalist wishing to initiate practice meets the
established training criteria, including those of the ACC Task
Force on Training in Cardiac Catheterization and
Interventional Cardiology (310-312). The ACC Training
Statement (312) for coronary invasive training requires a 3-
year comprehensive cardiac program with 12 months of
training in diagnostic catheterization, during which the
trainee performs 300 diagnostic catheterizations, with at least
200 of those as the primary operator. Interventional training
requires a fourth year of fellowship, during which the trainee
should perform more than 250 but not more than 600 inter-
ventional procedures (312). The physician’s training pro-
gram director should certify that the candidate has complet-
ed the program and has achieved the necessary competence
to perform coronary interventional procedures independent-
ly. The certification should also include whether the candi-
date has achieved requisite competence in related interven-
Table 13. Key Components of a Quality-Assurance Program
Clinical proficiency
General indications/contraindications
Institutional and individual operator complication rates, mortality
and emergency CABG
Institutional and operator procedure volumes
Training and qualifications of support staff
Equipment maintenance and management
Quality of laboratory facility [See ACC/SCAI Expert Consensus
Document on Catheterization Laboratory Standards (309)]
Quality improvement process
Establishment of an active concurrent database to track clinical and
procedural information and patient outcomes for individual opera-
tors and the institution. The ACC-NCDR® or other databases are
strongly recommended for this purpose
Radiation safety
Educational program in the diagnostic use of X-ray
Patient and operator exposure
ACC indicates American College of Cardiology; CABG, coronary artery bypass graft sur-
gery; NCDR®, National Cardiovascular Data Registry; and SCAI, Society for
Cardiovascular Angiography and Interventions.
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Class IIb
The benefit of primary PCI for STEMI patients eligi-
ble for fibrinolysis when performed by an operator
who performs fewer than 75 procedures per year (or
fewer than 11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
Class III
It is not recommended that elective PCI be performed
by low-volume operators (fewer than 75 procedures
per year) at low-volume centers (200 to 400) with or
without onsite cardiac surgery (310,312). An institu-
tion with a volume of fewer than 200 procedures per
year, unless in a region that is underserved because of
geography, should carefully consider whether it
should continue to offer this service. (Level of
Evidence: B)
Operator and Institution Volume-Outcome
Relationships
Threshold activity level standards for institutions and opera-
tors have been particularly controversial. Such standards are
cardiovascular characteristics including type of presentation,
coronary anatomy, ventricular function, procedures per-
formed, and periprocedural complications. These data are
necessary to permit appropriate risk adjustment. Institutions
should carefully monitor their risk-adjusted outcomes at the
level of the institution and of the individual operators and
should ascertain that their outcomes fall within national
norms. One example is the ACCF CathKit®, a tool that pro-
vides templates and guidance for the quality assessment
process.
This Writing Committee agrees with the ACC Task Force
recommendations for the Assessment and Maintenance of
Proficiency in Coronary Interventional Procedures (310).
Institutions and healthcare providers performing PCI should
meet the standards outlined in Table 14 (309,310,312) and in
Section 4.2.
4.2. Operator and Institutional Volume
Class I
1. Elective PCI should be performed by operators with
acceptable annual volume (at least 75 procedures) at
high-volume centers (more than 400 procedures) with
onsite cardiac surgery (310,312). (Level of Evidence:
B)
2. Elective PCI should be performed by operators and
institutions whose historical and current risk-adjust-
ed outcomes statistics are comparable to those report-
ed in contemporary national data registries. (Level of
Evidence: C)
3. Primary PCI for STEMI should be performed by
experienced operators who perform more than 75
elective PCI procedures per year and, ideally, at least
11 PCI procedures for STEMI per year. Ideally, these
procedures should be performed in institutions that
perform more than 400 elective PCIs per year and
more than 36 primary PCI procedures for STEMI per
year. (Level of Evidence B)
Class IIa
1. It is reasonable that operators with acceptable volume
(at least 75 PCI procedures per year) perform PCI at
low-volume centers (200 to 400 PCI procedures per
year) with onsite cardiac surgery (310,312). (Level of
Evidence: B)
2. It is reasonable that low-volume operators (fewer than
75 PCI procedures per year) perform PCI at high-vol-
ume centers (more than 400 PCI procedures per year)
with onsite cardiac surgery (310,312). Ideally, opera-
tors with an annual procedure volume less than 75
should only work at institutions with an activity level
of more than 600 procedures per year. Operators who
perform fewer than 75 procedures per year should
develop a defined mentoring relationship with a high-
ly experienced operator who has an annual procedur-
al volume of at least 150 procedures per year. (Level of
Evidence: B)
Table 14. Considerations for the Assessment and Maintenance of
Proficiency in Coronary Interventional Procedures
Institutions
Quality-assessment monitoring of privileges and risk-stratified out-
comes
Provide support for a quality-assurance staff person (e.g., nurse) to
monitor complications
Minimal institutional performance activity of 200 interventions per
year, with ideal minimum of 400 interventions per year
Interventional program director who has a career experience of
more than 500 PCI procedures and who is board certified by the
ABIM in interventional cardiology
Facility and equipment requirements to provide high-resolution flu-
oroscopy and digital video processing
Experienced support staff to respond to emergencies (see Section
4.3, Role of On-Site Cardiac Surgical Backup for discussion)
Establishment of a mentoring program for operators who perform
fewer than 75 procedures per year by individuals who perform at
least 150 procedures per year
Physicians
Procedural volume of 75 per year or more
Continuation of privileges based on outcome benchmark rates, with
consideration of not granting privileges to operators who exceed
adjusted case mix benchmark complication rates for a 2-year peri-
od
Ongoing quality assessment comparing results with current bench-
marks, with risk stratification of complication rates
Board certification by ABIM in interventional cardiology
ABIM indicates American Board of Internal Medicine; and PCI, percutaneous coronary
intervention.
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Other studies have also supported the relationship of com-
plication rate to procedural volume (47,306,314). Although
some investigators have suggested that low procedure vol-
ume does not contribute to poor outcomes (44,309), these
studies are small in number and underpowered for analysis
(318). 
Progress in technique and instrumentation has reduced
absolute complication rates, which makes the procedure
safer and more effective. This has fueled the opinion that the
volume-outcome relationship has weakened, justifying advo-
cacy that PCI be diffused to smaller-volume institutions and
lower-volume operators. Although it is possible to consider
earlier studies anachronistic because of the lack of availabil-
ity of coronary stents and other adjunctive therapies, studies
based on data sets accumulated in the stent era continue to
show a volume-outcome relationship (albeit with lower
absolute event rates).
Brown evaluated the outcomes of PCI at all hospitals in
California in 1997 (324). Mortality for PCI in which a stent
was used was 1.5% in hospitals performing fewer than 400
procedures per year compared with 1.1% in hospitals per-
forming more than 400 procedures per year. The rate of
emergent CABG was 1.2% in hospitals performing fewer
than 400 procedures per year compared with 0.8% in hospi-
tals that performed more than 400 procedures per year.
Moscucci et al. studied the outcomes of 18 504 consecutive
PCIs performed at 14 hospitals in Michigan in 2002 (325).
Operator volume was divided in quintiles (1-33, 34-89, 90-
139, 140-206, and 207-582 procedures per year). The pri-
mary end point was a composite of MACE including death,
CABG, stroke or TIA, MI, and repeat PCI at the same site
during the index hospitalization. The unadjusted MACE rate
was significantly higher in quintiles 1 and 2 of operator vol-
ume than in quintile 5 (7.38% and 6.13% vs 4.15%, P equals
0.002 and P equals 0.0001, respectively). A similar trend was
observed for in-hospital death. After adjustment for comor-
bidities, patients treated by low-volume operators had a 63%
increased odds of MACE (adjusted odds ratio [OR] 1.63,
95% CI 1.29-2.06, P less than 0.0001 for quintile 1; adjusted
OR 1.63, 95% CI 1.34-1.90, P less than 0.0001 for quintile 2
vs quintile 5) but not of in-hospital death. Overall, high-vol-
ume operators had better outcomes than low-volume opera-
tors in both low-risk and high-risk patients (325).
Distinction Between Elective PCI and 
Primary PCI for STEMI
Elective PCI and primary PCI for STEMI are different,
although related, disciplines. Experience in elective PCI
translates only partially to experience with primary PCI for
STEMI. Throughout this guideline, a distinction is drawn
between primary PCI, which is performed under emergency
circumstances, and all other PCI procedures, which are
included under the term “elective.” The volume-outcome
relationship exists for both elective procedures and primary
angioplasty for STEMI (326-328) but has important differ-
ences. Available data indicate that the best results are
derived from the principle that proper skill maintenance
requires a requisite activity level. It is logical that both a
threshold experience and an ongoing activity level are nec-
essary to achieve and maintain requisite proficiency in PCI. 
Standards originally formulated for the earliest versions of
these guidelines were based on opinion (Level of Evidence:
C) drawing on the well-documented existence of volume-
outcome relationships for other complex surgical procedures.
Initially, a panel of experts identified a threshold activity
level of 75 procedures per year as necessary for maintenance
of competence in PCI (313). Subsequent studies of PCI con-
tinue to identify annual procedural volume both at the pro-
gram level and at the operator level as strongly correlated
with complication rates. Most studies’ findings are consistent
with the operator threshold of 75 procedures per year (47,
306,309,314-320). 
Most studies of the PCI volume-outcome relationship focus
on mortality and emergent bypass surgery as quality-deter-
mining outcome variables. These variables, while important,
encompass only a portion of the overall quality determinants
for PCI.
McGrath et al. examined volume outcome relationships
using procedures performed on 167 208 Medicare recipients
in 1997 (321). Procedures performed by low-volume physi-
cians (fewer than 30 Medicare procedures per year) had a
greater emergency CABG rate (2.25%) than procedures per-
formed by high-volume physicians (more than 60 Medicare
procedures per year; 1.55%, P less than 0.001). An increased
30-day mortality rate was found for low-volume programs
(fewer than 80 Medicare procedures per year) versus high-
volume programs (more than 160 Medicare procedures per
year; 4.29% vs 3.15%, P less than 0.001).
Kimmel et al., using data from the SCAI, found that an
inverse relationship existed between the number of angio-
plasty procedures performed at a hospital and the rate of
major complications (315). These results were risk stratified
and independent of the patient-risk profile. Significantly
fewer complications occurred in laboratories that performed
at least 400 angioplasty procedures per year.
Jollis et al. found that low-volume hospitals were associat-
ed with higher rates of emergency coronary artery bypass
surgery and death (316). Improved outcomes were identified
with a threshold volume of 75 Medicare angioplasties per
physician and 200 Medicare angioplasty procedures per hos-
pital. Using a 35% to 50% ratio of Medicare patients, the
threshold value was 150 to 200 angioplasty procedures per
cardiologist and 400 to 600 angioplasty procedures per insti-
tution (322). 
Epstein et al., using an administrative data set, analyzed
risk-adjusted mortality in 362748 admissions to 1000 United
States hospitals between 1997 and 2000 during which a PCI
was performed (323). They found a consistent trend of
decreasing risk-adjusted mortality with increasing hospital
volume. The differences between groups were small, and
there was considerable heterogeneity within groups, which
indicates that hospital volume is not the sole determinant of
outcome. 
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obtained by operators who are highly experienced both in
elective PCI and in primary PCI for STEMI who work in
institutions that have established an active program for per-
forming primary PCI for STEMI. 
Operator experience in elective PCI is not sufficient to con-
fer expertise in primary PCI for STEMI. This finding is not
surprising, because there are aspects of procedure conduct
that are unique to primary PCI for STEMI. 
Vakili et al., analyzing primary PCI procedures for STEMI
performed in New York State, found no relationship between
physician total angioplasty procedure volume and mortality
after primary PCI for STEMI but did find an association
between an operator’s primary PCI activity level and the out-
come of primary PCI for STEMI that was independent of the
operator’s experience in elective PCI (328,329). Low-vol-
ume physicians, who performed 1 to 10 primary PCI proce-
dures per year, had an unadjusted mortality rate of 7.1%
compared with 3.8% for physicians who performed 11 or
more primary PCI procedures per year. 
Magid et al. analyzed the National Registry of Myocardial
Infarction (NRMI) database and grouped acute-care hospi-
tals by volume tertiles of primary PCI for STEMI procedures
(327). They found a reduction in risk-adjusted mortality with
increasing hospital volume of PCI: low volume (fewer than
16 procedures), 6.2%; intermediate volume (17 to 48 proce-
dures), 4.5%; and high volume (more than 49 procedures),
3.4% (327). Canon et al. analyzed or reviewed 20 080 con-
secutive patients with STEMI in the NRMI-2 database (330).
A multivariate model was used to show that overall adjusted
mortality was lower as volume increased, with the greatest
reduction in mortality occurring at hospitals performing
more than 3 angioplasties per month (330). Different studies
identified different cutpoints. The relationship between the
studies is graded, and the individual cutpoints are artifacts of
analysis methodology. 
Vakili et al. found a doubling of mortality in STEMI
patients who underwent PCI in hospitals that performed
fewer than 400 total PCI procedures per year compared with
hospitals that performed more than 400 (8.1% vs 4.3%)
(329). Furthermore, they found that high-volume hospitals
that performed more than 56 primary PCI procedures per
year had a nonsignificant trend toward a lower crude mortal-
ity rate (4.0% vs 5.8%), with a multivariate OR for mortali-
ty of 0.53 (0.29 to 1.1). The best outcomes were achieved by
high-volume physicians working in high-volume hospitals
(crude mortality rate 3.7% compared with 7.1% for low-vol-
ume physicians in low-volume hospitals; adjusted relative
risk 0.51, 95% CI 0.26 to 0.99). 
Canto et al. (331) also found a graded relationship between
hospital volume and mortality after PCI for STEMI. The
highest quartile of hospital volume performed more than 33
primary PCIs for STEMI per year and achieved a 28% reduc-
tion in mortality compared with the lowest-volume hospitals.
Appropriateness of Activity Levels as a 
Surrogate for Quality
The documented relationships between activity level and
outcome are statistical associations, and activity level is not
a surrogate for quality. The heterogeneity within hospital
volume groups found by Epstein et al. (323) validates that
activity level is an incomplete surrogate for quality. An activ-
ity level above a threshold value does not guarantee good
quality, and an activity level below a threshold value may not
necessarily indicate lower quality. Thus, high-volume opera-
tors and institutions are not necessarily of uniformly high
quality, and low-volume operators and institutions are not,
by definition, poor.
However, an activity level below a threshold necessarily
raises the question of whether an operator or institution has
sufficient ongoing experience to maintain expertise and
skills. In particular, it is plausible that an operator or institu-
tion that is below a threshold activity level cannot accrue the
necessary ongoing experience to perform complex proce-
dures skillfully, to acquire experience with new techniques
and devices, and to respond effectively to adverse and emer-
gency situations. The emergency response consideration is
particularly relevant, because the likelihood of a serious
complication cannot be predicted from patient baseline char-
acteristics.
Quality Assessed by Outcomes: Statistical Power
Considerations and the Importance of Case Reviews
The quality of both institutions and operators should ulti-
mately be judged through the quality-assessment process as
outlined in Section 4.1. Because expected adverse event rates
are low, a large number of procedures are required to achieve
the requisite statistical power to assign an interpretable con-
fidence interval to an operator’s or a program’s adverse event
rate estimate. Furthermore, adverse event rates cannot be
interpreted without appropriate risk adjustment. 
The first approximation in assessing an operator’s or a pro-
gram’s quality is to compare the actual adverse event rate to
an expected rate as predicted by an accepted risk-prediction
model (ACC-NCDR® model or Dynamic Registry model).
Calculation of an expected adverse event rate can be con-
ducted by entering the characteristics of the group of patients
treated into the model. The model yields an expected adverse
event rate with confidence intervals that can then be com-
pared with the actual event rate. Interpretation of the expect-
ed adverse event rate is complex because of the precision of
the estimate. An arbitrary criterion will need to be applied to
determine whether a particular actual adverse event rate is an
outlier when compared with the expected event rate. For
example, 50% of operators may be expected to have an
adverse event rate above the expected value purely by
chance. Thus, merely being above the predicted mean value
does not automatically identify an operator or a program as
an outlier.
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10.6%. Thus, if 50 cases are performed with 1 adverse event,
it is possible that the true adverse event rate is as high as
10.6%. However, it is also possible that it is as low as 0.05%.
The upper-bound value decreases as the number of cases
increases such that if 400 cases are available, it is only 3.9%. 
If only a small number of cases are available, even if no
adverse events occur, it may be difficult to exclude that an
increased risk of adverse events exists. Figure 4 plots the
upper bound of the 95% CI for very low numbers of cases
Furthermore, valid assessment of an operator’s or an insti-
tution’s actual adverse event rate becomes problematic if the
number of procedures available for analysis is small. The sta-
tistical basis for this issue is illustrated in Figures 3 and 4. 
Figure 3 plots the upper and lower 95% CI bounds of an
observed adverse event rate of 2% (1 adverse event per 50
procedures) as a function of the number of procedures avail-
able for analysis. It demonstrates that if only 50 cases are
available, the upper bound of the confidence interval is
Figure 4. Plot of an actual complication rate of 0% over a procedure number range from 10 to 100. The format is similar to Figure
3. The horizontal line at 0 represents the actual complication rate. The curved line above the horizontal line represents the upper
bound of the 95% confidence interval of the estimate of the complication rate. Note that if 50 procedures are performed without a
complication, the upper bound of the 95% confidence interval of the estimated rate is 6%.
Figure 3. Plot of an actual adverse event rate of 2% over a procedure number range from 25 to 400. The horizontal line at 0.02 rep-
resents the actual adverse event rate. The curved lines above and below the horizontal line represent the upper and lower bounds
of the 95% confidence interval of the estimate of the adverse event rate. Note that as the number of procedures decreases, the
range between the upper and lower bounds increases, which indicates lack of stability of any adverse event rate estimate at pro-
cedure numbers below 200.
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performed with a zero adverse event rate. It demonstrates
that if 10 consecutive cases are performed without a compli-
cation, the upper bound of the 95% CI is 25%. If 50 cases
are performed without an adverse event, the upper bound is
5.8%.
Thus, although it is likely that certain low-volume opera-
tors and institutions perform procedures with acceptable
quality, satisfactory quality is difficult to prove unless a suf-
ficient number of procedures are compiled for analysis. The
quality-assessment process must take the above issues into
consideration. This means that it is essential that institution
and operator outcomes be tracked over sufficiently long
periods of time to assemble a sufficient number of proce-
dures to permit a satisfactory analysis. 
In addition, mere tabulation of adverse event rates, even
with appropriate risk adjustment, is inadequate to judge
operator or program quality. Such tabulations do not address
numerous other quality issues, in particular, appropriateness.
Thus, the quality-assessment process should also conduct
detailed reviews both of cases that have adverse outcomes
(to determine the cause(s) of the adverse event) and of
uncomplicated cases (to judge case selection appropriate-
ness and procedure execution quality). These reviews should
be conducted by recognized experienced interventionalists
drawn either from within the institution or externally if a
requisite number of appropriately qualified, unconflicted
individuals are not available.
Role of Low-Volume PCI Programs
There is an ongoing debate as to whether PCI services
should be diffused widely to be available in most healthcare
institutions or whether the service should be regionalized
and concentrated in specialized high-volume centers. Given
the widespread availability of sophisticated interventional/
surgical programs in the United States, it is difficult to
demonstrate a need for additional low-volume programs to
perform elective angioplasty except in underserved areas
that are geographically distant from major centers. At this
writing, outcome data that link activity level to outcomes
indicate that the development of small cardiovascular surgi-
cal programs to support angioplasty is a poor use of
resources that will likely lead to suboptimal results (320). In
general, the proliferation of small angioplasty or small sur-
gical programs to support such angioplasty programs is not
needed to improve patient access to PCI services and would
appear not to be in the interest of fostering optimal quality;
thus, it should be discouraged. An exception to this principle
should be when geographic considerations become impor-
tant determinants of patient access.
These data support the conclusion that not every cardiolo-
gist desiring to perform PCI should perform these proce-
dures, and not every hospital that would like to have an
interventional program should start one (322). This caveat is
particularly true where high-volume programs and operators
are already nearby. 
The Writing Committee, therefore, recommends that elec-
tive PCI be performed by higher-volume operators (75 cases
per year) with advanced technical skills (e.g., subspecialty
certification) at institutions with fully equipped interven-
tional laboratories and an experienced support staff. This
setting is optimally a high-volume center (more than 400
cases per year) with an onsite cardiovascular surgical pro-
gram (332). 
It is recommended that primary PCI for STEMI be per-
formed by higher-volume operators experienced in both
elective PCI and primary PCI for STEMI with ongoing
activity levels of more than 75 elective PCI procedures per
year and, ideally, annual PCI for STEMI activity levels of at
least 11 per year. It is clear that an effective PCI for STEMI
program, irrespective of whether cardiac surgery is available
onsite, requires appropriate physician operator expertise,
appropriate institutional commitment, and the achievement
of the requisite utilization levels. The nursing and technical
catheterization laboratory staff must be experienced in han-
dling acutely ill patients, must be skilled in all aspects of
interventional equipment, and must participate in a 24-
hours-per-day, 365-days-per-year call schedule. Ideally,
these procedures should be performed in institutions that
perform more than 400 elective PCIs per year and more than
36 primary PCIs for STEMI per year and that achieve risk-
adjusted outcomes that are comparable to national bench-
mark standards. 
The Writing Committee cannot recommend angioplasty by
low-volume operators (fewer than 75 cases per year) work-
ing in low-volume institutions (200 to 400 cases per year)
with or without onsite surgical coverage. As noted earlier,
ongoing investigational experience and clinical data are
mandatory if these recommendations are to be modified.
Any change in this recommendation awaits further data
assessing the safety and outcomes for patients treated in var-
ious settings.
4.3. Role of Onsite Cardiac Surgical Back-Up
Class I
1. Elective PCI should be performed by operators with
acceptable annual volume (at least 75 procedures per
year) at high-volume centers (more than 400 proce-
dures annually) that provide immediately available
onsite emergency cardiac surgical services. (Level of
Evidence: B)
2. Primary PCI for patients with STEMI should be per-
formed in facilities with onsite cardiac surgery. (Level
of Evidence: B)
Class III
Elective PCI should not be performed at institutions
that do not provide onsite cardiac surgery. (Level of
Evidence: C)*
*Several centers have reported satisfactory results based on careful
case selection with well-defined arrangements for immediate trans-
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Many emergency surgery patients did not receive a coronary
stent, which indicates that either a stent delivery was not fea-
sible or a stent would not solve the problem that required
surgical intervention. Data from the ACC-NCDR® indicate
that PCI programs staffed by highly experienced practition-
ers still experience a 0.4% likelihood of a patient requiring
emergency cardiac surgery for a complication that developed
during a procedure. Roughly half of patients who require
emergency surgery are severely hemodynamically unstable
at the time of transfer to the operating room. Furthermore,
analyses of series of patients requiring emergency cardiac
surgery indicate that patient baseline characteristics do not
predict the risk of the need for emergency surgery (305,342). 
It has been argued that a well-planned strategy to provide
rapid transfer to a surgical center in the event of a complica-
tion is tantamount to providing onsite surgical backup sup-
port. Such strategies are unrealistic because they are logisti-
cally difficult to achieve and require that a critically ill
patient be transported outside of a hospital environment, pos-
sibly without a physician in attendance. Furthermore, if an
institution without cardiac surgery is sufficiently close to one
that provides surgery to permit sufficiently timely transfer,
there is little justification for not transferring the patient elec-
tively in the first place.
Although individual programs have reported successful
results, the national experience with PCI programs at institu-
tions that do not offer onsite cardiac surgery has been less
satisfactory. Wennberg et al. (356) analyzed the Medicare
database for a 2-year period from 1999 to 2001 (when stents
and IIb/IIIa inhibitors were in widespread use). They identi-
fied 178 hospitals without onsite cardiac surgical facilities
and 943 hospitals with onsite cardiac surgery that performed
PCI during that period. After adjusting for baseline differ-
ences, they found similar mortality rates in patients who
underwent primary PCI for STEMI. However, for the larger
nonprimary/rescue PCI population, mortality was higher in
hospitals without onsite cardiac surgery (adjusted OR 1.38;
95% CI 1.14 to 1.67; P equals 0.001). This increase in mor-
tality was primarily confined to hospitals that performed 50
or fewer Medicare PCIs per year. This experience is consis-
tent with the concept that expansion of PCI services outside
of large, full-service centers creates small, low-volume pro-
grams with inadequate infrastructure that are not able to per-
form PCI at the same level of sophistication and quality that
a larger institution can.
This Writing Committee concludes that performance of
elective PCI in a setting without immediately available
onsite cardiac surgery potentially compromises patient safe-
ty and is not recommended. Although the frequency of PCI
complications for which the outcome is favorably affected by
prompt surgery is small, it is nonetheless finite.
Consequently, performance of PCI in such a setting exposes
the patient to a small but very real additional and medically
unnecessary risk. In addition, an institution without an estab-
lished cardiac surgery program is likely to be a low-volume
institution less able to offer as high quality PCI service as a
larger, full-service institution. Therefore, at this time, the
fer to a surgical program (333-337,348-353). A small, but real frac-
tion of patients undergoing elective PCI will experience a life-threat-
ening complication that could be managed with the immediate onsite
availability of cardiac surgical support but cannot be managed effec-
tively by urgent transfer. Wennberg, et al., found higher mortality in
the Medicare database for patients undergoing elective PCI in insti-
tutions without onsite cardiac surgery (356). This recommendation
may be subject to revision as clinical data and experience increase. 
The purpose of cardiac surgical backup for PCI is to pro-
vide emergent hemodynamic support and revascularization
to salvage complications that cannot be addressed by
catheter-based techniques. PCI can be complicated by life-
threatening hemodynamic and ischemic emergencies that
can be addressed only by the availability of emergency car-
diac surgery. The role of onsite cardiac surgical backup is 2-
fold: onsite cardiac surgical backup provides prompt avail-
ability of cardiac surgical support in the event of a hemody-
namic or ischemic emergency, and onsite cardiac surgical
backup is a surrogate for an institution’s overall capability to
provide a highly experienced and promptly available team to
respond to a catheterization laboratory emergency.
Cardiac surgical backup for PCI has evolved from a formal
surgical standby in the 1980s to an informal arrangement of
first-available operating room and, in some cases, off-site
surgical backup (44,333-337). With the advent of intracoro-
nary stenting, there has been a decrease in the need for emer-
gency CABG ranging between 0.4% and 2% (49,305,338-
342). Not surprisingly, emergency CABG surgery for a
patient with an occluded or dissected coronary artery is asso-
ciated with a higher mortality than elective surgery (146,343-
347). Emergency procedures are also associated with high
rates of perioperative infarction and less frequent use of arte-
rial conduits. Complex CAD intervention, hemodynamic
instability, and prolonged time to reperfusion are contribut-
ing factors to the increased risk of emergency bypass surgery. 
Technical improvements in PCI instruments and technique
have led to the concept that the requirement for emergency
cardiac surgery is sufficiently rare that PCI can be performed
safely without onsite surgery. This has led to the develop-
ment of elective angioplasty programs without onsite surgi-
cal coverage. Several centers have reported satisfactory
results based on careful case selection with well-defined
arrangements for immediate transfer to a surgical program
(333-337,348-352). These studies of angioplasty without
onsite surgical coverage have not identified significant dif-
ferences in the outcomes, which recalls the infrequent rate of
complications (353). Despite many reported successful
angioplasty series without onsite surgical backup and a very
low percentage of need for off-site surgery in failed angio-
plasty, some clinicians have expressed concern (354,355)
about the appropriateness of elective angioplasty in centers
without onsite surgical coverage. 
Even with current interventional techniques, life-threaten-
ing complications requiring surgical intervention still occur.
Such complications include left main coronary dissection,
spiral coronary trunk dissection, and coronary perforation.
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raised the question of whether primary PCI should be per-
formed at institutions with diagnostic cardiac catheterization
laboratories that do not perform elective PCI or have onsite
cardiac surgery. For this reason, the establishment of PCI
programs at institutions without onsite cardiovascular sur-
gery has been promoted as necessary to maintain quality of
care (333-335,367-376). 
PCI in the early phase of a STEMI requires a cognitive
knowledge base and technical skill set that is somewhat dif-
ferent from that required to perform elective PCI. Primary
PCI for STEMI can be technically difficult and requires even
more skill and experience than routine PCI in the stable
patient. The linkage between experience in performing elec-
tive PCI and primary PCI is incomplete (328). A successful
primary PCI program requires an experienced operator and
an experienced laboratory technical staff accustomed to
managing critically ill patients (377). In addition, it is neces-
sary to have available a broad range of catheters, guidewires,
stents, and other devices (e.g., IABP) that are required to
achieve results in an acutely ill patient (Table 15) (368). 
Observational data from large, multi-institutional data sets
have demonstrated that patients with STEMI who are treated
with primary PCI performed by interventionalists with limit-
ed experience at institutions with low volume experience
outcomes comparable to those achieved by fibrinolytic ther-
apy (331). Thus, the benefits of primary PCI for STEMI
require the infrastructure of a well-organized program with
requisite experience and capabilities. In the absence of such
capabilities, either onsite fibrinolytic therapy or transfer to a
center that routinely performs complex PCI will often be a
more effective and efficient course of action (123). The
Danish Myocardial Infarction Study (DANAMI-2) demon-
strated superior results in patients with STEMI who were
urgently transferred to an experienced PCI center compared
with those for whom fibrinolytic therapy was administered
locally. In addition, the results in patients emergently trans-
ferred for primary PCI were comparable to those achieved in
patients receiving primary PCI who initially presented to the
PCI center institution (378). Nonetheless, fibrinolysis
remains an acceptable form of therapy (379) and is likely
preferable to acute PCI by an inexperienced team (62,379). 
There are important institutional considerations in creating
an effective program of primary PCI for STEMI. An institu-
tion must commit its catheterization facility to be capable of
a 24-hours-per-day, 7-days-per-week rapid response to a
patient presenting with STEMI. In addition, the institution’s
catheterization facility staff must be sufficiently trained and
experienced in the management of the seriously ill patient
with STEMI. In general, this means that the institution best
positioned to provide effective PCI for STEMI is the institu-
tion with an active high-quality elective PCI program. 
It has been demonstrated that institutions without an elec-
tive PCI program that care for a large number of patients
with STEMI can create high-quality programs of PCI for
STEMI. These programs require the 24-hours-per-day, 7-
days-per-week availability of experienced interventionalists
and an institutional commitment to invest in the physical and
Writing Committee continues to support the recommenda-
tion that elective PCI should not be performed in facilities
without onsite cardiac surgery. Mere convenience should not
replace safety and efficacy in establishing an elective PCI
program without onsite surgery. As with many dynamic areas
in interventional cardiology, these recommendations may be
subject to revision as clinical data and experience increase.
4.4. Primary PCI for STEMI Without 
Onsite Cardiac Surgery
Class IIb
Primary PCI for patients with STEMI might be con-
sidered in hospitals without onsite cardiac surgery,
provided that appropriate planning for program
development has been accomplished, including appro-
priately experienced physician operators (more than
75 total PCIs and, ideally, at least 11 primary PCIs per
year for STEMI), an experienced catheterization team
on a 24 hours per day, 7 days per week call schedule,
and a well-equipped catheterization laboratory with
digital imaging equipment, a full array of interven-
tional equipment, and intra-aortic balloon pump
capability, and provided that there is a proven plan
for rapid transport to a cardiac surgery operating
room in a nearby hospital with appropriate hemody-
namic support capability for transfer. The procedure
should be limited to patients with STEMI or MI with
new or presumably new left bundle-branch block on
ECG and should be performed in a timely fashion
(goal of balloon inflation within 90 minutes of presen-
tation) by persons skilled in the procedure (at least 75
PCIs per year) and at hospitals performing a mini-
mum of 36 primary PCI procedures per year. (Level of
Evidence: B)
Class III
Primary PCI should not be performed in hospitals
without onsite cardiac surgery and without a proven
plan for rapid transport to a cardiac surgery operat-
ing room in a nearby hospital or without appropriate
hemodynamic support capability for transfer. (Level
of Evidence: C)
Fibrinolytic trials in STEMI have demonstrated that early
reperfusion saves myocardium and reduces mortality (357-
360). Randomized trials comparing primary PCI for STEMI
have shown that primary PCI performed by a highly experi-
enced team achieves superior results. Primary PCI, com-
pared with fibrinolytic therapy, has achieved modest reduc-
tions in overall mortality, but its overall benefit is chiefly
leveraged by a reduction in early recurrent ischemic events
(361-364). 
In patients who have a contraindication to fibrinolytic ther-
apy, or when there are complications such as cardiogenic
shock, catheter-based therapy may limit infarct size
(365,366). Thus, the potential overall superiority and greater
applicability of primary PCI for the treatment of STEMI has
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may choose to concentrate PCI in a subset of its healthcare
institutions, identifying well-qualified and experienced cen-
ters to perform this procedure. Suboptimal results may relate
to operator/staff inexperience and capabilities and delays in
performing angioplasty for logistical reasons (382). 
From clinical data and expert consensus, the Writing
Committee recommends that primary PCI for STEMI per-
formed at hospitals without established elective PCI pro-
grams be restricted to those institutions capable of perform-
ing a requisite minimum number of primary angioplasty pro-
cedures (36 per year) by highly experienced operators after
careful program development according to the procedures
used by the C-PORT (Cardiovascular Patient Outcomes
Research Team trial) and PAMI-No SOS (PAMI with No
Surgery On Site) studies, including a proven plan for rapid
and effective PCI and rapid access to cardiac surgery in a
nearby facility (383). Although some experience suggests
that an institution can develop an effective stand-alone pri-
mary PCI program, currently available data also indicate that
concentration rather than diffusion of this capability will pro-
vide the most effective patient care. Thus, a strategy of emer-
gency transfer to an established center with a well-developed
primary PCI program is preferred to the development of new
freestanding primary PCI programs.
cognitive resources needed to support a high-quality pro-
gram. The feasibility of such an undertaking was first
demonstrated by Wharton et al. in a 2-center study (368) and
subsequently confirmed in multicenter studies by Aversano
et al. (380) and Wharton et al. (375).
Before the use of stenting and GP receptor blockers, pri-
mary angioplasty in certain hospitals had been associated
with acute mortality rates greater than those reported from
centers with established primary angioplasty programs.
Overall, in-hospital mortality rates have ranged from 1.4% to
13% (334,335,370). 
Criteria have been suggested for the performance of pri-
mary PCI at hospitals without onsite cardiac surgery (Tables
15 and 16) (319,368,381). Of note, large-scale registries have
shown an inverse relationship between the number of pri-
mary angioplasty procedures performed and in-hospital mor-
tality (321,327,331). These data suggest that both door-to-
balloon time and in-hospital mortality are significantly lower
in institutions that perform more than 36 primary angioplas-
ty procedures per year (330). It is important to point out that
these data were achieved in hospitals with established elec-
tive PCI programs, and the numerical data may not extrapo-
late directly to hospitals that perform only primary PCI. 
As an alternative to establishing numerous freestanding,
modest-sized, primary PCI-only programs, a community
Table 15. Criteria for the Performance of Primary PCI at Hospitals Without On-Site Cardiac Surgery
The operators must be experienced interventionalists who regularly perform elective PCI at a surgical center (greater than
or equal to 75 cases per year). The catheterization laboratory must perform a minimum of 36 primary PCI procedures per
year.
The nursing and technical catheterization laboratory staff must be experienced in handling acutely ill patients and must be
comfortable with interventional equipment. They must have acquired experience in dedicated interventional laboratories
at a surgical center. They participate in a 24-hours-per-day, 365-days-per-year call schedule.
The catheterization laboratory itself must be well-equipped, with optimal imaging systems, resuscitative equipment, and
IABP support, and must be well-stocked with a broad array of interventional equipment.
The cardiac care unit nurses must be adept in hemodynamic monitoring and IABP management.
The hospital administration must fully support the program and enable the fulfillment of the above institutional require-
ments.
There must be formalized written protocols in place for immediate and efficient transfer of patients to the nearest cardiac
surgical facility that are reviewed/tested on a regular (quarterly) basis.
Primary PCI must be performed routinely as the treatment of choice around the clock for a large proportion of patients
with AMI, to ensure streamlined care paths and increased case volumes.
Case selection for the performance of primary PCI must be rigorous. Criteria for the types of lesions appropriate for pri-
mary PCI and for the selection for transfer for emergency aortocoronary bypass surgery are shown in Table 14.
There must be an ongoing program of outcomes analysis and formalized periodic case review.
Institutions should participate in a 3- to 6-month period of implementation, during which time development of a formal-
ized primary PCI program is instituted that includes establishment of standards, training of staff, detailed logistic devel-
opment, and creation of a quality-assessment and error-management system.
AMI indicates acute myocardial infarction; IABP, intra-aortic balloon pump; and PCI, percutaneous coronary intervention. 
Adapted with permission from Wharton et al. J Am Coll Cardiol 1999;33:1257-65 (368).
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not been reduced to negligible levels. A small but valid frac-
tion of patients undergoing elective PCI will experience a
life-threatening complication that could be managed with the
immediate onsite availability of cardiac surgical support but
cannot be managed effectively by urgent transfer. Lotfi et al.
reported the experience of a large, high-quality coronary
interventional center (384). Of 6582 PCI procedures per-
formed between 1996 and 2000, 45 (0.7%) required emer-
gency cardiac surgery. Of the 45 patients, 11 (0.2%) required
truly emergent surgery because they were too unstable to tol-
erate an interhospital transfer. Thus, under the best of cir-
cumstances 1 in 500 patients undergoing elective PCI will
experience a life-threatening complication that can be sal-
vaged by immediate access to onsite cardiac surgery. As pre-
viously noted, Section 4.4, Wennberg, et al., found higher
mortality in the Medicare database for patients undergoing
elective PCI in institutions without onsite cardiac surgery
(356). Furthermore, the availability of onsite cardiac surgery
is a surrogate for overall program size and capability, as well
as for the availability of many other experienced support
services. 
Caution is warranted before an unrestricted policy for PCI
in hospitals without appropriate facilities is endorsed.
Several outstanding and critically important clinical issues,
such as timely management of ischemic complications, ade-
quacy of specialized postinterventional care, logistics for
managing cardiac surgical or vascular complications and
operator/laboratory volumes, and accreditation, must be
addressed. Mere convenience should not replace safety and
efficacy in the establishment of an elective PCI program
without onsite surgery. 
At this time, the Writing Committee, therefore, continues
to support the recommendation that elective PCI should not
be performed in facilities without onsite cardiac surgery. As
with many dynamic areas in interventional cardiology, these
recommendations may be subject to revision as clinical data
and experience increase.
5. CLINICAL PRESENTATIONS
A broad spectrum of clinical presentations exists wherein
patients may be considered candidates for PCI, ranging from
asymptomatic to severely symptomatic or unstable, with
variable degrees of jeopardized myocardium. In this guide-
line, the CCS classification system for grading angina pec-
toris is used to summarize the severity of angina, as shown
below (Table 17) (385).
Each time a patient is considered for revascularization, the
potential risk and benefits of the particular procedure under
consideration must be weighed against alternative therapies
(Table 18). When PCI is considered, the benefits and risks of
surgical revascularization and medical therapy always
deserve thoughtful discussion with the patient and family.
The initial simplicity and associated low morbidity of PCI
compared with surgical therapy is always attractive, but the
patient and family must understand the limitations inherent
in current PCI procedures, including a realistic presentation
4.5. Elective PCI Without Onsite Surgery
Class III
Elective PCI should not be performed at institutions
that do not provide onsite cardiac surgery. (Level of
Evidence: C)*
*Several centers have reported satisfactory results based on careful
case selection with well-defined arrangements for immediate transfer
to a surgical program (333-337,348-353). A small, but real fraction of
patients undergoing elective PCI will experience a life-threatening
complication that could be managed with the immediate onsite avail-
ability of cardiac surgical support but cannot be managed effectively
by urgent transfer. Wennberg et al., found higher mortality in the
Medicare database for patients undergoing elective PCI in institu-
tions without onsite cardiac surgery (356). This recommendation
may be subject to revision as clinical data and experience increase. 
Technical improvements in interventional cardiology have
led to the development of elective angioplasty programs
without onsite surgical coverage. Several centers have
reported satisfactory results based on careful case selection
with well-defined arrangements for immediate transfer to a
surgical program (333-337,348-353). The studies of angio-
plasty without onsite surgical coverage have not identified
significant differences in outcomes, which recalls the infre-
quent rate of complications (353). Despite many reported
successful angioplasty series without onsite surgical backup
and a very low percentage need for off-site surgery in failed
angioplasty, some clinicians have expressed concern
(354,355) about the appropriateness of elective angioplasty
in centers without onsite surgical coverage. Life-threatening
complications of elective PCI are, fortunately, rare but have
Table 16. Patient Selection for Primary PCI and Emergency
Aortocoronary Bypass at Hospitals Without On-Site Cardiac Surgery
Avoid intervention in hemodynamically stable patients with:
Significant (greater than or equal to 60%) stenosis of an unprotected
left main coronary artery upstream from an acute occlusion in the
left coronary system that might be disrupted by the angioplasty
catheter
Extremely long or angulated infarct-related lesions with TIMI grade
3 flow
Infarct-related lesions with TIMI grade 3 flow in stable patients with
3-vessel disease (319, 381)
Infarct-related lesions of small or secondary vessels
Hemodynamically significant lesions in other than the infarct artery
Transfer for emergency aortocoronary bypass surgery patients
with:
High-grade residual left main or multivessel coronary disease and
clinical or hemodynamic instability present after primary PCI of
occluded vessels, preferably with IABP support.
IABP indicates intra-aortic balloon pump; PCI, percutaneous coronary intervention; and
TIMI, Thrombolysis In Myocardial Infarction.
Adapted with permission from Wharton et al. J Am Coll Cardiol 1999;33:1257-65 (368).
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Class IIb
1. The effectiveness of PCI for patients with asympto-
matic ischemia or CCS class I or II angina who have
2- or 3-vessel disease with significant proximal LAD
CAD who are otherwise eligible for CABG with 1
arterial conduit and who have treated diabetes or
abnormal LV function is not well established. (Level of
Evidence: B)
2. PCI might be considered for patients with asympto-
matic ischemia or CCS class I or II angina with non-
proximal LAD CAD that subtends a moderate area of
viable myocardium and demonstrates ischemia on
noninvasive testing. (Level of Evidence: C)
Class III
PCI is not recommended in patients with asympto-
matic ischemia or CCS class I or II angina who do not
meet the criteria as listed under the class II recom-
mendations or who have 1 or more of the following: 
a. Only a small area of viable myocardium at risk
(Level of Evidence: C)
b. No objective evidence of ischemia. (Level of
Evidence: C)
c. Lesions that have a low likelihood of successful
dilatation. (Level of Evidence: C)
d. Mild symptoms that are unlikely to be due to
myocardial ischemia. (Level of Evidence: C)
e. Factors associated with increased risk of morbidity
or mortality. (Level of Evidence: C)
f. Left main disease and eligibility for CABG. (Level
of Evidence: C)
g. Insignificant disease (less than 50% coronary
stenosis). (Level of Evidence: C)
In the previous ACC/AHA guidelines for PCI, specific rec-
ommendations were made separately for patients with sin-
gle-vessel or multivessel disease (1,123). The current tech-
niques of PCI have matured to the point at which, in patients
with favorable anatomy, the competent practitioner can per-
form either single-vessel or multivessel PCI with low risk
and with a high likelihood of initial success. For this reason,
in this update of the guidelines, recommendations have been
made largely based on the patient’s clinical condition, spe-
of the likelihood of restenosis and the potential for incom-
plete revascularization compared with CABG surgery. In
patients with CAD who are asymptomatic or have only mild
symptoms, the potential benefit of antianginal drug therapy
along with an aggressive program of risk reduction must also
be understood by the patient before a revascularization pro-
cedure is performed. In those clinical settings in which PCI
is recommended without evidence that it will reduce cardio-
vascular mortality but in which it does hold a promise to
reduce symptoms, a class IIa or IIb classification has been
chosen, which indicates a role for patient preference.
5.1. Patients With Asymptomatic Ischemia or 
CCS Class I or II Angina
Class IIa
1. PCI is reasonable in patients with asymptomatic
ischemia or CCS class I or II angina and with 1 or
more significant lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of success and
a low risk of morbidity and mortality. The vessels to
be dilated must subtend a moderate to large area of
viable myocardium or be associated with a moderate
to severe degree of ischemia on noninvasive testing.
(Level of Evidence: B)
2. PCI is reasonable for patients with asymptomatic
ischemia or CCS class I or II angina, and recurrent
stenosis after PCI with a large area of viable
myocardium or high-risk criteria on noninvasive test-
ing. (Level of Evidence: C)
3. Use of PCI is reasonable in patients with asympto-
matic ischemia or CCS class I or II angina with sig-
nificant left main CAD (greater than 50% diameter
stenosis) who are candidates for revascularization but
are not eligible for CABG. (Level of Evidence: B)
Table 17. Grading of Angina Pectoris According to CCS
Classification
Class Description of Stage
I “Ordinary physical activity does not cause…angina,” such 
as walking or climbing stairs. Angina occurs with strenuous,
rapid, or prolonged exertion at work or recreation.
II “Slight limitation of ordinary activity.” Angina occurs on
walking or climbing stairs rapidly; walking uphill; walking
or stair climbing after meals; in cold, in wind, or under emo-
tional stress; or only during the few hours after awaking.
Angina occurs on walking more than 2 blocks on the level
and climbing more than 1 flight of ordinary stairs at a nor-
mal pace and under normal conditions.
III “Marked limitations of ordinary physical activity.” Angina
occurs on walking 1 to 2 blocks on the level and climbing1
flight of stairs under normal conditions and at a normal pace.
IV “Inability to carry on any physical activity without discom-
fort—anginal symptoms may be present at rest.”
CCS indicates Canadian Cardiovascular Society.
Adapted with permission from Campeau. Circulation 1976;54:522-3 (385).
Table 18. Provider Checklist: Key Areas for Consideration
Patients at High Risk
Assess key clinical and anatomic variables 
Consider alternative therapies such as CABG in consultation with
the patient
Ensure that formalized surgical standby is available
Ensure periprocedural hemodynamic support is available
Patients at Low Risk
Assess key clinical and anatomic variables
Consider alternative therapies such as medical therapy in consulta-
tion with the patient
CABG indicates coronary artery bypass graft surgery.
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cific coronary lesion morphology and anatomy, LV function,
and associated medical conditions, and less emphasis has
been placed on the number of lesions or vessels requiring
PCI. The CCS classification of angina (I to IV) is used to
define the severity of symptoms. The categories described in
this section refer to an initial PCI procedure in a patient with-
out prior CABG surgery. The randomized trials comparing
PCI and medical therapy have been discussed (Table 12)
(11,12,279,282-290). 
The Writing Committee recognizes that the majority of
patients with CCS class I or II angina should be treated med-
ically. The published ACIP study (301) casts some doubt on
the wisdom of medical management for those higher-risk
patients who are asymptomatic or have mild angina but have
objective evidence by both treadmill testing and ambulatory
monitoring of significant myocardial ischemia and CAD. In
addition, a substantial portion of the middle-aged and older-
age populations in the United States remain physically
active, participating in sports, such as tennis and skiing, or
performing regular and vigorous physical exercise, such as
jogging, have CAD. For such individuals with moderate or
severe ischemia and few symptoms, revascularization with
PCI or CABG surgery may reduce their risk of serious or
fatal cardiac events (301). For this reason, patients in this cat-
egory of higher-risk asymptomatic ischemia or mild symp-
toms and severe anatomic CAD are placed in class IIa or IIb
recommendations. PCI may be considered if there is a high
likelihood of success and a low risk of morbidity or mortali-
ty. The judgment of the experienced physician is deemed
valuable in assessing the extent of ischemia.
5.2. Patients With CCS Class III Angina
Class IIa
1. It is reasonable that PCI be performed in patients
with CCS class III angina and single-vessel or multi-
vessel CAD who are undergoing medical therapy and
who have 1 or more significant lesions in 1 or more
coronary arteries suitable for PCI with a high likeli-
hood of success and low risk of morbidity or mortali-
ty. (Level of Evidence: B)
2. It is reasonable that PCI be performed in patients
with CCS class III angina with single-vessel or multi-
vessel CAD who are undergoing medical therapy with
focal saphenous vein graft lesions or multiple stenoses
who are poor candidates for reoperative surgery.
(Level of Evidence: C)
3. Use of PCI is reasonable in patients with CCS class III
angina with significant left main CAD (greater than
50% diameter stenosis) who are candidates for revas-
cularization but are not eligible for CABG. (Level of
Evidence: B)
Class IIb
1. PCI may be considered in patients with CCS class III
angina with single-vessel or multivessel CAD who are
undergoing medical therapy and who have 1 or more
lesions to be dilated with a reduced likelihood of suc-
cess. (Level of Evidence: B)
2. PCI may be considered in patients with CCS class III
angina and no evidence of ischemia on noninvasive
testing or who are undergoing medical therapy and
have 2- or 3-vessel CAD with significant proximal
LAD CAD and treated diabetes or abnormal LV func-
tion. (Level of Evidence: B)
Class III
PCI is not recommended for patients with CCS class
III angina with single-vessel or multivessel CAD, no
evidence of myocardial injury or ischemia on objec-
tive testing, and no trial of medical therapy, or who
have 1 of the following:
a. Only a small area of myocardium at risk. (Level of
Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of suc-
cess. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mor-
tality. (Level of Evidence: C)
d. Insignificant disease (less than 50% coronary
stenosis). (Level of Evidence: C)
e. Significant left main CAD and candidacy for
CABG. (Level of Evidence: C)
The primary benefit of PCI among patients with CCS class
III angina and single-vessel or multivessel CAD resides in
the relief of symptoms, which may be accomplished with
medical therapy. However, many patients with moderate or
severe stable angina do not respond adequately to medical
therapy and often have significant coronary artery stenoses
that are suitable for revascularization with CABG surgery or
PCI. In addition, a proportion of these patients have reduced
LV systolic function, which places them in a group that is
known to have improved survival with CABG surgery and
possibly with revascularization by PCI (386-389). In patients
without diabetes with 1- or 2-vessel disease in whom angio-
plasty of 1 or more lesions has a high likelihood of initial
success, PCI is the preferred approach. In a minority of such
patients, CABG surgery may be preferred, particularly for
those in whom the LAD can be revascularized with the IMA
or in those with left main coronary disease. (See Section
3.5.1.2 on left main CAD.)
5.3. Patients With UA/NSTEMI
Class I
An early invasive PCI strategy is indicated for
patients with UA/NSTEMI who have no serious
comorbidity and coronary lesions amenable to PCI.
Patients must have any of the following high-risk fea-
tures:
a. Recurrent ischemia despite intensive anti-ischemic
therapy. (Level of Evidence: A)
b. Elevated troponin level. (Level of Evidence: A)
c. New ST-segment depression. (Level of Evidence: A)
d. HF symptoms or new or worsening MR. (Level of
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e. Significant left main CAD and candidacy for
CABG. (Level of Evidence: B)
Clinical investigations have evaluated the use of routine
catheterization and PCI for patients with UA or NSTEMI and
have yielded inconsistent results. TIMI-IIIB was the first
trial to compare strategies of routine catheterization and
revascularization in addition to medical therapy and selective
use of aggressive treatment. In TIMI-IIIB, there was no dif-
ference in the incidence of death or recurrent MI at 1 year
between the 2 strategies, but patients treated by the aggres-
sive strategy experienced less angina and repeat hospitaliza-
tions for ischemia and required fewer medications (390). In
the VANQWISH trial (Veterans Affairs Non–Q-Wave
Infarction Strategies in Hospital) performed by the US
Veterans Administration, no difference in death or death and
MI was observed between the 2 strategies at late follow-up,
but the minority of patients in the aggressive strategy
received revascularization, and the mortality rate for those
having CABG was high (391). The FRISC II trial compared
medical and revascularization approaches among patients
after 6 days of low-molecular-weight heparin therapy before
a decision regarding PCI (304). Those randomized to the
conservative therapy only underwent PCI if they had at least
3 mm of ST-segment depression on stress testing. Compared
with prior studies, patients assigned to the aggressive strate-
gy in FRISC II experienced a 22% reduction (P equals
0.031) in the incidence of death or MI at 6 months (9.4%)
compared with conservatively treated patients (12.1%). In
addition, there was a significant decrease in the MI rate alone
and a nonsignificantly lower mortality rate in the treated
group (1.9% vs 2.9%; P equals 0.10). Symptoms of angina
and hospital readmission were decreased 50% by the inva-
sive strategy. These findings were supported by long-term
follow-up from the FRISC II study that indicated that low-
molecular-weight heparin and early intervention lowered the
risk of death, MI, and revascularization in unstable coronary
syndromes, at least during the first month of therapy. Early
protective therapy could be used to reduce the risk of late
events in patients waiting for definitive PCI (392). This treat-
ment benefit was most pronounced for high-risk patients.
The FRISC II trial (304) results support the use of catheteri-
zation and revascularization for selected patients with an
acute coronary syndrome. The TACTICS trial randomized
2220 patients to an early invasive strategy in which cardiac
catheterization and revascularization were performed 4 to 48
h after randomization or to a conservative strategy in which
revascularization was reserved for those patients who devel-
oped recurrent ischemia after medical stabilization (393). All
patients were treated with aspirin, heparin, beta-blockers,
cholesterol-lowering therapy, and tirofiban. The primary end
point, a composite of death, MI, and rehospitalization for
worsening chest pain by 6 months, was lower in patients
assigned to the invasive strategy (15.9% vs 19.4% in patients
assigned to conservative therapy; P equals 0.0025). The rate
of death or MI was also significantly reduced at 6 months in
the invasive strategy arm (7.3% vs 9.5% in patients assigned
Evidence: A)
e. Depressed LV systolic function. (Level of Evidence:
A)
f. Hemodynamic instability. (Level of Evidence: A)
g. Sustained ventricular tachycardia. (Level of
Evidence: A)
h. PCI within 6 months. (Level of Evidence: A)
i. Prior CABG. (Level of Evidence: A)
Class IIa
1. It is reasonable that PCI be performed in patients
with UA/NSTEMI and single-vessel or multivessel
CAD who are undergoing medical therapy with focal
saphenous vein graft lesions or multiple stenoses who
are poor candidates for reoperative surgery. (Level of
Evidence: C)
2. In the absence of high-risk features associated with
UA/NSTEMI, it is reasonable to perform PCI in
patients with amenable lesions and no contraindica-
tion for PCI with either an early invasive or early
conservative strategy. (Level of Evidence: B)
3. Use of PCI is reasonable in patients with UA/NSTE-
MI with significant left main CAD (greater than 50%
diameter stenosis) who are candidates for revascular-
ization but are not eligible for CABG. (Level of
Evidence: B)
Class IIb
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI may be considered in patients with
single-vessel or multivessel CAD who are undergoing
medical therapy and who have 1 or more lesions to be
dilated with reduced likelihood of success. (Level of
Evidence: B)
2. PCI may be considered in patients with UA/NSTEMI
who are undergoing medical therapy who have 2- or
3-vessel disease, significant proximal LAD CAD, and
treated diabetes or abnormal LV function. (Level of
Evidence: B)
Class III
In the absence of high-risk features associated with
UA/NSTEMI, PCI is not recommended for patients
with UA/NSTEMI who have single-vessel or multi-
vessel CAD and no trial of medical therapy, or who
have 1 or more of the following: 
a. Only a small area of myocardium at risk. (Level of
Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of suc-
cess. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or
mortality. (Level of Evidence: C)
d. Insignificant disease (less than 50% coronary
stenosis). (Level of Evidence: C)
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shock, unless further support is futile because of the
patient’s wishes or contraindications/unsuitability for
further invasive care. (Level of Evidence: A)
3. Primary PCI should be performed in patients with
severe congestive heart failure and/or pulmonary
edema (Killip class 3) and onset of symptoms within
12 hours. The medical contact-to-balloon or door-to-
balloon time should be as short as possible (i.e., goal
within 90 minutes). (Level of Evidence: B)
Class IIa
1. Primary PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block or who develop shock within 36 hours of MI and
are suitable for revascularization that can be per-
formed within 18 hours of shock. Patients with good
prior functional status who are suitable for revascu-
larization and agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform primary PCI for patients
with onset of symptoms within the prior 12 to 24
hours and 1 or more of the following: 
a. Severe congestive heart failure (Level of Evidence:
C)
b. Hemodynamic or electrical instability (Level of
Evidence: C)
c. Evidence of persistent ischemia (Level of Evidence:
C)
Class IIb
The benefit of primary PCI for STEMI patients eligi-
ble for fibrinolysis when performed by an operator
who performs fewer than 75 PCI procedures per year
(or fewer than 11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
Class III
1. Elective PCI should not be performed in a non-
infarct-related artery at the time of primary PCI of
the infarct related artery in patients without hemody-
namic compromise. (Level of Evidence: C)
2. Primary PCI should not be performed in asympto-
matic patients more than 12 hours after onset of
STEMI who are hemodynamically and electrically
stable. (Level of Evidence: C)
Acute STEMI results from a severe and sudden cessation
of myocardial blood flow, most commonly due to athero-
sclerotic-thrombotic occlusion of a major epicardial coro-
nary artery. PCI is a very effective method for re-establishing
coronary perfusion and is suitable for 90% of patients.
Considerable data support the use of PCI for patients with
STEMI (53,364,398). Reported rates of achieving TIMI 3
flow, the goal of reperfusion therapy, range from 70% to 90%
(399). Late follow-up angiography demonstrates that 87% of
infarct arteries remain patent (400). Although most studies of
primary PCI have been in patients who are eligible to receive
fibrinolytic therapy, considerable experience supports the
to conservative therapy; P less than 0.05) (393). The TIMI-
TACTICS group (394) has proposed a new risk stratification.
The early invasive strategy was particularly effective for
patients at moderate to high risk. The greater benefits derived
from PCI in the TACTICS and FRISC trials compared with
the TIMI III and VANQWISH trials can be explained in part
by the use of stents and GP-receptor blockers and lower
periprocedural complications in the TACTICS and FRISC II
trials. In several studies published to date, the use of routine
invasive therapy in patients with UA/NSTEMI, accompanied
by IIb/IIIa receptor antagonists, has been shown to improve
survival (205,302,393,395-397). New trials such as RITA-3
(302) further demonstrate the safety and effectiveness of an
early invasive strategy.
It is recognized by the Committee that the assessment of
risk of unsuccessful PCI or serious morbidity or mortality
must always be made with consideration of the alternative
therapies available for the patient, including more intensive
or prolonged medical therapy or surgical revascularization
(Table 19) (302,304,390,391,393), especially in patients with
UA/NSTEMI. 
When CABG surgery is a poor option because of high risk
due to special considerations or other organ system disease,
patients otherwise in class IIb may be appropriately managed
with PCI. Under these special circumstances, formal surgical
consultation is recommended.
5.4. Patients With STEMI
5.4.1. General and Specific Considerations
Class I
General considerations:
1. If immediately available, primary PCI should be per-
formed in patients with STEMI (including true poste-
rior MI) or MI with new or presumably new left bun-
dle-branch block who can undergo PCI of the infarct
artery within 12 hours of symptom onset, if per-
formed in a timely fashion (balloon inflation goal
within 90 minutes of presentation) by persons skilled
in the procedure (individuals who perform more than
75 PCI procedures per year, ideally at least 11 PCIs
per year for STEMI). The procedure should be sup-
ported by experienced personnel in an appropriate
laboratory environment (one that performs more than
200 PCI procedures per year, of which at least 36 are
primary PCI for STEMI, and that has cardiac sur-
gery capability). (Level of Evidence: A) Primary PCI
should be performed as quickly as possible, with a
goal of a medical contact-to-balloon or door-to-bal-
loon time within 90 minutes. (Level of Evidence: B)
Specific Considerations:
2. Primary PCI should be performed for patients less
than 75 years old with ST elevation or presumably
new left bundle-branch block who develop shock
within 36 hours of MI and are suitable for revascular-
ization that can be performed within 18 hours of
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each 30-minute delay from symptom onset to balloon infla-
tion, P equals 0.04) (424).
The enthusiasm for primary PCI has led to the concept of
emergency interhospital transfer for catheter-based reperfu-
sion rather than fibrinolytic therapy in the initial hospital
(425-427). Five randomized trials have enrolled 2466
patients with favorable results for PCI versus fibrinolytic
therapy (378,381,407,412). Mortality was reduced with PCI
(6.8% vs 9.6%, relative risk 0.69, 95% CI 0.51 to 0.0.92, P
equals 0.01), as was the combined end point of death, nonfa-
tal reinfarction, and stroke (8.5% vs 15.5%, relative risk
0.51, 95% CI 0.39 to 0.65, P less than 0.0001). Importantly,
mean time to treatment was delayed only 44 min in these
studies (Figure 8) (378,415). In contrast, first hospital door-
to-balloon time, as recorded in 1346 patients undergoing
hospital transfer before PCI in NRMI-4, was 185 min in the
United States in 2002 (Figure 9) (428). Emergency transport
in Europe is centrally organized and more efficient than in
the United States (Table 20) (378,381,407,412,415). Delays
in door-to-balloon time versus door-to-needle time of more
than 60 min because of interhospital transfer might negate
the potential mortality benefit of transfer for primary PCI
over immediate intravenous fibrinolysis demonstrated in
these trials (421). However, transfer of patients to PCI-capa-
ble centers should be accomplished when fibrinolytic thera-
py is contraindicated or unsuccessful, when cardiogenic
shock ensues, when the anticipated delay is less than 60 min,
or when symptoms have been present for more than 2 to 3 h
(410,415). To achieve optimal results, a systems approach
for rapid triage and transfer must be established. Time from
first hospital door to balloon inflation in the second hospital
should be as short as possible, with a goal within 90 min.
Significant reductions in door-to-balloon times might be
achieved by transporting patients directly to PCI centers,
rather than transporting them to the nearest hospital, if inter-
hospital transfer will subsequently be required to obtain pri-
mary PCI. Central to the success of all of the acute reperfu-
sion strategies is a well-developed process of triage, as dis-
cussed in the STEMI guidelines (332,429).
Primary PCI with stenting has been compared with fibri-
nolytic therapy in 12 randomized clinical trials
(366,378,380,381,407-412,415,430). These investigations
demonstrate that PCI-treated patients experience lower mor-
tality rates (5.9% vs 7.7%, OR 0.75, 95% CI 0.60 to 0.94, P
equals 0.013), fewer reinfarctions (1.6% vs 5.1%, OR 0.31,
95% CI 0.21 to 0.44, P equals 0.0001), and fewer hemor-
rhagic strokes than those treated by fibrinolysis (53).
Compared with PTCA, intracoronary stents achieve a better
immediate angiographic result with a larger arterial lumen,
less reclosure of the infarct-related artery, and fewer subse-
quent ischemic events (431-433). Primary stenting has been
compared with primary angioplasty in 9 studies (64,106,433-
440) (Table 21). There were no differences in mortality
(3.0% vs 2.8%) or reinfarction (1.8% vs 2.1%) rates.
However, subsequent target-vessel revascularization rates
were lower with stenting (440). 
value of PCI for patients who may not be suitable for fibri-
nolytic therapy owing to an increased risk of bleeding (401). 
Primary PCI has been compared with fibrinolytic therapy
in 23 randomized clinical trials (361-363,378,380,381,402-
415), including the SHOCK (SHould we emergently revas-
cularize Occluded Coronaries in cardiogenic shocK?) trial
(366). The recommendations for primary PCI in patients
with cardiogenic shock are discussed and summarized sepa-
rately in Section 5.4.6. These investigations consistently
demonstrate that PCI-treated patients experience lower
short-term mortality rates (7.0% vs 9.0%, relative risk 0.73,
96% CI 0.62 to 0.86, P equals 0.0002, and 5.0% vs 7.0%, rel-
ative risk 0.70, 95% CI 0.58 to 0.85, P equals 0.003 exclud-
ing the SHOCK trial), fewer nonfatal reinfarctions (3.0% vs
7.0%, relative risk 0.35, 95% CI 0.27 to 0.45, P equals
0.0003), and fewer hemorrhagic strokes (0.05% vs 1.0%, rel-
ative risk 0.05, 95% CI 0.006 to 0.35, P equals 0.0001) than
those treated by fibrinolysis (53), albeit with an increased
risk of bleeding (7.0% vs 5.0%, RR 1.3, 95% CI 1.02 to 1.65,
P equals 0.032). These results have been achieved in medical
centers and by providers experienced in the performance of
primary PCI and under circumstances in which angioplasty
can be performed promptly after patient presentation. The
magnitude of the treatment differences for death, nonfatal
reinfarction, and stroke vary depending on whether PCI is
compared with streptokinase or a fibrin-specific lytic. The
short- and long-term outcomes of patients with STEMI treat-
ed by fibrinolysis versus PCI and the numbers of patients
who need to be treated to prevent 1 event or to cause a harm-
ful complication when PCI is selected instead of fibrinolysis
as the reperfusion strategy are shown in Figure 5
(53,416,417).
Time from symptom onset to reperfusion is an important
predictor of patient outcome. Two studies (330,418) have
reported increasing mortality rates with increasing door-to-
balloon times. Other studies have shown better LV function
and fewer complications when reperfusion occurs before PCI
(419,420). An analysis of the randomized controlled trials
comparing fibrinolysis with primary PCI suggests that the
mortality benefit with PCI exists when treatment is delayed
by no more than 60 min (Figure 6) (421). Mortality increas-
es significantly with each 15-minute delay in the time
between arrival and restoration of TIMI-3 flow (door-
to–TIMI-3 flow time), which further underscores the impor-
tance of timely reperfusion in patients who undergo primary
PCI (422). Given that the door-to-needle time goal is 30 min,
this Writing Committee joins the Task Force on the
Management of Acute Myocardial Infarction of the
European Society of Cardiology (423) and the ACC/AHA
STEMI Guidelines Writing Committee (332) in lowering the
door-to-balloon time goal from 120 to 90 min in an attempt
to maximize the benefits for reperfusion by PCI (Figure 7)
(418). Importantly, after adjustment for baseline characteris-
tics, time from symptom onset to balloon inflation is signifi-
cantly correlated with 1-year mortality in patients undergo-
ing primary PCI for STEMI (relative risk equals 1.08 for
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Figure 5. Percutaneous coronary intervention vs fibrinolysis for STEMI. The short-term (4 to 6 weeks; top left) and long-term (top
right) outcomes for the various end points shown are plotted for STEMI patients randomized to PCI or fibrinolysis for reperfusion in
23 trials (n=7739). Based on the frequency of events for each end point in the 2 treatment groups, the number needed to treat (NNT)
or number needed to harm (NNH) is shown for the short-term (bottom left) and long-term (bottom right) outcomes. Modified with per-
mission from Elsevier (Keeley et al. The Lancet, 2003, 361, 13-20). Note: The magnitude of the treatment differences for death, non-
fatal reinfarction, and stroke vary depending on whether PCI is compared with streptokinase or a fibrin-specific lytic. For example,
when primary PCI is compared with alteplase (tPA) and the SHOCK trial is excluded, the mortality rate is 5.5% vs 6.7% (OR 0.81,
95% CI 0.64 to 1.03, P equals 0.081). Source: Melandri. Circulation 2003;108:e162. CVA indicates cerebrovascular accident; Hem.
Stroke, hemorrhagic stroke; MI, myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal
coronary angioplasty; Rec. Isch, recurrent ischemia; ReMI, recurrent MI; and STEMI, ST-elevation myocardial infarction.
Preliminary reports suggest that compared with conven-
tional BMS, DES are not associated with increased risk when
used for primary PCI in patients with STEMI. Postprocedure
vessel patency, biomarker release, and the incidence of short-
term adverse events were similar in patients receiving SES or
BMS. Thirty-day event rates of death, reinfarction, or revas-
cularization were 7.5% versus 10.4%, respectively (P equals
0.4) (441).
Furthermore, the impact of IIb/IIIa platelet receptor antag-
onists in the setting of primary PCI has undergone consider-
able evaluation. In a randomized trial of stents plus abcix-
imab compared with fibrinolysis plus abciximab in patients
with STEMI, myocardial salvage and salvage index meas-
ured by technetium-99m sestamibi scintigraphy was signifi-
cantly greater in the stent group (430). In a similar study
comparing primary PCI with stent plus abciximab to fibri-
nolysis with alteplase, infarct size was smaller and the cumu-
lative incidence of death, reinfarction, or stroke at 6 months
significantly lower in the primary PCI group (411).
However, results of studies comparing primary PCI with
stents with or without IIb/IIIa platelet receptor antagonists
have been less consistent. In the CADILLAC trial, a com-
posite of death, reinfarction, disabling stroke, and ischemia-
driven target-vessel revascularization was similar in patients
treated with stents with or without abciximab (64). Yet, in a
similar randomized comparison of stent plus abciximab ver-
sus stent alone in patients with STEMI (ADMIRAL trial;
Abciximab before Direct angioplasty and stenting in
Myocardial Infarction Regarding Acute and Long-term fol-
low-up), a composite of death, reinfarction, or urgent target-
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Figure 7. Relationship between 30-day mortality and time from study enrollment to first balloon inflation. Patients assigned to angio-
plasty in whom angioplasty was not performed are also shown. n indicates number of patients; and PTCA, percutaneous translumi-
nal coronary angioplasty. Reprinted with permission from Berger et al. Circulation 1999;100:14-20 (418).
Figure 6. PCI versus fibrinolysis with fibrin-specific agents: is timing (almost) everything? PCI indicates percutaneous coronary inter-
vention. Modified with permission from Nallamothu and Bates. Am J Cardiol 2003;92:824-6 (421).
vessel revascularization at 30 days occurred significantly
less often in the abciximab group than in the control group
(6.0% vs 14.6%, P equals 0.01), a difference that was sus-
tained at 6 months of follow-up (442). The less favorable
comparable clinical outcomes in patients treated with abcix-
imab in the CADILLAC trial compared with those in the
ADMIRAL trial have been attributed to the earlier adminis-
tration of abciximab in the latter trial. The results of a pooled
analysis of these 2 trials plus 3 similar trials (RAPPORT,
ISAR-2, and ACE) (443-445) suggest that early (before coro-
nary angiography) administration of abciximab will be asso-
ciated with the most favorable clinical outcomes (446).
PCI appears to have its greatest mortality benefit in high-
risk patients. In patients with cardiogenic shock, an absolute
9% reduction in 30-day mortality with mechanical revascu-
larization instead of immediate medical stabilization was
reported in the SHOCK trial (366) (see Section 5.4.6, PCI for
Cardiogenic Shock). In NRMI-II, patients with HF had a
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delays in reperfusion and performance by low-volume or
poor-outcome operators/centers do not occur. The physi-
cians, nursing, and technical catheterization laboratory staff
must be experienced in handling acutely ill patients, must be
skilled in all aspects of interventional equipment and proce-
dures, and must participate in a 24-hours-per-day, 365-days-
per-year call schedule. Interventional cardiologists and cen-
ters should strive for 1) balloon dilation within 90 min of
admission and diagnosis of STEMI (452); 2) TIMI 2 to 3
flow attained in more than 90% of patients; 3) emergency
CABG rate less than 2% among all patients undergoing the
procedure; 4) actual performance of PCI in 85% of patients
brought to the laboratory; and 5) a risk-adjusted in-hospital
mortality rate less than 7% in patients without cardiogenic
33% relative risk reduction with primary PCI compared with
a 9% relative risk reduction with fibrinolytic therapy (447-
449). Primary PCI in patients with anterior STEMI reduces
mortality compared with fibrinolytic therapy, but there is no
difference in patients with nonanterior STEMI (450,451).
Despite the evidence supporting primary PCI in the treat-
ment of STEMI, there is serious concern that a routine poli-
cy of primary PCI for patients with STEMI will result in
unacceptable delays in achieving reperfusion in a substantial
number of patients and less than optimal outcomes if per-
formed by less experienced operators. The mean time delay
for PCI instead of fibrinolysis in the randomized trials was
only 40 min (364). Strict performance criteria must be man-
dated for primary angioplasty programs so that excessive
Figure 8. Comparison of elapsed time to fibrinolysis versus primary PCI. Time is presented as a continuous variable in minutes on
the horizontal axis. For DANAMI-2, times reflect components of delay from symptom onset to randomization (vertical bar) and are
further separated according to whether patients presented at community referral hospitals or those equipped for primary PCI. For
those patients randomized to PCI at a referral hospital, the 3 components of delay after randomization are related to duration of stay
at referral hospital, time for transport to PCI hospital, and delay from arrival at PCI hospital to balloon inflation. Lysis indicates fibri-
nolysis; PCI, percutaneous coronary intervention; Rand, randomization; SK, streptokinase; and Transp, transportation. Top graph
reprinted with permission from Anderson et al. N Engl J Med 2003;349:733-42 (378). Copyright 2003 Massachusetts Medical Society.
All rights reserved. Bottom graph reprinted from Widimsky et al. Eur Heart J 2003;24:94-104 (415) with permission from the
European Society of Cardiology.
(378)
(415)
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shock. Otherwise, the focus of treatment should be the early
use of fibrinolytic therapy, with further referral to PCI when
indicated.
5.4.2. PCI in Fibrinolytic-Ineligible Patients
Class I
Primary PCI should be performed in fibrinolytic-inel-
igible patients who present with STEMI within 12
hours of symptom onset. (Level of Evidence: C)
Class IIa
It is reasonable to perform primary PCI for fibri-
nolytic-ineligible patients with onset of symptoms
within the prior 12 to 24 hours and 1 or more of the
following: 
a. Severe congestive heart failure. (Level of Evidence:
C)
b. Hemodynamic or electrical instability. (Level of
Evidence: C)
c. Evidence of persistent ischemia. (Level of Evidence:
C)
Randomized, controlled clinical trials evaluating the out-
come of PCI for patients who present with STEMI but who
are ineligible for fibrinolytic therapy have not been per-
formed. Nevertheless, these patients are at increased risk for
mortality (453), and there is a general consensus that PCI is
an appropriate means for achieving reperfusion in those who
cannot receive fibrinolytic drugs because of an increased risk
of bleeding (401,454-456). Other reasons also exclude
STEMI patients from fibrinolytic therapy, and the outcome
of PCI in these patients may differ from those eligible for fib-
rinolytic therapy. Few data are available to characterize the
value of primary PCI for this subset of STEMI patients
(Table 22) (332,401).
Table 20. Transport of Patients With STEMI for Primary PCI
Time Between 
Study Number Randomization and First 
(Reference) Transported Distance, km Balloon Inflation, min
Vermeer et al. (412) 75 25 to 50 85*
PRAGUE-1 (407) 101 5 to 74 80*
AIR-PAMI (381) 71 52* 155†
PRAGUE-2 (415) 429 5 to 120 97*
DANAMI-2 (378) 567 3 to 150 90†
Total 1243 3 to 150 
min indicates minutes; km, kilometer; PCI, percutaneous coronary intervention; and STEMI, ST-elevation myocar-
dial infarction.
*Mean. 
†Median.
Figure 9. Door-to-balloon times: patients transferred in NRMI 4. Data are expressed in minutes as median time (25th percentile to
75th percentile). Cath Lab indicates catheterization laboratory. Modified, with permission, from NRMI-4 Investigators: The National
Registry of Myocardial Infarction-4 Quarterly Report. Genentech, South San Francisco, Calif; March, 2003:2 (428).
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5.4.3. Facilitated PCI
Class IIb
Facilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not imme-
diately available and bleeding risk is low. (Level of
Evidence: B)
Facilitated PCI refers to a strategy of planned immediate
PCI after an initial pharmacological regimen such as a full-
dose fibrinolytic, a half-dose fibrinolytic, a GP IIb/IIIa
inhibitor, or a combination of reduced-dose fibrinolytic ther-
apy and a platelet GP IIb/IIIa inhibitor. Facilitated PCI
should be differentiated from primary PCI without fibrinoly-
sis; from primary PCI with a GP IIb/IIIa inhibitor started at
the time of PCI; from immediate, early, or delayed PCI after
successful full-dose fibrinolysis; and from rescue PCI after
unsuccessful fibrinolysis. Potential advantages include earli-
er time to reperfusion, improved patient stability, greater pro-
cedure success rates, higher TIMI flow rates, and improved
survival rates (419,420,442,457-460). However, preliminary
studies have not demonstrated any benefit in reducing infarct
size or improving outcomes. It is unlikely that this strategy
would be beneficial in low-risk patients.
A strategy of facilitated PCI holds promise in higher-risk
patients when PCI is not immediately available. Potential
risks include increased bleeding complications, especially in
older patients, and potential limitations include added cost.
Several randomized trials of facilitated PCI with a variety of
pharmacological regimens are in progress.
5.4.4. PCI After Failed Fibrinolysis (Rescue PCI)
Class I
1. Rescue PCI should be performed in patients less than
75 years old with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be per-
formed within 18 hours of shock, unless further sup-
port is futile because of the patient’s wishes or con-
traindications/unsuitability for further invasive care.
(Level of Evidence: B)
2. Rescue PCI should be performed in patients with
severe congestive heart failure and/or pulmonary
edema (Killip class 3) and onset of symptoms within
12 hours. (Level of Evidence: B)
Class IIa
1. Rescue PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block or who develop shock within 36 hours of MI and
are suitable for revascularization that can be per-
formed within 18 hours of shock. Patients with good
prior functional status who are suitable for revascu-
larization and agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform rescue PCI for patients
with 1 or more of the following: 
a. Hemodynamic or electrical instability. (Level of
Evidence: C)
b. Evidence of persistent ischemia. (Level of Evidence:
C)
Class III
Rescue PCI in the absence of 1 or more of the above
class I or IIa indications is not recommended. (Level of
Evidence: C)
PCI Immediately After Failed Fibrinolysis
Intravenous fibrinolytic therapy successfully restores ante-
grade coronary flow at 90 min in 50% to 80% of patients
with acute STEMI (461). In those in whom it is unsuccess-
ful, antegrade coronary flow can usually be restored with
PCI. Several studies have demonstrated the marked benefi-
cial effect of infarct-related artery patency (obtained via
endogenous, pharmacological, or mechanical recanalization)
on survival in patients with acute STEMI (462). Survivors of
STEMI with a patent infarct-related artery demonstrated at
90 min after treatment have an improved long-term outcome
Table 22. Contraindications and Cautions for Fibrinolysis in
STEMI*
Absolute contraindications
Any prior intracranial hemorrhage
Known structural cerebral vascular lesion (e.g., AVM)
Known malignant intracranial neoplasm (primary or metastatic)
Ischemic stroke within 3 months, EXCEPT acute ischemic stroke
within 3 hours
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Significant closed head or facial trauma within 3 months
Relative contraindications
History of chronic severe, poorly controlled hypertension 
Severe uncontrolled hypertension on presentation (SBP greater
than 180 mm Hg or DBP greater than 110 mm Hg)†
History of prior ischemic stroke greater than 3 months, dementia,
or known intracranial pathology not covered in contraindications
Traumatic or prolonged (greater than 10 minutes) CPR or major
surgery (less than 3 weeks)
Recent (within 2 to 4 weeks) internal bleeding 
Noncompressible vascular punctures 
For streptokinase/anistreplase: prior exposure (more than 5 days
ago) or prior allergic reaction to these agents
Pregnancy
Active peptic ulcer 
Current use of anticoagulants: the higher the INR, the higher the
risk of bleeding
AVM indicates arteriovenous malformation; CPR, cardiopulmonary resuscitation; DBP,
diastolic blood pressure; INR, international normalized ratio; SBP, systolic blood pres-
sure; and STEMI, ST-elevation myocardial infarction.
*Viewed as advisory for clinical decision making and may not be all inclusive or defini-
tive.
†Could be an absolute contraindication in low-risk patients with STEMI (see Section
6.3.1.6.3.2 in the ACC/AHA Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction, available at: http://www.acc.org/clinical/guidelines/
stemi/index.pdf).
Reprinted from Antman et al. J Am Coll Cardiol 2004;44:e1-e211 (332).
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coronary reperfusion occurs over the subsequent h after fib-
rinolytic therapy in many patients. Although infarct-related
artery patency is achieved in only 50% to 85% of patients 90
min after fibrinolytic therapy, it rises to 90% by 24 h (473).
Such “late” reperfusion may improve survival without the
risk of invasive procedures coupled with fibrinolytic therapy.
Confounding the issue, both fibrinolysis and PCI may suc-
cessfully restore flow in the epicardial artery but fail to
improve microvascular perfusion. 
Hours to Days After Failed Fibrinolysis
Patency of the infarct-related artery is an important predictor
of mortality in survivors of STEMI (462,463,474).
Compared with those with a patent infarct artery, survivors
of STEMI with a persistently occluded artery after fibrinoly-
sis, PCI, or no reperfusion therapy have 1) increased LV
dilatation (475), 2) a greater incidence of spontaneous and
inducible ventricular arrhythmias (476), and 3) a poorer
prognosis (477). On the basis of observational and experi-
mental data, it has been hypothesized that infarct artery
patency may favorably influence LV remodeling and electri-
cal stability, even if accomplished at a time when salvage of
ischemic myocardium is unlikely (i.e., more than 12 h to
days after coronary artery occlusion). Five small randomized
trials, which enrolled a total of 562 patients, have directly
tested the hypothesis that mechanical opening of persistent
total occlusions late after MI will improve long-term LV
remodeling and clinical outcomes (the late open artery
hypothesis). Most studies enrolled a combination of patients,
including those who had failed fibrinolysis and those who
had not received reperfusion therapy (478-480), with a range
from almost no fibrinolytic therapy (481) to fibrinolytic ther-
apy in nearly all patients (482). There was wide variation in
the effect of routine PCI compared with medical therapy only
on LV size and function. Most studies showed no significant
differences between the treatment groups (478,479). One
single-center study of 83 patients with LAD occlusions
reported improved LV volumes and clinical outcomes (com-
posite of HF, MI, and death) at 6 months in the PCI group
(481). In contrast, a multicenter study of 66 patients with
LAD occlusions reported significantly worse LV remodel-
ing, with progressive LV dilation at 1 year and more clinical
events in the PCI group than in those assigned to optimal
medical therapy alone (482). The latter included very high
rates of beta-blocker and angiotensin converting enzyme
inhibitor use. The largest multicenter study, DECOPI
(DEsobstruction COronaire en Post-Infarctus), enrolled 212
patients and reported no difference in the primary end point,
the composite of death, ventricular tachycardia, and MI at 6
months (483). Stents were used in 80% of patients in the PCI
group, and GP IIb/IIIa antagonists were used in 9%. The
study reached less than one third of the target sample size
and was severely underpowered, as were all the other stud-
ies, to assess clinical events.
Selection of patients for revascularization based on viabil-
ity testing has gained a great deal of investigational support,
i.e., delayed enhancement or low-dose dobutamine cardiac
compared with those with an occluded infarct-related artery,
even when LV systolic function is similar (463,464). The
REACT trial (Rapid Early Action for Coronary Treatment)
was a randomized trial comparing medical therapy, immedi-
ate PCI, or repeat fibrinolytic in patients previously treated
with fibrinolytic therapy. Preliminary data at 30 days demon-
strated a significant advantage to rescue PCI [A.H.
Gershlick, oral presentation, American Heart Association
Scientific Sessions, New Orleans, LA, November 2004.]
Rescue (also known as salvage) PCI is defined as PCI with-
in 12 h after failed fibrinolysis for patients with continuing
myocardial ischemia. Rescue PCI has resulted in higher rates
of early infarct-artery patency, improved regional infarct-
zone wall motion, and greater freedom from adverse in-hos-
pital clinical events compared with a deferred PCI strategy or
medical therapy (465). The Randomized Evaluation of
Rescue PCI with Combined Utilization Endpoints (RES-
CUE) trial demonstrated a reduction in rates of in-hospital
death and combined death and HF that was maintained up to
1 year after study entry for patients presenting with anterior
wall STEMI who failed fibrinolytic therapy when performed
a mean of 8 h after symptom onset (466,467). Improvement
in TIMI grade flow from 2 to 3 may offer additional clinical
benefit. Similar data are not available for patients with
nonanterior STEMI. 
A major problem in adopting a strategy of rescue PCI lies
in the limitation of accurate identification of patients in
whom fibrinolytic therapy has not restored antegrade coro-
nary flow. Unless unsuccessful fibrinolysis is recognized and
corrected quickly (within 3 to 6 h of onset of symptoms), sal-
vage of ischemic myocardium is unlikely. Unfortunately,
clinical markers of reperfusion, such as relief of ischemic-
type chest discomfort, partial resolution of ST-segment ele-
vation, and reperfusion arrhythmias, have limited predictive
value in identifying failure of fibrinolysis (468). Immediate
catheterization of all patients after fibrinolytic therapy to
identify those with an occluded infarct-related artery in a
prior era in which the practice of PCI was less mature failed
to show a significant benefit and was associated with bleed-
ing complications. However, there was no specific study
using stents and current pharmacotherapy. This strategy is
being re-evaluated in clinical trials testing facilitated PCI in
the contemporary PCI setting.
Even in the patient with documented failure of fibrinolysis,
rescue PCI has limitations. First, because extensive myocar-
dial necrosis occurs when coronary occlusion has been pres-
ent for more than 3 h (469), PCI may not salvage a substan-
tial amount of myocardium, considering the time delay asso-
ciated with presentation of the patient to the hospital after
onset of symptoms, infusion of the fibrinolytic agent, recog-
nition of failed fibrinolysis, and subsequent initiation of PCI.
Second, rescue PCI fails to reestablish antegrade coronary
flow in about 10% of patients, and reocclusion of the infarct-
related artery occurs in as many as 20% of the remainder
(470), although GP IIb/IIIa inhibitors and stent implantation
may have improved these results. Third, unsuccessful rescue
PCI is associated with a high mortality (471,472). Finally,
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tine PCI immediately after fibrinolysis may increase the
chance for vascular complications at the catheterization
access site and hemorrhage into the infarct-related vessel
wall (491). 
Hours to Days After Successful Fibrinolysis
It was initially suggested that elective PCI of the stenotic
infarct-related artery hours to days after fibrinolysis might
allow sufficient time for development of a more stable hemo-
static milieu at the site of previous thrombotic occlusion. In
this setting, PCI would be safer and more effective in reduc-
ing the incidence of reocclusion and improving survival.
Two large randomized, prospective trials from an earlier PCI
era tested this hypothesis, with both concluding that 1) there
are fewer complications if PCI is delayed for several days
after fibrinolytic therapy, and 2) routine PCI in the absence
of spontaneous or provocable ischemia does not improve LV
function or survival (226,489,490,492). Thus, in unselected
patients receiving fibrinolytic therapy, PCI of the stenotic
infarct-related artery in the absence of evidence of recurrent
ischemia within 48 h did not appear to be beneficial. 
Great improvements in equipment, operator experience,
and adjunctive pharmacotherapy have increased PCI success
rates and decreased complications. More recently, the inva-
sive strategy for patients with NSTEMI has been given a
class I recommendation by the ACC/AHA 2002 Guideline
Update for the Management of Patients With UA/NSTEMI
(493). Patients with STEMI are increasingly being treated
similarly as an extension of this approach. Although 7 pub-
lished reports (474,480,494-498) support this strategy, ran-
domized studies similar to those in NSTEMI are needed.
One study supports the policy of performing catheteriza-
tion and subsequent revascularization for patients who do
have spontaneous or inducible angina after STEMI. The
DANAMI trial (499) randomly assigned 1008 survivors of a
first acute MI treated with fibrinolytic therapy within 12 h of
onset of symptoms to catheterization and subsequent revas-
cularization or standard medical therapy if they showed evi-
dence of spontaneous or inducible angina. Those who under-
went revascularization had less UA and fewer nonfatal MIs
during a 2.5-year period of follow-up than those patients ran-
domly assigned to medical treatment only (18% and 5.6% vs
30% and 10.5%, respectively). Among 500 patients undergo-
ing fibrinolysis for STEMI, the GRACIA-1 (randomized
trial comparing stenting within 24 hours of thrombolysis ver-
sus ischemia-guided approach to thrombolysed acute
myocardial infarction with ST elevation) trial compared a
strategy of angiography and intervention within 6 to 24 h of
fibrinolysis to an ischemia-guided conservative approach for
intervention. Eighty percent of patients assigned to angiogra-
phy and intervention underwent stenting of the culprit artery
compared with 20% in the ischemia-guided group. At 1 year,
patients in the invasive group had a lower frequency of the
primary end point (death, reinfarction, or revascularization;
9% vs 21%, P equals 0.008), and they tended to have a
reduced rate of death or reinfarction (7% vs 12%, P equals
MRI assessment. If viability is shown, outcomes are excel-
lent, whereas if transmural MI is present, it is not, and revas-
cularization is not recommended (484-486).
There are no convincing data to support the routine use of
late adjuvant PCI days after failed fibrinolysis or for patients
who do not receive reperfusion therapy. Nevertheless, this is
being done in some STEMI patients as an extension of the
invasive strategy for NSTEMI patients. The Occluded Artery
Trial (OAT) is currently randomizing patients to test whether
routine PCI days to weeks after MI improves long-term clin-
ical outcomes in asymptomatic high-risk patients with an
occluded infarct-related artery (487).
5.4.5. PCI After Successful Fibrinolysis or for
Patients Not Undergoing Primary Reperfusion
Class I
1. In patients whose anatomy is suitable, PCI should be
performed when there is objective evidence of recur-
rent MI. (Level of Evidence: C)
2. In patients whose anatomy is suitable, PCI should be
performed for moderate or severe spontaneous or
provocable myocardial ischemia during recovery
from STEMI. (Level of Evidence: B)
3. In patients whose anatomy is suitable, PCI should be
performed for cardiogenic shock or hemodynamic
instability. (Level of Evidence: B)
Class IIa
1. It is reasonable to perform routine PCI in patients
with LV ejection fraction less than or equal to 0.40,
HF, or serious ventricular arrhythmias. (Level of
Evidence: C)
2. It is reasonable to perform PCI when there is docu-
mented clinical heart failure during the acute episode,
even though subsequent evaluation shows preserved
LV function (LV ejection fraction greater than 0.40).
(Level of Evidence: C)
Class IIb
PCI might be considered as part of an invasive strate-
gy after fibrinolytic therapy. (Level of Evidence: C)
PCI Immediately After Successful Fibrinolysis 
In early studies, asymptomatic patients undergoing routine
PCI of the stenotic infarct-related artery immediately after
successful fibrinolysis showed no benefit with regard to sal-
vage of jeopardized myocardium or prevention of reinfarc-
tion or death. In addition, in some studies, this approach was
associated with an increased incidence of adverse events,
including bleeding, recurrent ischemia, emergency CABG
surgery, and death (488-491). However, these studies have
not been repeated in the modern interventional era with
improved equipment, improved antiplatelet and anticoagu-
lant therapy, and coronary stents. Notwithstanding this, rou-
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reduction in 30-day mortality (P less than 0.02), whereas
there was no apparent benefit for the small cohort (n equals
56) of patients more than 75 years old. These data strongly
support the approach that patients younger than 75 years
with STEMI complicated by cardiogenic shock should
undergo emergency revascularization and support measures.
Three registries (504-506) have demonstrated a marked sur-
vival benefit for elderly patients who are clinically selected
for revascularization (approximately 1 of 5 patients), so age
alone should not disqualify a patient for early revasculariza-
tion (see Section 3.5.9).
Several additional discussions elsewhere in this guideline
are important to consider in these patients. Intra-aortic bal-
loon pump support or ventricular assist devices can stabilize
hemodynamics so that revascularization procedures can be
performed (see Section 3.5.8). Post hoc analyses (507-509)
have suggested that GP IIb/IIIa inhibitors may reduce mor-
tality, but the studies are limited by lower than expected mor-
tality rates, larger than expected mortality reduction, and
small sample sizes. Although PCI in a noninfarct artery is not
recommended in stable patients, it can be beneficial in
hemodynamically compromised patients if the stenotic artery
perfuses a large area of myocardium and the procedure can
be performed efficiently. In patients with significant left
main disease or severe 3-vessel disease and without right
ventricular infarction or major comorbidities such as renal
insufficiency or severe pulmonary disease, CABG can be
considered as the revascularization strategy (Figure 10)
(510).
5.4.7. PCI in Selected Patient Subgroups
5.4.7.1. Young and Elderly Postinfarct Patients
Although not supported by randomized trials, routine cardiac
catheterization after fibrinolytic therapy for STEMI has been
a frequently performed strategy in all age groups. Young
patients (less than 50 years old) often undergo cardiac
catheterization after fibrinolytic therapy owing to a “per-
ceived need” to define coronary anatomy and thus establish
psychological as well as clinical outcomes. In contrast, older
patients (greater than 75 years of age) have higher in-hospi-
tal and long-term mortality rates and enhanced clinical out-
comes when treated with primary PCI (511-514). In addition,
patients thought to be candidates for implantable cardiovert-
er-defibrillator placement and those with small infarcts may
undergo cardiac catheterization for further evaluation after
STEMI. 
In a secondary analysis of the TIMI-IIB study that com-
pared angiographic findings and clinical outcomes among
841 young (aged less than 50 years) and 859 older (aged 65
to 70 years) patients randomly assigned to an invasive or
conservative post-lytic management strategy (515), the
younger patients assigned to the invasive strategy common-
ly had insignificant (i.e., less than 60% diameter stenosis)
and single-vessel CAD. Severe 3-vessel or left main coro-
nary disease findings were infrequent (3-vessel incidence,
4%; left main, 0%). Fatal and nonfatal MI and death through-
0.07). In the angiography and intervention group, 81% had
TIMI-3 flow before PCI was performed (494).
Days to Weeks After Successful Fibrinolysis
Continued thrombus lysis and remodeling of the infarct
artery stenosis occur over the days to weeks after successful
fibrinolysis, which makes the underlying residual coronary
stenosis more stable and less prone to rethrombosis and reoc-
clusion. Thus, a delay in performing PCI for days to weeks
after fibrinolysis might improve survival, even though earli-
er routine PCI does not. To date, there have not been ade-
quately sized trials to evaluate this treatment strategy. Two
older, small, randomized trials (488,500) demonstrated simi-
lar LV function, rates of reinfarction, and mortality in
patients randomized to PCI or conservative therapy.
5.4.6. PCI for Cardiogenic Shock
Class I
Primary PCI is recommended for patients less than 75
years old with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be per-
formed within 18 hours of shock, unless further sup-
port is futile because of the patient’s wishes or con-
traindications/unsuitability for further invasive care.
(Level of Evidence: A)
Class IIa
Primary PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be per-
formed within 18 hours of shock. Patients with good
prior functional status who are suitable for revascu-
larization and agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
Observational studies support the value of PCI for patients
who develop cardiogenic shock in the early hours of MI. For
patients who do not have mechanical causes of shock, such
as acute mitral regurgitation or septal or free wall rupture,
mortality among those having PCI is lower than among those
treated by medical means (366). However, undergoing car-
diac catheterization alone, with or without PCI, is associated
with a lower mortality because of patient selection bias
(501).
Two randomized clinical trials (366,502) have further clar-
ified the role of emergency revascularization in STEMI com-
plicated by cardiogenic shock. Both showed a statistically
insignificant, but clinically important, absolute 9% reduction
in 30-day mortality. In the SHOCK trial (366), the survival
curves continued to progressively diverge such that at 6
months and 1 year, there was a significant mortality reduc-
tion with emergency revascularization (53% vs 66%, P less
than 0.03) (503). The prespecified subgroup analysis of
patients less than 75 years old showed an absolute 15%
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come when treated with primary PTCA compared with fibri-
nolysis (512). In a review of more than 37 000 patients with
STEMI from a national cohort of the Medicare database,
after age adjustment, fibrinolytic therapy was not associated
with a better 30-day survival than no therapy, whereas pri-
mary angioplasty was (OR 0.79, 95% CI 0.66 to 0.94). The
benefit of primary angioplasty was noted at 1 year as well
(513). In the GUSTO-IIB (Global Use of Strategies to Open
occluded coronary arteries in acute coronary syndromes)
angioplasty study, 1138 patients were randomized to receive
primary angioplasty or fibrinolytic therapy. Irrespective of
treatment, the risk of hospital mortality increased with age.
For each 10-year increment in patient age, outcome was
improved with angioplasty compared with fibrinolytic thera-
py. After adjustment for baseline characteristics, each incre-
ment of 10 years of age increased the risk of death or MI by
a factor of 1.3 (95% CI 1.04 to 1.76, P equals 0.022).
Advancing age was found to be associated with worse out-
comes, and the risks increased in proportion to age. Primary
angioplasty improved outcome compared with fibrinolysis
but was not incrementally better in older than in younger
patient groups (514). Given the current data, with the excep-
tion of patients presenting with cardiogenic shock, use of
out the first year after study entry were also infrequent. There
were no differences in the rates of in-hospital recurrent
ischemia, reinfarction, or death among patients assigned to
the conservative strategy of selective cardiac angiography
and coronary revascularization compared with an invasive
strategy, which consisted of routine post-lytic coronary
angiography. Compared with younger patients, older patients
had a higher prevalence of multivessel CAD (i.e., 44%) and
higher 42-day rates of reinfarction and death. 
In spite of these observations, there was no difference in
the 42-day rates of reinfarction or death among the older
patient subgroup, regardless of the post-lytic management
strategy. The TIMI-II data of younger and older infarct
patients are consistent with the overall results of other ran-
domized trials of fibrinolysis/PTCA. More recent studies
have examined PCI compared with fibrinolysis in young and
elderly patients. The Primary Angioplasty in Myocardial
Infarction (PAMI) investigators reviewed 3362 patients with
ST-elevation MI enrolled in the various PAMI trials. All
underwent primary angioplasty. Hospital mortality was high-
er for older patients, but the improvement in survival was
also significant. Patients with high-risk infarction, including
those with age greater than 70 years, had an improved out-
Figure 10. Recommendations for initial reperfusion therapy when cardiogenic shock complicates STEMI. Early mechanical revascu-
larization with PCI/CABG is a Class I recommendation for candidates less than 75 years of age with ST elevation or left bundle-branch
block who develop shock less than 36 hours from STEMI and in whom revascularization can be performed within 18 hours of shock,
and it is a Class IIa recommendation for patients 75 years of age or older with the same criteria. Eighty-five percent of shock cases
are diagnosed after initial therapy for STEMI, but most patients develop shock within 24 hours. IABP is recommended when shock is
not quickly reversed with pharmacological therapy, as a stabilizing measure for patients who are candidates for further invasive care.
Dashed lines indicate that the procedure should be performed in patients with specific indications only. Recommendations for staged
CABG and PCI are discussed in the text, as are definitions of moderate and severe 3-vessel CAD. CABG indicates coronary artery
bypass graft surgery; CAD, coronary artery disease; IABP, intra-aortic balloon pump; IRA, infarct-related artery; and STEMI, ST-ele-
vation myocardial infarction. Modified with permission from Hochman. Circulation 2003;107:2998-3002 (510).
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evidence of ischemia should be obtained.) (Level of
Evidence: B)
3. PCI is reasonable in patients with diseased vein grafts
more than 3 years after CABG. (Level of Evidence: B)
4. PCI is reasonable when technically feasible in patients
with a patent left internal mammary artery graft who
have clinically significant obstructions in other ves-
sels. (Level of Evidence: C)
Class III
1. PCI is not recommended in patients with prior CABG
for chronic total vein graft occlusions. (Level of
Evidence: B)
2. PCI is not recommended in patients who have multi-
ple target lesions with prior CABG and who have mul-
tivessel disease, failure of multiple SVGs, and
impaired LV function unless repeat CABG poses
excessive risk due to severe comorbid conditions.
(Level of Evidence: B)
5.5.1. Early Ischemia After CABG
Recurrent ischemia early (less than 30 days) postoperatively
usually reflects graft failure, often secondary to thrombosis
(522-524), and may occur in both saphenous vein and arteri-
al graft conduits (525). Incomplete revascularization and
unbypassed native vessel stenoses or stenoses distal to a
bypass graft anastomosis may also precipitate recurrent
ischemia. Urgent coronary angiography is indicated to define
the anatomic cause of ischemia and to determine the best
course of therapy. Emergency PCI of a focal graft stenosis
(venous or arterial) or recanalization of an acute graft throm-
bosis may successfully relieve ischemia in the majority of
patients. Balloon dilatation across suture lines has been
accomplished safely within days of surgery (526-528).
Intracoronary fibrinolytic therapy should be administered
with caution during the first week postoperatively (529-532),
and if required, residual thrombus may be “targeted” in low
doses through a local drug delivery system. Conversely,
mechanical thrombectomy with newer catheter technologies
may be effective without the attendant risk of fibrinolysis
(533). Adjunctive therapy with abciximab for percutaneous
intervention during the first week after bypass surgery has
been limited but intuitively may pose less risk for hemor-
rhage than fibrinolysis. Because flow in vein graft conduits
is pressure dependent, IABP support should be considered in
the context of systemic hypotension or severe LV dysfunc-
tion. If feasible, PCI of both bypass graft and native vessel
offending stenoses should be attempted, particularly if intra-
coronary stents can be deployed successfully. 
When ischemia occurs 1 to 12 months after surgery, the
cause is usually perianastomotic graft stenosis. Distal anas-
tomotic stenoses (both arterial and venous) respond well to
balloon dilation alone and have a more favorable long-term
prognosis than stenoses involving the midshaft or proximal
vein graft anastomosis (250,251,534-537). Midshaft vein
graft stenoses occurring during this time frame are usually
PCI should be determined by clinical need without special
consideration of age.
5.4.7.2. Patients With Prior MI
A prior MI is an independent predictor of death, reinfarction,
and need for urgent coronary bypass surgery (516). In fibri-
nolytic trials, 14% to 20% of enrolled patients had a history
of prior MI (490,517,518), and patients with prior MI have
higher rates of reinfarction after fibrinolytic therapy (519).
In the TIMI-II study, patients with a history of prior MI had
a higher 42-day mortality (8.8% vs 4.3%; P less than 0.001),
higher prevalence of multivessel CAD (60% vs 28%; P less
than 0.001), and a lower LV ejection fraction (42% vs 48%;
P less than 0.001) than patients with a first MI (520). Among
patients assigned to the conservative post-lytic strategy,
those with a prior MI had a significantly higher 42-day mor-
tality than patients with a first MI (11.5% vs 3.5%; P less
than 0.001), whereas in the invasive strategy, the mortality
outcome was essentially the same in the 2 patient groups.
Mortality tended to be lower among patients with a prior MI
undergoing the invasive versus the conservative strategy, a
benefit that persisted up to 1 year after study entry (492). 
In a registry involving almost 12 000 patients with acute
coronary syndromes, with and without ST-segment eleva-
tion, a history of prior MI was noted in almost one third of
patients. There was no significant increase in relative risk for
hospital mortality in this group (521). Some analyses of pre-
dictors of mortality for angioplasty after fibrinolytic therapy
have found relatively little importance for prior infarction
and emphasized the much greater importance of time delays
in achieving reperfusion among patients with failed fibrinol-
ysis (418). 
Given the above findings and current practice, PCI should
be based on clinical need. The presence of prior MI places
the patient in a higher-risk subset and should be considered
in the PCI decision.
5.5. Percutaneous Intervention in Patients With
Prior Coronary Bypass Surgery
Class I
1. When technically feasible, PCI should be performed
in patients with early ischemia (usually within 30
days) after CABG. (Level of Evidence: B)
2. It is recommended that distal embolic protection
devices be used when technically feasible in patients
undergoing PCI to saphenous vein grafts. (Level of
Evidence: B)
Class IIa
1. PCI is reasonable in patients with ischemia that
occurs 1 to 3 years after CABG and who have pre-
served LV function with discrete lesions in graft con-
duits. (Level of Evidence: B)
2. PCI is reasonable in patients with disabling angina
secondary to new disease in a native coronary circula-
tion after CABG. (If angina is not typical, objective
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stent deployment (244,245,562-569) than with balloon
angioplasty of SVG stenoses, long-term prognosis remains
guarded, and late recurrent ischemic events may be due to
both restenosis of the target lesion and diffuse vein graft dis-
ease (570-572). Final patency after PCI is greater for distal
SVG lesions than for ostial or mid-SVG lesions (535), and
stenosis location appears to be a better determinant of final
patency than graft age or the type of interventional device
used. 
Percutaneous intervention for chronic vein graft occlusion
has been problematic. Balloon angioplasty alone has been
associated with high complication rates and low rates of sus-
tained patency (572). Although prolonged intragraft infusion
of fibrinolytic therapy was reported to successfully recanal-
ize 69% of a selected group of patients with chronic SVG
occlusion of less than 6 months’ duration, long-term patency
rates with or without adjunctive stent deployment were low
(573-575). In addition, prolonged fibrinolytic therapy has
been associated with thromboembolic MI (576-579),
intracranial hemorrhage (580), and intramyocardial hemor-
rhage (581), as well as vascular access-site complications.
Favorable results have been obtained with both local “target-
ed” and more prolonged infusion of fibrinolytic agents for
nonocclusive intragraft thrombus (582,583). Fibrinolytic
catheter-based systems appear to successfully treat SVG
thrombosis as well as or better than fibrinolytic agents (584). 
5.5.3. Early and Late Outcomes of 
Percutaneous Intervention
Before the general availability of coronary stenting, overall
angioplasty procedural success rates exceeded 90%, and
adverse outcomes of emergency repeat coronary bypass sur-
gery (2.3%) and death (0.8%) were infrequent as reported in
combined series of over 2000 patients with prior bypass sur-
gery undergoing percutaneous intervention (250,585-597).
These results are comparable to those achieved in patients
without prior bypass surgery, an observation confirmed by
NHLBI registry data (7). The most common complications
observed in this population are NSTEMI and atheroem-
bolism, particularly after SVG intervention (538,598). 
Patients with prior bypass surgery who undergo successful
PCI have a long-term outcome that is dependent on patient
age, the degree of LV dysfunction, and the presence of mul-
tivessel coronary atherosclerosis. The best long-term results
are observed after recanalization of distal anastomotic
stenoses occurring within 1 year of operation. Angioplasty of
distal anastomotic stenoses involving IMA grafts has been
associated with similar, favorable long-term patency rates
(543,544). Conversely, event-free survival is less favorable
after angioplasty of totally occluded SVGs, ostial vein graft
stenoses, or grafts with diffuse or multicentric disease (570-
572). Coexistent multisystem disease, the presence of which
may have prompted the choice of a percutaneous revascular-
ization strategy, may also influence long-term outcomes in
this population. 
due to intimal hyperplasia. Restenosis may be less frequent
and event-free survival may be enhanced after angioplasty of
SVGs dilated within 6 months of surgery compared with
grafts of older age. The immediate results of PCI in midshaft
ostial or distal anastomotic vein graft stenoses may be
enhanced by coronary stent deployment (537,538). Ablative
technologies such as directional atherectomy or excimer
laser coronary angioplasty may facilitate angioplasty and
stent deployment in patients with aorto-ostial vein graft
stenoses (539,540). 
Stenoses in the midportion or origin of the IMA graft are
uncommon but respond to balloon dilation (541,542) with
stent deployment as feasible. Long-term follow-up of
patients after IMA angioplasty has demonstrated sustained
benefit and relief of ischemia in the majority of patients
(543,544). Balloon angioplasty with or without stent deploy-
ment can be performed successfully in patients with distal
anastomotic stenoses involving the gastroepiploic artery
bypass graft and in patients with free radial artery bypass
grafts (545). Percutaneous intervention has also been effec-
tive in relieving ischemia for patients with stenosis of the
subclavian artery proximal to the origin of a patent left IMA
bypass graft (546,547).
5.5.2. Late Ischemia After CABG
Ischemia occurring more than 1 year postoperatively usually
reflects the development of new stenoses in graft conduits
and/or native vessels that may be amenable to PCI (548). At
3 years or more after SVG implantation, atherosclerotic
plaque is frequently evident and is often progressive. These
lesions may be friable and often have associated thrombus
formation, which may contribute to the occurrence of slow
flow, distal embolization, and periprocedural MI after
attempted percutaneous intervention (56). Slow flow occurs
more frequently in grafts that have diffuse atherosclerotic
involvement, angiographically demonstrable thrombus, and
irregular or ulcerative lesion surfaces, and with long lesions
that have large plaque volume (549,550). Although a reduced
incidence of distal embolization has been reported after the
use of the extraction atherectomy catheter to recanalize
stenoses in older vein graft conduits (551-555), embolization
may still complicate adjunctive balloon dilation. Distal
embolic protection devices have significantly reduced the
occurrence of complications of embolization in SVGs and
should be used when possible (254,255). Slow flow with
signs and symptoms of myocardial ischemia may be amelio-
rated by the intragraft administration of agents such as
adenosine, diltiazem, nitroprusside, and verapamil (549,556-
559). The adjunctive administration of abciximab during
vein graft intervention was evaluated in a meta-analysis of 5
studies that demonstrated no improvement in outcomes after
PCI and in the absence of distal protection and was associat-
ed with a high incidence of death and nonfatal ischemic
events (252). 
Although postprocedural minimum lumen diameter is larg-
er after directional coronary atherectomy (243,560,561) or
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a. Assessment of the adequacy of deployment of coro-
nary stents, including the extent of stent apposition
and determination of the minimum luminal diame-
ter within the stent. (Level of Evidence: B) 
b. Determination of the mechanism of stent restenosis
(inadequate expansion versus neointimal prolifera-
tion) and to enable selection of appropriate thera-
py (vascular brachytherapy versus repeat balloon
expansion). (Level of Evidence: B)
c. Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with
a suspected flow-limiting stenosis. (Level of
Evidence: C)
d. Assessment of a suboptimal angiographic result
after PCI. (Level of Evidence: C)
e. Establishment of the presence and distribution of
coronary calcium in patients for whom adjunctive
rotational atherectomy is contemplated. (Level of
Evidence: C)
f. Determination of plaque location and circumferen-
tial distribution for guidance of directional coro-
nary atherectomy. (Level of Evidence: B)
Class IIb
IVUS may be considered for the following: 
a. Determination of the extent of atherosclerosis in
patients with characteristic anginal symptoms and
a positive functional study with no focal stenoses or
mild CAD on angiography. (Level of Evidence: C)
b. Preinterventional assessment of lesional character-
istics and vessel dimensions as a means to select an
optimal revascularization device. (Level of
Evidence: C)
c. Diagnosis of coronary disease after cardiac trans-
plantation. (Level of Evidence: C)
Class III
IVUS is not recommended when the angiographic
diagnosis is clear and no interventional treatment is
planned. (Level of Evidence: C)
IVUS imaging provides a tomographic 360-degree sagittal
scan of the vessel from the lumen through the media to the
vessel wall. IVUS measurements of arterial dimensions
(minimal and maximal diameters, cross-sectional area, and
plaque area) complement and enhance angiographic infor-
mation. IVUS has been used to refine device selection
through plaque characterization (e.g., calcified) and artery
sizing. IVUS has contributed to the understanding of the
mechanisms of coronary angioplasty in general and specifi-
cally to the advancement of coronary stenting without long-
term anticoagulation (612-617). In a large observational
study, IVUS-guided angioplasty resulted in a decreased final
residual plaque area from 51% to 34%, despite a final angio-
graphic percent stenosis of 0% (612). IVUS-facilitated stent
deployment was associated with a subacute thrombosis rate
of 0.3% without systemic anticoagulation, although
5.5.4. General Considerations 
Aged, diffuse, friable, and degenerative SVG disease in the
absence of a patent arterial conduit to the LAD represents a
prime consideration for repeat surgical revascularization. In
contrast, the presence of a patent arterial conduit to the LAD
favors a percutaneous interventional approach to other ves-
sels (599). The overall risk of repeat operation, especially the
presence of comorbidities such as concomitant cerebrovas-
cular, renal, or pulmonary disease and the potential for jeop-
ardizing patent, nondiseased bypass conduits, must be con-
sidered carefully. Isolated, friable stenoses in vein grafts may
be approached with primary stenting or the combination of
extraction atherectomy and stenting in an attempt to reduce
the likelihood of distal embolization. Distal embolic protec-
tion devices have reduced the occurrence of complications of
embolization significantly and should be used when possible
(254,255) (see Sections 5.5.2 and 6.1.1).
Another therapeutic option for patients with prior coronary
bypass surgery that has become available is grafting with the
IMA through a “minimally invasive” surgical approach
(273,600-604). This strategy, which avoids both the risk of
cardiopulmonary bypass (stroke or coagulopathy) and repeat
median sternotomy, may be particularly applicable to
patients with chronic native-vessel LAD coronary occlusion
and friable atherosclerotic disease that involves a prior SVG
to this vessel. The role of combining a minimally invasive
surgical approach with PCI requires further study (605,606). 
In general, patients with multivessel disease, failure of
multiple SVGs, and moderately impaired LV function derive
the greatest benefit from the durability provided by surgical
revascularization with arterial conduits. Regardless of repeat
revascularization strategy, risk factor modification with ces-
sation of smoking (607,608) and lipid-lowering therapy
(609,610) should be implemented in patients with prior
CABG surgery. An aggressive lipid-lowering strategy that
targets a low-density lipoprotein cholesterol level substan-
tially less than 100 mg per dL (optional therapeutic target for
low-density lipoprotein cholesterol less than 70 mg per dL in
very-high-risk patients) (611) can be effective in reducing
recurrent ischemic events and the need for subsequent revas-
cularization procedures (610).
5.6. Use of Adjunctive Technology 
(Intracoronary Ultrasound Imaging, 
Flow Velocity, and Pressure)
The limitations of coronary angiography for diagnostic and
interventional procedures can be reduced by the use of
adjunctive technology such as intracoronary ultrasound
imaging, flow velocity, and pressure. Information obtained
from the adjunctive modalities of intravascular imaging and
physiology can improve PCI methods and outcomes.
5.6.1. Intravascular Ultrasound Imaging
Class IIa
IVUS is reasonable for the following: 
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tal studies to evaluate the efficacy of systemic and locally
delivered antirestenotic therapies (624-628) or in clinical
research trials to assess the effect of therapies for dyslipi-
demia on vascular wall and plaque structure.
5.6.2. Coronary Artery Pressure and Flow: 
Use of Fractional Flow Reserve and Coronary
Vasodilatory Reserve
Class IIa
It is reasonable to use intracoronary physiologic
measurements (Doppler ultrasound, fractional flow
reserve) in the assessment of the effects of intermedi-
ate coronary stenoses (30% to 70% luminal narrow-
ing) in patients with anginal symptoms. Coronary
pressure or Doppler velocimetry may also be useful as
an alternative to performing noninvasive functional
testing (e.g., when the functional study is absent or
ambiguous) to determine whether an intervention is
warranted. (Level of Evidence: B)
Class IIb
1. Intracoronary physiologic measurements may be con-
sidered for the evaluation of the success of PCI in
restoring flow reserve and to predict the risk of
restenosis. (Level of Evidence: C)
2. Intracoronary physiologic measurements may be con-
sidered for the evaluation of patients with anginal
symptoms without an apparent angiographic culprit
lesion. (Level of Evidence: C)
Class III
Routine assessment with intracoronary physiologic
measurements such as Doppler ultrasound or frac-
tional flow reserve to assess the severity of angio-
graphic disease in patients with a positive, unequivo-
cal noninvasive functional study is not recommended.
(Level of Evidence: C)
Historically, translesional pressure gradients were used as
end points for early interventional cardiology procedures.
The use of a translesional pressure gradient measured at rest
was abandoned because of difficult technique and improved
angiographic imaging. Pijls et al. (545) introduced the con-
cept of fractional flow reserve (FFR) of the myocardium, the
ratio of distal coronary pressure to aortic pressure measured
during maximal hyperemia, which correlates with the frac-
tion of normal blood flow through the stenotic artery
(629,630). The coronary pressure measuring technique is rel-
atively simple, especially with pressure guidewires, a
method superior to small catheters. The normal FFR value
for all vessels under all hemodynamic conditions, regardless
of the status of microcirculation, is 1.0. FFR values less than
0.75 are associated with abnormal stress tests (631). Unlike
coronary flow velocity reserve (CVR), the FFR is relatively
independent of microcirculatory disturbances. FFR does not
use measurements in a reference vessel and is thought to be
epicardial lesion-specific. FFR provides no information on
antiplatelet agents are still required for stenting (612). In the
placement of coronary stents, because radiographic contrast
material can be located between stent struts and the vascular
wall, an angiographic appearance of a large lumen may exist
when the stent has not been fully deployed. IVUS documents
full apposition of stent struts to the vessel wall (612). 
IVUS is not necessary for all stent procedures. The results
of the French Stent Registry study of 2900 patients treated
without warfarin and without IVUS reported a subacute clo-
sure rate of 1.8% (618). In the Stent Anticoagulation
Regimen Study (STARS) (619), a subacute closure rate of
0.6% in patients having optimal stent implantation supports
the approach that IVUS does not appear to be required rou-
tinely in all stent implantations. However, the use of IVUS to
evaluate results in high-risk procedures (e.g., those patients
with multiple stents, impaired TIMI grade flow or coronary
flow reserve, and marginal angiographic appearance)
appears warranted. 
The long-term outcomes when adjunctive IVUS is used are
currently under study. In the Multicenter Ultrasound Stent In
Coronaries (MUSIC) trial of 161 patients (620), which eval-
uated optimal stent expansion (defined as complete apposi-
tion of the stent over its length) with symmetrical expansion
(defined as a ratio of minimum to maximum luminal diame-
ter greater than 0.7) and minimal luminal area (compared
with greater than 80% of the reference area), the subacute
closure rate was 1.3% with monotherapy of aspirin. The
angiographic restenosis rate was less than 10% when stent
cross-sectional areas were greater than 9.0 mm2. 
Fitzgerald et al. reported that the degree of stent expansion
as measured by IVUS directly correlates to clinical outcomes
in the CRUISE (Can Routine Ultrasound Influence Stent
Expansion) study (621). This multicenter study compared
270 patients with IVUS-guided stent implantation with
IVUS-documented, but not guided, stent implantation in 229
patients. At 9-month follow-up, there was no difference in
rates of death or MI, but the target-lesion revascularization
rate was substantially lower in the IVUS-guided group (8.5%
vs 15.3%; P equals 0.019). These data suggest that ultra-
sound guidance of stent implantation may result in more
effective stent expansion than angiographic guidance alone
and subsequently reduce the need for late target-lesion revas-
cularization. 
In several instances, IVUS has been useful in determining
the reason for reduced efficacy of new technology. In the
RESCUT (REStenosis CUTting balloon evaluation) trial
comparing cutting balloon with PTCA for ISR, IVUS exam-
inations showed that there was stent underexpansion when a
cutting balloon was used at low pressure compared with
high-pressure balloons (91).
IVUS has also identified complications of PCI that require
further therapy. Postprocedure hematomas that were not
identifiable by angiography were identified by IVUS (622).
Stent underexpansion was also shown to be common in
diabetic patients assessed with angiography. This can be
revealed by IVUS so that further expansion of the stent can
be accomplished (623). IVUS increasingly is also being used
to measure the volume of intimal hyperplasia in experimen-
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the microcirculation or on the absolute magnitude of the
change in coronary flow. 
On the other hand, CVR is the ratio of hyperemic to basal
flow and reflects flow resistance through the epicardial
artery and the microvascular bed. CVR less than 2.0 is posi-
tively correlated to abnormal stress perfusion imaging (632-
634). In some cases, the uncertainty as to whether the
impaired flow reserve is due to the target stenosis or to an
abnormal microcirculation may be reduced by use of relative
coronary flow reserve (rCVR, which is equal to CVR of the
target vessel divided by CVR of the reference vessel). From
preliminary studies, rCVR greater than 0.8 may have prog-
nostic values similar to those of negative stress testing (635).
There is a correlation between rCVR and pressure-derived
FFR (629,635). An abnormal CVR indicates that the stenosis
in the epicardial artery is significant when the microcircula-
tion is normal. For coronary lesion assessment, the best
measurement appears to be FFR. 
CVR measurement of less than 2 after stent placement was
an independent predictor of target-vessel revascularization.
CVR after PCI in DEBATE-2 (Doppler Endpoints Balloon
Angioplasty Trial Europe) also predicted early MACE due to
microcirculatory disturbances (636). However, because of
the complexity in the interpretation of CVR, pressure-
derived FFR is the preferred measurement for lesion assess-
ment and outcome of PCI. Coronary physiologic measure-
ments associated with major clinical outcomes are supported
by numerous studies (Table 23) (632,637).
Strong correlations exist between myocardial stress testing
and FFR or CVR (633,638-649). An FFR of less than 0.75
identified physiologically significant stenoses associated
with inducible myocardial ischemia with high sensitivity
(88%), specificity (100%), positive predicted value (100%),
and overall accuracy (93%). An abnormal CVR (less than
2.0) corresponded to reversible myocardial perfusion imag-
ing defects with high sensitivity (86% to 92%), specificity
(89% to 100%), predictive accuracy (89% to 96%), and pos-
itive and negative predictive values (84% to 100% and 77%
to 95%, respectively). 
The clinical outcomes of deferring coronary intervention
for intermediate stenoses with normal physiology are
remarkably consistent, with clinical event rates of less than
10% over a 2-year follow-up period (639,647-651). Bech et
al. (649) studied 325 patients with intermediate coronary
stenosis without documented myocardial ischemia and ran-
domly assigned those with FFR greater than 0.75 to a defer-
ral group of 91 patients or a performance group of 90
patients. PTCA was performed as planned in 144 patients
with FFR less than 0.75. At clinical follow-up of 1, 3, 6, 12,
and 24 months, event-free survival was similar between the
deferral and performance groups (92% vs 89% at 12 months
and 89% vs 83% at 24 months). However, these rates were
significantly lower in the reference (PTCA) group (80% at
12 months and 78% at 24 months). The percentage of
patients free from angina was similar between the deferral
and the performance group at 12 and 24 months, but there
was a significantly higher incidence of angina in the refer-
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Beta-radiation systems have been used most widely, result-
ing in an approximately 50% reduction in the need for rein-
tervention over the 9 months after the procedure (92,659).
In-stent restenosis is now significantly less than in prior
years, but even with drug-eluting stenting, the problem still
exists. Early observation of the use of DES to treat ISR has
shown mixed results. Studies are currently under way com-
paring placement of DES to brachytherapy for ISR. Results
of those trials are not available at this time.
6.1.1. Acute Results
Class I
It is recommended that distal embolic protection
devices be used when technically feasible in patients
undergoing PCI to saphenous vein grafts. (Level of
Evidence: B)
Historically, one of the important limitations of balloon
angioplasty has been its high rate of abrupt closure (4% to
7%) and less than optimal acute angiographic result (30%
residual diameter stenosis, with frequent evidence of dissec-
tions). Significant reductions in acute complication rates for
PTCA have resulted from the wide use of stenting, which has
been shown to reduce abrupt closure and periprocedural
emergency surgery rates. Improved acute outcomes in terms
of reduced target-lesion residual diameter stenosis have also
been seen with the use of coronary stents, directional coro-
nary atherectomy, and other adjunctive therapies. The
GuardWire distal protection device, as studied in the SAFER
(Saphenous vein graft Angioplasty Free of Emboli
Randomized) trial, has reduced the incidence of MI in
patients treated for SVG lesions (255), and the FilterWire
was shown not to be inferior to the GuardWire in the FIRE
(FilterWire EX Randomized Evaluation) trial (254) (see
Section 5.5.2.). However, “embolic” protection devices have
not shown a similar benefit in the setting of primary PCI for
STEMI, as noted in the EMERALD (Enhanced Myocardial
Efficacy and Recovery by Aspiration of Liberated Debris)
trial (GuardWire), in which distal protection did not convey
significant benefit (661). Thus, the use of distal embolic pro-
tection devices for STEMI patients undergoing PCI requires
further evaluation (253,661). 
6.1.2. Late-Term Results
PCI devices, especially coronary stents, offer the possibility
of lower restenosis than with PTCA in the native coronary
circulation. Lower restenosis rates have been demonstrated
for balloon-expandable stents in large (3 mm) native coro-
nary arteries (80,83) and in saphenous vein lesions (562). 
The use of stents in smaller arteries has shown mixed
results. Use of stenting in the treatment of chronic total
occlusions has been superior to balloon angioplasty alone
(652,653). The use of vascular brachytherapy has been
shown to reduce restenosis rates and improve clinical out-
comes in patients with ISR (92,658,660).
Directional coronary atherectomy, when applied aggres-
sively, produces a larger lumen and has been associated with
ence group (67% vs 50% at 12 months and 80% vs 50% at
24 months). These data indicated that in patients with coro-
nary stenosis without evidence of ischemia, coronary pres-
sure–derived FFR identifies those patients who will benefit
from PCI as well as those who will not.
FFR after stenting predicts adverse cardiac events at fol-
low-up. Pijls et al. (648) examined 750 patients with post-
procedural FFR and related these findings to MACE at 6
months. In 76 patients (10.2%), 1 adverse event occurred.
Five patients died, 19 experienced MI, and 52 underwent at
least 1 repeat target-vessel revascularization. Fractional flow
reserve immediately after stenting was an independent vari-
able related to all types of events. In 36% of patients, FFR
normalized (greater than 0.95) with an event rate of 5%. In
32% of patients with poststenting FFR between 0.90 and
0.95, the event rate was 6%. In the remaining 32% with FFR
less than 0.90, event rates were 20%. In 6% of patients with
FFR less than 0.80, the event rate was 30% (Table 23) (637).
FFR after stenting is a strong predictor of outcome at 6
months. These data suggest that both edge stent subnormal-
ization and diffuse disease are associated with worse long-
term outcome. 
6. MANAGEMENT OF PATIENTS
UNDERGOING PCI
6.1. Evolution of Technologies
The introduction of coronary stents and other devices has
broadened the scope of patients who can be approached by
PCI beyond those who could be safely treated by PTCA
alone. Coronary stenting has become the dominant final ther-
apy in patients undergoing PCI. The NHLBI registry, which
collects sampling of unselected patients from 15 medium- to
large-volume institutions, shows increasing use of stenting
over the past 5 years. In the most recent wave of this registry,
83.6% of PCI patients received stents, and stents were placed
in 79.4% of all lesions treated. Stenting has been more suc-
cessful than balloon angioplasty in mid-sized coronary
lesions, chronic total occlusions (652,653), and SVGs (562).
Directional coronary atherectomy has been used successful-
ly in proximal anterior descending lesions and bifurcation
lesions (638). Rotational atherectomy successfully treats cal-
cific and diffusely diseased coronary vessels (654) and ostial
stenoses (655,656). Excimer laser has been used to treat dif-
fuse disease (657). Vascular brachytherapy has been success-
ful in treating restenosis occurring within stents
(92,658,659). Other adjunctive therapies for ISR have shown
mixed results. The cutting balloon has been used successful-
ly; however, a recent trial did not show superiority for the
cutting balloon compared with the normal balloon (95).
Rotary ablation, excimer laser, and restenting have also been
used for ISR; however, there are no data to indicate that these
methods are better than balloon angioplasty.
Intracoronary brachytherapy with both gamma and beta
radiation sources has been effective in treatment of ISR, and
both radiation sources were approved by the FDA as therapy
approved specifically for ISR (92,658-660).
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Evidence: C)
4. It is reasonable that patients undergoing brachyther-
apy be given daily clopidogrel 75 mg indefinitely and
daily aspirin 75 to 325 mg indefinitely unless there is
significant risk for bleeding. (Level of Evidence: C)
Class IIb
In patients in whom subacute thrombosis may be cat-
astrophic or lethal (unprotected left main, bifurcating
left main, or last patent coronary vessel), platelet
aggregation studies may be considered and the dose of
clopidogrel increased to 150 mg per day if less than
50% inhibition of platelet aggregation is demonstrat-
ed. (Level of Evidence: C)
Aspirin reduces the frequency of ischemic complications
after PCI. Although the minimum effective aspirin dosage in
the setting of PCI has not been established, for those patients
not already taking chronic aspirin therapy (75 to 162 mg per
day), an empiric dose of aspirin (300 to 325 mg ) given at
least 2 h and preferably 24 h before the PCI procedure is gen-
erally recommended (665-668). Although other antiplatelet
agents have antiplatelet effects similar to aspirin (669), only
the thienopyridine derivatives (670) ticlopidine and clopido-
grel have been used routinely as alternative antiplatelet
agents in aspirin-sensitive patients during coronary angio-
plasty. Glycoprotein IIb/IIIa antagonists might also be sub-
stituted for aspirin before PCI. However, aspirin desensitiza-
tion can be performed safely in selected patients (671,672).
A strategy of pretreatment with clopidogrel in patients who
have not already had their coronary anatomy defined is con-
troversial, because patients who undergo CABG within 5 to
7 days of clopidogrel treatment have an increased risk of
bleeding (665,673).
Clopidogrel and ticlopidine have similar side effects, which
include gastrointestinal distress (20%), cutaneous rashes
(4.8% to 15%), and abnormal liver function tests (674).
Severe neutropenia has been reported to occur in approxi-
mately 1% of patients taking ticlopidine (674,675). Rare
(less than 1:1000) but fatal episodes of thrombotic thrombo-
cytopenic purpura have also been reported (676-678).
Patients receiving ticlopidine should be monitored for the
occurrence of this untoward sequela. A shorter duration (10
to 14 days) of ticlopidine therapy may reduce untoward side
effects of therapy while maintaining therapeutic efficacy
(679). For these reasons, clopidogrel has become the pre-
ferred thienopyridine for patients undergoing PCI. Available
data show that approximately 4% to 30% of patients treated
with conventional doses of clopidogrel do not display ade-
quate platelet response (680). Preliminary data suggests that
clopidogrel “nonresponders” may be at higher risk for
thrombotic events. Thus, in patients in whom stent thrombo-
sis may be catastrophic or lethal (ULM, bifurcating left
main, and last patent coronary vessel), platelet aggregation
studies may be considered and the dose of clopidogrel
increased to 150 mg per day if less than 50% inhibition of
platelet aggregation is demonstrated.
a lower angiographic restenosis rate (85). Despite the
improvement in acute results seen for rotational atherectomy
and excimer laser, there is no evidence that these devices
improve late outcomes in lesions that can be safely treated
with balloon angioplasty or stenting alone (662-664).
6.2. Antiplatelet and Antithrombotic Adjunctive
Therapies for PCI
6.2.1. Oral Antiplatelet Therapy 
Class I
1. Patients already taking daily chronic aspirin therapy
should take 75 to 325 mg of aspirin before the PCI
procedure is performed. (Level of Evidence: A)
2. Patients not already taking daily chronic aspirin ther-
apy should be given 300 to 325 mg of aspirin at least 2
hours and preferably 24 hours before the PCI proce-
dure is performed. (Level of Evidence: C)
3. After the PCI procedure, in patients with neither
aspirin resistance, allergy, nor increased risk of bleed-
ing, aspirin 325 mg daily should be given for at least 1
month after bare-metal stent implantation, 3 months
after sirolimus-eluting stent implantation, and 6
months after paclitaxel-eluting stent implantation,
after which daily chronic aspirin use should be con-
tinued indefinitely at a dose of 75 to 162 mg. (Level of
Evidence: B)
4. A loading dose of clopidogrel should be administered
before PCI is performed. (Level of Evidence: A) An
oral loading dose of 300 mg, administered at least 6
hours before the procedure, has the best established
evidence of efficacy. (Level of Evidence: B)
5. In patients who have undergone PCI, clopidogrel 75
mg daily should be given for at least 1 month after
bare-metal stent implantation (unless the patient is at
increased risk of bleeding; then it should be given for
a minimum of 2 weeks), 3 months after sirolimus stent
implantation, and 6 months after paclitaxel stent
implantation, and ideally up to 12 months in patients
who are not at high risk of bleeding. (Level of
Evidence: B)
Class IIa
1. If clopidogrel is given at the time of procedure, sup-
plementation with GP IIb/IIIa receptor antagonists
can be beneficial to facilitate earlier platelet inhibition
than with clopidogrel alone. (Level of Evidence: B)
2. For patients with an absolute contraindication to
aspirin, it is reasonable to give a 300-mg loading dose
of clopidogrel, administered at least 6 hours before
PCI, and/or GP IIb/IIIa antagonists, administered at
the time of PCI. (Level of Evidence: C)
3. When a loading dose of clopidogrel is administered, a
regimen of greater than 300 mg is reasonable to
achieve higher levels of antiplatelet activity more rap-
idly, but the efficacy and safety compared with a 300-
mg loading dose are less established. (Level of
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Before the advent of potent combination antiplatelet thera-
py in recent years, enthusiasm for stenting during MI (with
or without ST elevation) or UA was tempered by the sudden
and often unpredictable occurrence of subacute stent throm-
bosis, which developed in 3.5% to 8.6% of stent-treated
patients (80,83,681,682). Anatomic factors (e.g., underdila-
tion of the stent, proximal and distal dissections, poor inflow
or outflow obstruction, less than 3-mm vessel diameter) were
believed to predispose some patients to the occurrence of
subacute stent thrombosis (612,683,684). With the advance-
ments in PCI technology and adjunctive antiplatelet therapy
(aspirin plus thienopyridine) after PCI, the incidence of stent
thrombosis is now approximately 1% (685,686). The poten-
tial risk of stent occlusion should be considered when dis-
continuation of antiplatelet therapy is contemplated in
patients undergoing stent implantation (687,688).
The efficacy of combination antiplatelet therapy in patients
undergoing urgent and elective stent implantation has been
shown by the Intracoronary Stenting and Antithrombotic
Regimen (ISAR) trial of 517 patients treated with BMS for
MI, suboptimal angioplasty, or other high-risk clinical and
anatomic features. Patients were randomly assigned to treat-
ment with aspirin plus ticlopidine or aspirin, intravenous
heparin, and phenprocoumon after successful stent place-
ment (689). The primary end point of cardiac death, MI,
coronary bypass surgery, or repeat angioplasty occurred in
1.5% of patients assigned to antiplatelet therapy and 6.2% of
those assigned to anticoagulant therapy (relative risk 0.25;
95% CI 0.06 to 0.77) (689). 
In the STARS trial (619), the efficacy of aspirin (325 mg
daily), the combination of aspirin (325 mg daily) plus ticlo-
pidine (500 mg daily for 1 month), and aspirin (325 mg
daily) plus warfarin on ischemic end points at 30 days in
1653 in low-risk patients after optimal BMS placement
demonstrated more adverse events in patients not receiving
ticlopidine as part of the therapeutic regimen. The primary
30-day composite end point of death, target-lesion revascu-
larization, subacute thrombosis, or MI was 3.6% in patients
assigned to aspirin only, 2.7% in those assigned to aspirin
plus warfarin, and 0.5% in those assigned to aspirin plus
ticlopidine (aspirin plus ticlopidine vs aspirin alone, P less
than 0.001; aspirin plus ticlopidine vs aspirin plus warfarin,
P equals 0.014) (619). Pretreatment with ticlopidine without
a loading dose for more than 72 h may allow more effective
inhibition of platelet activation than shorter durations of ther-
apy (691,692). 
In the CURE (Clopidogrel in Unstable angina to prevent
Recurrent Events) trial, the effects of clopidogrel in addition
to aspirin were tested in 12 562 patients with non–ST-eleva-
tion acute coronary syndromes with either positive biomark-
ers of myocardial injury or new ECG changes (665). The
patients were randomized to receive an immediate 300-mg
loading dose of clopidogrel in the emergency room followed
by 75 mg a day for 1 year or to a matching placebo.
The primary end points of MI, stroke, and cardiovascular
death from randomization to 1 year were reported. There was
a 20% RRR in the primary outcome of MI, stroke, or cardio-
vascular death, a highly significant result at 12 months in
patients treated with clopidogrel. The most pronounced ben-
efit was observed in the reduction of MIs, with the largest
reductions of 40% in Q-wave or ST-elevation MI, also sta-
tistically significant. In parallel with the reduction in large
MI was a 43% reduction in the use of fibrinolytic therapy
after randomization and an 18% reduction in radiologically
confirmed HF, both of which reached statistical significance.
In PCI CLARITY, patients treated with fibrinolysis for
STEMI who underwent PCI 2 to 8 days after receiving a 300
mg loading dose of clopidogrel, had reduced incidence of
CV death or ischemic complications when compared to those
receiving 300 mg clopidogrel immediately prior to PCI
(665a). In another trial (ISAR-REACT [Intracoronary Stent-
ing and Antithrombotic Regimen-Rapid Early Action for
Coronary Treatment]), a higher loading dose of clopidogrel
(600 mg) was used before elective, low-risk stent procedures
with favorable results compared with routine abciximab
administration (693). However, the sample size was such that
it may have been underpowered to show a benefit of abcix-
imab administration in low-risk populations.
After PCI with BMS implantation, short term (at least 1
month) clopidogrel therapy in addition to aspirin leads to
greater protection from thrombotic complications than
aspirin alone. The benefits of long-term treatment with
clopidogrel after PCI and the benefit of initiating pretreat-
ment with clopidogrel with a preprocedural loading dose in
addition to aspirin therapy were tested in CREDO
(Clopidogrel for the Reduction of Events During
Observation), a randomized, double-blind, controlled trial of
early and sustained dual oral antiplatelet therapy after PCI
(666). In this trial of 2116 patients undergoing PCI from 99
North American centers, the patients received either a 300-
mg loading dose of clopidogrel (n equals 1053) or placebo
(no loading dose; n equals 1063) 3 to 24 h before PCI. All
patients thereafter received clopidogrel 75 mg daily through
day 28. For the following 12 months, patients in the loading
dose group received clopidogrel and those in the control
group received placebo. All patients received aspirin (325
mg per day through day 28, 81 to 325 mg daily thereafter)
throughout the study. At 1 year, long-term clopidogrel thera-
py was associated with a 27% RRR in the combined risk of
death, MI, or stroke for an absolute reduction of 3% (P
equals 0.02). Clopidogrel pretreatment did not significantly
reduce MACE at 28 days. However, in a prespecified sub-
group analysis, the patients who received clopidogrel at least
6 h before PCI had a RRR of 39% (P equals 0.051) for the
combined end point compared with no reduction with treat-
ment less than 6 h before PCI. Major bleeding risk at 1 year
increased but not significantly (8.8% with clopidogrel vs
6.7% with placebo, P equals 0.07). These data suggest that
after PCI, long-term clopidogrel therapy (1 year) significant-
ly reduced the risk of adverse ischemic events. A 300-mg
loading dose of clopidogrel given at least 3 h before the pro-
cedure did not reduce events at 28 days, but longer intervals
between the loading dose and PCI appeared to be associated
with a highly favorable trend toward reduced events.
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than 3 times the upper limit of normal), or target-vessel
revascularization up to 30 days after the procedure occurred
in 4% of patients in the 600-mg loading dose group and 12%
in the 300-mg loading dose group (P equals 0.041) owing to
a reduction in periprocedural MI. This was a small study of
relatively low-risk patients, with only a few patients receiv-
ing IIb/IIIa inhibitors. Thus, whether the results would also
apply to higher-risk patients taking IIb/IIIa blockers is
unknown (695). Some insights may be derived from the
CLEAR PLATELETS study (Clopidogrel Loading With
Eptifibatide to Arrest the Reactivity of Platelets), which eval-
uated a 300-mg and 600-mg clopidogrel loading dose with or
without eptifibatide in 120 patients undergoing elective
stenting procedures. Clopidogrel was administered immedi-
ately after stenting. Aggregometry and flow cytometry were
used to assess platelet reactivity. The authors concluded that
a strategy of eptifibatide administration was associated with
superior platelet inhibition and lower cardiac biomarker
release than high-dose (600 mg) or standard-dose (300 mg)
clopidogrel at the time of PCI (696). Further study is needed
to determine the relationship of platelet reactivity to clinical
outcomes such as bleeding, myocardial necrosis, and stent
thrombosis, which could not be derived from this small,
pharmacodynamic study.
Continuation of combination treatment with aspirin and
clopidogrel after PCI appears to reduce rates of cardiovascu-
lar ischemic events (666,667,697,698). On the basis of ran-
domized clinical trial protocols, aspirin 325 mg daily should
be given for at least 1 month after BMS implantation (unless
there is a risk of bleeding, in which case it should be given
for 2 weeks), 3 months after SES implantation, and 6 months
after paclitaxel-eluting stent (PES) implantation, after which
daily chronic aspirin should be continued indefinitely at a
dose of 75 to 162 mg. Likewise, clopidogrel 75 mg daily
should be given for at least 1 month after BMS implantation,
3 months after SES implantation, and 6 months after PES
implantation and ideally up to 12 months in patients who are
not at high risk of bleeding. To reduce the incidence of bleed-
ing complications associated with dual antiplatelet therapy,
lower-dose aspirin (75 to 162 mg daily) is recommended for
long-term therapy (665).
6.2.2. Glycoprotein IIb/IIIa Inhibitors 
Class I
In patients with UA/NSTEMI undergoing PCI with-
out clopidogrel administration, a GP IIb/IIIa inhibitor
(abciximab, eptifibatide, or tirofiban) should be
administered. (Level of Evidence: A)*
Class IIa
1. In patients with UA/NSTEMI undergoing PCI with
clopidogrel administration, it is reasonable to admin-
ister a GP IIb/IIIa inhibitor (abciximab, eptifibatide,
or tirofiban). (Level of Evidence: B)*
2. In patients with STEMI undergoing PCI, it is reason-
able to administer abciximab as early as possible.
Importantly, the CREDO trial did not have a control group
that was given a loading dose at the time of the procedure. 
The effects of pretreatment with clopidogrel and aspirin
followed by long-term therapy in patients undergoing PCI
was also evaluated in the PCI CURE study (667). The PCI
CURE study examined 2658 patients with non–ST-elevation
acute coronary syndromes undergoing PCI assigned random-
ly to double-blind treatment with clopidogrel (n equals 1313)
or placebo (n equals 1345). The patients were pretreated with
aspirin and the study drug for 6 days before PCI during ini-
tial hospital admission and for 10 days overall. After PCI,
80% of patients in both groups received open-label clopido-
grel for 4 weeks, after which the study drug was restarted for
a mean of 8 months. Fifty-nine patients (4.5% in the clopi-
dogrel group) experienced the primary end point of cardio-
vascular death, MI, or urgent target-lesion revascularization
within 30 days compared with 6.4% in the placebo group (P
equals 0.03). Long-term clopidogrel administration after PCI
conferred a lower rate of cardiovascular death, MI, or any
revascularization (P equals 0.03) and cardiovascular death or
MI (P equals 0.047). Including events before and after PCI,
there was an overall reduction of 31% in cardiovascular
death and MI (P equals 0.002).
The use of clopidogrel in patients with diabetes had espe-
cially favorable results. The CAPRIE (Clopidogrel versus
Aspirin in Patients at Risk of Ischemic Events) trial showed
a 9% RRR that favored clopidogrel versus aspirin for car-
diovascular events. A subgroup analysis in patients who had
prior cardiac surgery and who had been randomized to clopi-
dogrel revealed a significant reduction in risk of MI, stroke,
and cardiovascular death compared with those taking aspirin.
In patients with diabetes in the CAPRIE substudy, the bene-
fit of clopidogrel appeared larger compared with aspirin
alone, especially in those who required insulin (694).
Tabulation of the number of adverse events prevented per
1000 patients treated for 1 year with clopidogrel compared
with aspirin revealed 9 events prevented in the patients with-
out diabetes, with 21 events in all patients with diabetes and
38 in insulin-requiring patients with diabetes.
Further trials are needed to identify the optimum loading
dose and timing of clopidogrel administration before PCI. A
strategy of administering a 300-mg loading dose 6 h before
PCI has the best established evidence of efficacy (666).
Higher loading doses increase the magnitude and speed of
inhibition of platelet aggregation; however, no large-scale
randomized trials have been conducted to date comparing the
efficacy and safety of different loading doses of clopidogrel.
Furthermore, an important consideration in the decision for
pretreatment is the increased risk of bleeding in patients
managed with CABG. The ARMYDA-2 trial (Antiplatelet
therapy for the Reduction of MYocardial Damage during
Angioplasty) is a randomized, prospective, double-blind
study of patients with stable angina or UA/NSTEMI and
indications for coronary angiography. In this trial, 126
patients were randomized to a 600-mg loading dose and 129
patients to a 300-mg loading dose 4 to 8 h before PCI. The
primary end point of death, MI (defined as CK-MB greater
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
e230
Smith et al. 2005
ACC/AHA/SCAI Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
(Level of Evidence: B)
3. In patients undergoing elective PCI with stent place-
ment, it is reasonable to administer a GP IIb/IIIa
inhibitor (abciximab, eptifibatide, or tirofiban). (Level
of Evidence: B)
Class IIb
In patients with STEMI undergoing PCI, treatment
with eptifibatide or tirofiban may be considered.
(Level of Evidence: C)
*It is acceptable to administer the GP IIb/IIIa inhibitor before perform-
ance of the diagnostic angiogram (“upstream treatment”) or just before
PCI (“in-lab treatment”).
Aspirin is only a partial inhibitor of platelet aggregation
(699,700), because it affects only cyclooxygenase, thereby
preventing the formation of thromboxane A2. Functionally
active GP IIb/IIIa receptors aggregate platelets through fibrin
bound at the receptor sites. These receptors are activated by
a variety of agonists, including thromboxane A2, serotonin,
adenosine diphosphate, and collagen, among others. The
binding of fibrinogen and other adhesive proteins to adjacent
platelets by means of the GP IIb/IIIa receptor serves as the
“final common pathway” of platelet-thrombus formation and
can be effectively attenuated by GP IIb/IIIa antagonists.
These agents have reduced the frequency of ischemic com-
plications after coronary angioplasty. Individual studies eval-
uating the impact of intravenous GP IIb/IIIa receptor antag-
onists on survival for patients undergoing PCI have not had
adequate power to examine a difference in mortality. Two
meta-analyses of GP IIb/IIIa trials (abciximab, eptifibatide,
and tirofiban) have been performed to examine this potential
benefit. In 1 meta-analysis involving 12 trials of 20 186
patients, overall 30-day mortality was significantly reduced
by GP IIb/IIIa inhibition, although no individual trial showed
a mortality benefit. At 6 months, the survival benefit was not
significant. The trials included in this analysis encompassed
a range of patient characteristics (e.g., UA, NSTEMI, and
STEMI), therapeutic regimens (e.g., elective PCI, primary
PCI), and adjunctive drugs. In another meta-analysis, which
involved 19 trials of 20 137 patients, 30-day and 6-month
mortality were both significantly reduced for those receiving
IIb/IIIa receptor antagonists (Tables 24a and 24b)
(64,111,112,191,195,198,200,201,442,443,701-717). Thus,
patients undergoing PCI can expect a lower 30-day mortali-
ty when GP IIb/IIIa therapy is utilized. The RRR appears to
be similar in trials of patients with or without acute MI and
for trials using stents or another PCI as the intended primary
procedure. Similar reductions in nonfatal MI are seen in
association with the use of GP IIb/IIIa receptor antagonists. 
There is no consistent evidence that the GP IIb/IIIa
inhibitors reduce the frequency of late restenosis in patients
without diabetes. In EPISTENT, patients with diabetes who
received abciximab therapy in conjunction with stent deploy-
ment had a 51% reduction in target-vessel revascularization
at 6 months (230,718). This trial is the only one that has
shown a reduction in target-vessel revascularization in the
diabetic group. 
A long-term mortality benefit of abciximab in patients with
diabetes undergoing PCI was demonstrated in a pooled
analysis of 3 trials (EPIC, EPILOG, and EPISTENT; 4.5% vs
2.5%, P equals 0.03) (718). A meta-analysis showed that the
30-day mortality benefit in patients with diabetes in the set-
ting of UA/NSTEMI was greater in patients undergoing PCI
(719).
In a meta-analysis of invasive versus conservative therapy
of patients with UA/NSTEMI, men demonstrated a clear sur-
vival advantage with routine invasive therapy with GP
IIb/IIIa inhibitors and intracoronary stents; however, with
similar therapy, the results for women were not improved
significantly (205).
On the basis of the numerous trials to date, intravenous GP
IIb/IIIa receptor inhibitors should be considered in patients
undergoing PCI, particularly those with UA/NSTEMI or
with other clinical characteristics of high risk (Table 25).
Detailed discussion of the trials applicable to UA/NSTEMI
and STEMI patients can be found in the respective
ACC/AHA guidelines (332,493).
6.2.2.1. Abciximab
Trials of GP IIb/IIIa inhibitors have utilized different defini-
tions for adjuncting end points. These should be considered
when the results are evaluated.
The clinical safety and efficacy of abciximab have been
evaluated extensively in many randomized trials of patients
with acute coronary syndromes with and without high-risk
clinical features. These studies include EPIC (Evaluation of
7E3 for the Prevention of Ischemic Complications) (704),
EPILOG (Evaluation of Percutaneous transluminal coronary
angioplasty to Improve Long-term Outcome with abciximab
GP IIb/IIIA blockade) (705), and EPISTENT (Evaluation of
Platelet IIb/IIIa Inhibition in STENTing) (111). Despite early
problems with excessive bleeding when weight-adjusted
heparin dosing was not employed, abciximab was superior to
placebo in all settings for reducing MACE.
ISAR-REACT randomly compared abciximab (n equals
1079) versus placebo (n equals 1080) in low-risk PCI
patients pretreated with high-dose clopidogrel (600 mg oral-
ly) 2 h before the procedure, then with 75 mg BID for 3 days
followed by 75 mg per day for 3 months (693). At 30 days,
there was no difference between the groups. Thus, in that
trial of low-risk patients having elective PCI, there was no
benefit to the use of abciximab in patients receiving high-
dose pretreatment with clopidogrel. The sample size was
such that it may have been underpowered to show a benefit
in low-risk populations (693).
Heeschen et al. (192), for the CAPTURE (Chimeric c7E3
AntiPlatelet Therapy in Unstable angina REfractory to stan-
dard treatment ) investigators, demonstrated that troponin T,
but not C-reactive protein, was predictive of cardiac risk dur-
ing the initial 72-h period in the treatment of UA patients
with standard therapy or with abciximab. Hamm et al. (193),
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Readministration Registry (R3), there were no cases of ana-
phylaxis or other allergic manifestations whether or not
HACA was present, and HACA was not predictive of any
other measure of complication or success. From the R3
study, HACA has been shown to be an IgG (not IgE)
immunoglobulin that does not neutralize abciximab. The
more worrisome clinical phenomenon associated with read-
ministration is the potential for increased rates of thrombo-
cytopenia. In the 500-patient R3, a 4.4% incidence in throm-
bocytopenia (to a platelet count of less than 100 × 109 per
liter) was observed, with half of the patients developing
acute profound thrombocytopenia (to a platelet count of less
than 20 × 109 per liter). This potential complication should
always be monitored when treating a patient with abciximab
(194-197). Abciximab readministration poses greater risk
within 2 weeks of original abciximab dose.
6.2.2.2. Eptifibatide
The clinical utility of eptifibatide, a short-acting cyclic hep-
tapeptide that also inhibits the GP IIb/IIIa receptor, was eval-
uated in the Integrilin to Manage Platelet Aggregation to
prevent Coronary Thrombosis-II (IMPACT-II) trial, a dou-
ble-blind, randomized, placebo-controlled multicenter trial
that enrolled 4010 patients undergoing coronary angioplasty
(198). Patients were assigned to treatment with aspirin,
heparin and placebo, aspirin, heparin, and eptifibatide bolus
(135 mcg per kg) followed by a low-dose eptifibatide infu-
for the CAPTURE investigators, also reported that among
the 1265 patients with UA enrolled in the CAPTURE trial,
troponin T and CK-MB from 890 patients correlated with
subsequent 6-month adverse cardiac risk. In patients without
elevated troponin T levels, there was no benefit of treatment
with respect to the relative risk of death or MI at 6 months
(OR 1.26, CI 95% 0.74 to 2.31; P equals 0.47). Serum tro-
ponin T level, which is considered to be a surrogate marker
for thrombus formation, identified a high-risk subgroup of
patients with refractory UA suitable for coronary interven-
tion who would particularly benefit from antiplatelet treat-
ment with abciximab (192). 
One putative limitation of abciximab is the potential for
immune-mediated hypersensitivity reactions after subse-
quent readministration. Thrombocytopenia after readminis-
tration occurs in 3.5% to 6.3% of patients, which is similar to
the rate of occurrence in patients receiving abciximab for the
first time. Therefore, the absence of thrombocytopenia after
a first abciximab exposure does not guarantee protection
against its occurrence upon re-exposure. Moreover, the
prevalence of severe thrombocytopenia (2.8%) and profound
thrombocytopenia (2.0%) is greater with readministration
than the incidence observed after first-time administration
(1.0% and 0.4% for severe and profound thrombocytopenia,
respectively) (202). With the first administration, human
antichimeric antibodies (HACA) form in approximately 6%
of patients (702). The implications of HACA, however, are
unclear. Among 500 patients enrolled in the ReoPro
Table 24b. Subgroup Analyses for Mortality After PCI in Trials of Glycoprotein IIb/IIIa Inhibitors (See Table 24a for eligi-
ble trials)
30 Days 6 Months
No. of Studies RR (95% CI) No. of Studies RR (95% CI) 
20 (20 137)* 0.69 (0.53 to 0.90)* 14 (15 651)* 0.79 (0.64 to 0.97)*
Population
AMI 6 (3355) 0.69 (0.45 to 1.05) 6 (3355) 0.76 (0.55 to 1.05)
Mixed 2 (4240) 0.95 (0.54 to 1.68) 2 (4240) 0.97 (0.65 to 1.44)
Non-AMI 12 (12 542) 0.59 (0.39 to 0.89) 6 (8056) 0.71 (0.49 to 1.03)
Procedure
Stent 7 (5736) 0.69 (0.43 to 1.09) 7 (5736) 0.70 (0.49 to 1.01)
Other 13 (14 401) 0.70 (0.51 to 0.96) 7 (9915) 0.84 (0.65 to 1.09)
Postprocedure
Heparin 7 (4791) 0.72 (0.47 to 1.09) 5 (4548) 0.83 (0.60 to 1.13)
No heparin 13 (15 346) 0.68 (0.49 to 0.95) 9 (11 103) 0.77 (0.58 to 1.01)
Agent
Abciximab 14 (11 606) 0.69 (0.51 to 0.94) 12 (11 446) 0.77 (0.61 to 0.96)
Tirofiban 2 (2234) 1.05 (0.42 to 2.61) 1 (2141) 1.27 (0.65 to 2.48)
Eptifibatide 4 (6297) 0.60 (0.33 to 1.06) 1 (2064) 0.56 (0.24 to 1.34)
AMI indicates acute myocardial infarction; CI, confidence interval; No., number; and RR, risk ratio (fixed effects). 
There was no statistically significant heterogeneity in any case, and random effects estimates were similar (data not shown).
*Refers to all patients.
Reprinted with permission from Karvouni et al. J Am Coll Cardiol 2003;41:6-32 (701).
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sion (0.5 mcg per kg per min for 20 to 24 h), or aspirin,
heparin, and eptifibatide bolus (135 mcg per kg) and higher-
dose infusion (0.75 mcg per kg per min for 20 to 24 h) (198).
The 30-day composite primary end point of death, MI,
unplanned surgical or repeat percutaneous revascularization,
or coronary stent implantation for abrupt closure occurred in
11.4% of placebo-treated patients compared with 9.2% in the
135/0.5-mcg eptifibatide group (P equals 0.063) and 9.9% in
the 135/0.75-mcg eptifibatide group (P equals 0.22) (198).
The frequency of major bleeding events and transfusions was
similar among the 3 groups. 
A higher bolus and infusion of eptifibatide was evaluated in
10 948 patients with UA/NSTEMI who were assigned to
treatment with placebo or 1 of 2 doses of eptifibatide: 180
mcg per kg bolus plus 1.3 mcg per kg per min infusion
(180/1.3) or 180 mcg per kg bolus plus 2.0 mcg per kg per
min infusion (180/2.0) (199). Compared with placebo,
patients receiving 180/2.0-mcg eptifibatide had a lower fre-
quency of 30-day death or MI (15.7% vs 14.2%; P equals
0.042). In patients undergoing early (less than 72 h) coronary
intervention, 30-day composite events occurred less often in
patients receiving 180/2.0-mcg eptifibatide (11.6% and
16.7% in placebo-treated patients; P equals 0.01) (200, 201). 
The ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa
Receptor with Integrilin Therapy) trial evaluated the efficacy
and safety of eptifibatide treatment as adjunctive therapy
during nonemergency coronary stent implantation. A total of
2064 patients were enrolled from June 1999 to February
2000 in this multicenter, randomized, double-blind, parallel-
group, placebo-controlled (crossover-permitted) clinical
trial. A double-bolus regimen of eptifibatide (180 mcg per kg
bolus followed by a 2.0 mcg per kg per min infusion, with a
second 180 mcg per kg bolus given 10 min after the first
bolus) was compared with placebo treatment. The 48-h pri-
mary composite end point of death, MI, urgent target-vessel
revascularization, or bailout treatment with open-label GP
IIb/IIIa inhibitor therapy was reduced 37% from 10.5% to
6.6% (P equals 0.0015). There was a consistent treatment
benefit across all components of the end point and across all
subgroups of patients. At 30 days, the key secondary com-
posite end point of death, MI, and urgent target-vessel revas-
cularization was also improved 35% from 10.4% to 6.8% (P
equals 0.0034) (200,201). 
6.2.2.3. Tirofiban
Tirofiban is a nonpeptidyl tyrosine derivative that produces a
dose-dependent inhibition of GP IIb/IIIa–mediated platelet
aggregation (720). The clinical effect of tirofiban during
coronary angioplasty was evaluated in the Randomized
Efficacy Study of Tirofiban for Outcomes and Restenosis
(RESTORE) trial, a double-blind, placebo-controlled trial of
2139 patients with UA or acute MI defined by CK measured
at the end of 36 h or at the time of discharge (715). Patients
were randomly assigned to aspirin, heparin, and a tirofiban
bolus (10 mcg per kg over 3 min) plus infusion (0.15 mcg per
kg per minute), or to aspirin, heparin, and a placebo bolus
plus infusion for 36 h. The primary end point of the trial was
the occurrence of major events at 30-day, including death
due to any cause, MI, coronary bypass surgery due to angio-
plasty failure or recurrent ischemia, repeat target-vessel
angioplasty for recurrent ischemia, or insertion of a stent due
to threatened abrupt closure (715). The rate of primary 30-
day end point was reduced from 12.2% in the placebo group
to 10.3% in the tirofiban group (P equals 0.160). Patients
treated with tirofiban had a 38% relative reduction in the
composite end point at 48 h (P less than 0.005) and a 27%
relative reduction at 7 days (P equals 0.022). The incidence
of major bleeding was similar in the 2 groups with the TIMI
criteria (2.4% in tirofiban-treated patients and 2.1% in place-
bo-treated patients; P equals 0.662) (715), although major
bleeding tended to be higher in tirofiban-treated patients
(5.3% vs 3.7% in placebo-treated patients; P equals 0.096).
Thrombocytopenia was similar in both groups (0.9% for the
placebo group vs 1.1% for the tirofiban group; P equals
0.709) (721). A larger clinical benefit with tirofiban was seen
in patients with UA undergoing coronary angioplasty in the
PRISM-PLUS study, a randomized trial of 1570 patients
with UA or non–Q-wave MI assigned to 48- to 108-h treat-
ment with heparin plus tirofiban or heparin alone (722).
Coronary angioplasty was performed in 30.5% of patients
between 49 to 96 h after randomization (722). The compos-
ite end point of death, MI, or refractory ischemia was
reduced significantly in the heparin plus tirofiban group
compared with the heparin alone group (10.0% vs 15.7%; P
less than 0.01) (722).
Table 25. Recommendations for Use of GP IIb/IIIa Inhibitors in Patients Undergoing PCI
UA/NSTEMI and  UA/NSTEMI and 
Clopidogrel Used Clopidogrel Not Used STEMI Elective PCI
Abciximab, eptifibatide, Abciximab, eptifibatide, or Abciximab Abciximab, eptifibatide,
or tirofiban or tirofiban or tirofiban
Class IIa; LOE: B Class I; LOE: A Class IIa; LOE: B Class IIa; LOE: B
Eptifibatide or tirofiban
Class IIb; LOE: C
LOE indicates level of evidence; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and UA/NSTEMI, unstable
angina/non–ST-elevation myocardial infarction.
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400 to 600 s) of periprocedural anticoagulation are associat-
ed with an increased risk for bleeding complications (736). 
The safety of low-dose heparin during coronary angioplas-
ty has also been shown in a recent study. Fatal complications
(0.3%), emergency bypass surgery (1.7%), MI (3.3%), or
repeat angioplasty within 48 h (0.7%) were uncommon after
an empiric bolus of heparin 5000 U at the beginning of the
procedure (618). In a smaller randomized study of 400
patients assigned to fixed-dose heparin (15 000 international
units [IU]) or weight-adjusted heparin (100 IU per kg), there
were no differences in procedural success or bleeding com-
plications between the 2 groups (737), although use of the
weight-adjusted heparin resulted in earlier sheath removal
and more rapid transfer to a step-down unit (737). Another
advantage of weight-adjusted heparin dosing is that “over-
shooting” of the ACT value can be avoided. 
Two analyses of ACT and PCI-related complications have
not detected any relationship between ACT level and
ischemic complications, which suggests that the degree of
anticoagulation during PCI may be less of a factor in deter-
mining complications than in the earlier era of balloon angio-
plasty (738,739). The results of these limited studies suggest
that heparin is an intraprocedural component for PCI, despite
dosing uncertainties and an unpredictable therapeutic
response with the unfractionated preparation. It appears that
weight-adjusted heparin dosing may provide a clinically
superior anticoagulation method to fixed heparin dosing,
although definitive studies are lacking. 
Routine use of unfractionated heparin after an uncompli-
cated coronary angioplasty is no longer recommended
(72,740-743) and may be associated with more frequent
bleeding events (72,740), particularly when platelet GP
IIb/IIIa inhibitors are used (72,740). Subcutaneous adminis-
tration of unfractionated heparin (741) may provide a safer
and less costly means of extending antithrombin therapy than
intravenous unfractionated heparin if there are clinical rea-
sons to continue anticoagulation, such as residual thrombus
or significant residual dissections. 
In the SYNERGY (Superior Yield of the New strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa
Inhibitors) study, patients with NSTEMI were randomized to
treatment with either unfractionated heparin or subcuta-
neously administered enoxaparin. In patients who underwent
PCI within 8 h of the last subcutaneous dose, no additional
anticoagulation was administered. In those patients who
underwent PCI 8 to 12 h after the last subcutaneous dose, an
additional intravenous dose of enoxaparin 0.3 mg per kg was
administered at the time of PCI. The rates of major ischemic
complications in those patients undergoing PCI were similar
between those treated with unfractionated heparin and those
treated with enoxaparin (744). Bleeding was observed to be
higher in those patients who “crossed over” from one antico-
agulant to the other. Some of these crossover patients were
those who received a different anticoagulant than what they
had been randomized to and had received before. On the
basis of this observation, it appears prudent to not give an
additional anticoagulant to patients who are receiving one
6.2.3. Antithrombotic Therapy
6.2.3.1. Unfractionated Heparin, Low-Molecular-
Weight Heparin, and Bivalirudin
Class I
1. Unfractionated heparin should be administered to
patients undergoing PCI. (Level of Evidence: C)
2. For patients with heparin-induced thrombocytopenia,
it is recommended that bivalirudin or argatroban be
used to replace heparin. (Level of Evidence: B)
Class IIa
1. It is reasonable to use bivalirudin as an alternative to
unfractionated heparin and glycoprotein IIb/IIIa
antagonists in low-risk patients undergoing elective
PCI. (Level of Evidence: B)
2. Low-molecular-weight heparin is a reasonable alter-
native to unfractionated heparin in patients with
UA/NSTEMI undergoing PCI. (Level of Evidence: B)
Class IIb
Low-molecular-weight heparin may be considered as
an alternative to unfractionated heparin in patients
with STEMI undergoing PCI. (Level of Evidence: B)
Intravenous unfractionated heparin prevents clot formation
at the site of arterial injury (723) and on coronary guidewires
and catheters used for coronary angioplasty (724). Although
the intensity of anticoagulation with unfractionated heparin
is generally determined with activated partial thromboplastin
times, these values are less useful for monitoring anticoagu-
lation during coronary angioplasty, because higher levels of
anticoagulation are needed than can be discriminated with
the activated partial thromboplastin time alone. Instead, the
activated clotting time (ACT) has been more useful to follow
heparin therapy during coronary angioplasty (725). The
Hemochron and HemoTec devices are commonly used to
measure ACT values during coronary angioplasty (725-727).
The Hemochron ACT generally exceeds the HemoTec ACT
by 30 to 50 s, although considerable measurement variabili-
ty exists. 
Empiric recommendations regarding heparin dosage dur-
ing coronary angioplasty have been proposed (728,729), but
ACT levels after a fixed dose of unfractionated heparin may
vary substantially due to differences in body size (730), con-
comitant use of other medications, including intravenous
nitroglycerin (731,732), and in the presence of acute coro-
nary syndromes that increase heparin resistance. 
The relationship between the level of the ACT and devel-
opment of ischemic complications during coronary angio-
plasty has been controversial. Whereas some studies have
identified an inverse relationship between the initial ACT
and the risk of ischemic events (733,734), others found either
no relationship or a direct relationship between the degree of
anticoagulation and occurrence of complications (735). It is
generally believed that very high levels (ACTs greater than
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to achieve a target ACT of 200 s with either the HemoTec or
Hemochron device. The currently recommended target ACT
for eptifibatide and tirofiban is less than 300 s during coro-
nary angioplasty. Postprocedural heparin infusions are not
recommended during GP IIb/IIIa therapy (748-750). 
Transitioning of patients with acute coronary syndromes
who have been treated with enoxaparin from the medical
floor to the cardiac catheterization laboratory is based on
pharmacokinetic data, clinical experience, and expert opin-
ion. In patients who received the last subcutaneously admin-
istered dose of enoxaparin within 8 h, no additional antico-
agulant therapy is needed before PCI is performed. In
patients who received the last subcutaneously administered
dose of enoxaparin between 8 and 12 h before PCI, an addi-
tional 0.3 mg per kg dose of enoxaparin should be adminis-
tered intravenously before PCI (whether or not the patient is
to be treated with a GP IIb/IIIa inhibitor). Alternatively, in
the latter group of patients, supplemental anticoagulation
with unfractionated heparin can be used. Unfractionated
heparin 50 U per kg (with a target ACT of 200 to 250 s) may
be administered in those patients to be treated with a GP
IIb/IIIa inhibitor; 60 U per kg unfractionated heparin (with a
target ACT of 250 to 300 s) may be administered in those
patients who are not concomitantly treated with a GP IIb/IIIa
inhibitor. A higher risk of bleeding may result if patients
cross over between different anticoagulant therapies during
the index admission.
Low-molecular-weight heparins have little effect on meas-
urements of ACT. Therefore, the ACT should not be used as
a guide to anticoagulation therapy in patients currently being
treated with a low-molecular-weight heparin. Sheath
removal when followed by manual groin compression may
be performed 4 h after the last intravenous dose of enoxa-
parin or 6 to 8 h after the last subcutaneous dose of enoxa-
parin (751,752).
6.3. Post-PCI Management
After PCI, in-hospital care should focus on monitoring the
patient for recurrent myocardial ischemia, achieving hemo-
stasis at the catheter insertion site, detecting and preventing
contrast-induced renal failure, and monitoring results of the
vascular closure device, if used (753). Attention should also
be directed toward implementing appropriate secondary ath-
erosclerosis prevention programs. The patient should under-
stand and adhere to recommended medical therapies and
behavior modifications known to reduce subsequent morbid-
ity and mortality from coronary heart disease. 
Most patients can be safely discharged from the hospital
within the next calendar day after an uncomplicated elective
PCI. Special skilled nursing units have been developed by
many institutions to facilitate post-PCI management.
Specific protocols for sheath removal, continuation of anti-
coagulation or antiplatelet therapies, and observation for
recurrent myocardial ischemia/infarction and contrast-
induced renal failure are of particular assistance in ensuring
appropriate outcomes during this period. Pilot studies sug-
gest that selected patients may be discharged on the same day
form of anticoagulant (e.g., not to give unfractionated
heparin to those who have received subcutaneous enoxaparin
within the last 12 h and not to give intravenous enoxaparin to
those receiving intravenous heparin).
The safety and efficacy of low-molecular-weight heparin
therapy in patients undergoing PCI has been evaluated. In all
but 1 of these studies, the agent studied has been enoxaparin.
These studies have found bleeding and ischemic complica-
tion rates to be low and comparable to those observed in PCI
patients who had been treated with unfractionated heparin.
In those patients who have received subcutaneous enoxa-
parin for the treatment of NSTEMI and are to undergo PCI
within 8 h of the last subcutaneous dose, no additional anti-
coagulant should be administered. In those who undergo PCI
8 to 12 h after the last subcutaneous dose, an additional intra-
venous dose of 0.3 mg per kg should be administered imme-
diately before device activation.
Bivalirudin, a hirudin analog, is a direct thrombin inhibitor.
It has been tested against heparin and a GP IIb/IIIa inhibitor
in the REPLACE-2 trial of patients undergoing PCI without
high-risk features. The primary end point at 30 days includ-
ed major bleeding plus the usual end points of death, MI, and
urgent revascularization. These events occurred in 9.2% of
the bivalirudin group and 10% of the group given unfrac-
tionated heparin plus GP IIb/IIIa inhibitors (nonsignificant).
The secondary end point was freedom from death, MI, and
urgent revascularization and occurred in 7.6% of the
bivalirudin group and 7.1% of the group given unfractionat-
ed heparin plus GP IIb/IIIa inhibitors (also nonsignificant),
but bleeding (combined major and moderate bleeding) was
significantly reduced in the bivalirudin group (from 7.1% to
2.4%, P less than 0.001). Although a small, nonsignificant
increase in periprocedural NSTEMI was seen in the
bivalirudin-treated patients, by 1 year mortality was not sig-
nificantly increased in the bivalirudin group (1.89% vs 2.46
%) (744a). These results established that bivalirudin is not
superior to standard therapy, but it appears to be a reasonable
alternative in non-high-risk patients (745). Bivalirudin is a
good anticoagulant for use in patients with heparin-induced
thrombocytopenia and those with renal failure (746).
Argatroban is also an effective therapy for heparin-induced
thrombocytopenia (747). More data are needed to establish
its use for patients with STEMI, NSTEMI, and diabetes. 
6.2.3.2. Heparin Dosing Guidelines
In those patients who do not receive GP IIb/IIIa inhibitors,
sufficient unfractionated heparin should be given during
coronary angioplasty to achieve an ACT of 250 to 300 s with
the HemoTec device and 300 to 350 s (200,201) with the
Hemochron device. A weight-adjusted bolus heparin (70 to
100 IU per kg) can be used to avoid excess anticoagulation.
If the target values for ACT are not achieved after a bolus of
heparin, additional heparin boluses (2000 to 5000 IU) can be
given. Early sheath removal should be performed when the
ACT falls to less than 150 to 180 s. 
The unfractionated heparin bolus should be reduced to 50
to 70 IU per kg when GP IIb/IIIa inhibitors are given in order
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degree to which these technologies reduce length of hospital
stay and cost remains to be determined (764,770-772). 
Patients with pre-existing renal insufficiency, diabetes, and
dehydration are at higher risk and should be monitored for
contrast-induced nephropathy, generally defined as an
increase of greater than 25% or greater than 0.5 mg per dL in
serum creatinine that occurs within 48 h after PCI. In addi-
tion, those patients receiving higher contrast loads or a sec-
ond contrast load within 72 h and those undergoing IABP
placement should have renal function assessed. A risk score
based on 8 variables (hypotension, IABP, HF, chronic renal
insufficiency, diabetes, age more than 75 years, anemia, and
contrast volume) has been developed to assist in the identifi-
cation of patients at risk for contrast-induced nephropathy
after PCI (773). Whenever possible, nephrotoxic drugs (cer-
tain antibiotics, nonsteroidal anti-inflammatory agents, and
cyclosporine) and metformin (especially in those with pre-
existing renal dysfunction) should be withheld for 24 h
before PCI is performed, and consideration should be given
to withholding angiotensin converting enzyme inhibitors and
angiotensin receptor blockers on the day of the procedure
(774-776). Although data on the prevention of contrast-
induced nephropathy are inconclusive, several measures
including preprocedural and postprocedural hydration, use of
low and iso-osmolar contrast agents, and pretreatment with
acetylcysteine or sodium bicarbonate may be helpful in
reducing the incidence of contrast-induced nephropathy
among higher-risk patients (774,775,777).
6.3.1. Postprocedure Evaluation of Ischemia
After PCI, chest pain may occur in as many as 50% of
patients. ECG evidence of ischemia identifies those with sig-
nificant risk for acute vessel closure (6,118,119,778-780).
When angina pectoris or ischemic ECG changes occur after
PCI, the decision to proceed with further interventional pro-
cedures, CABG surgery, or medical therapy should be indi-
vidualized on the basis of factors such as hemodynamic sta-
bility, amount of myocardium at risk, and the likelihood that
the treatment will be successful. 
A 12-lead ECG should be obtained before and soon after
PCI and again if symptoms should occur. Angina-like symp-
toms with ECG changes will assist in determining the need
for repeat angiography and for additional therapy. 
As discussed in Section 6.2.2, coronary stents and platelet
GP receptor inhibitors have reduced the incidence of acute
closure significantly. Factors that correlate with a poor out-
come after acute coronary closure include age greater than
70 years, large ischemic burden, presentation with acute
coronary syndromes, and LV ejection fraction less than 30%
(778-780).
Elevated levels of CK or the MB subfraction (CK-MB) or
ECG abnormalities are reported to occur in 5% to 30% of
patients after PCI (23). The mechanisms associated with CK
release include side-branch occlusion, distal embolization,
intimal dissection, and coronary spasm (781). A more fre-
quent requirement for revascularization procedures and a
after PCI (754,755) especially when the procedure is per-
formed by the percutaneous radial or brachial approach
(756). However, confirmation by larger studies is necessary
before widespread endorsement of this strategy. 
In the prior setting of aggressive systemic anticoagulation,
vascular complications may occur in as many as 14% of
patients after PCI, but those requiring surgical repair occur in
3.5% (736) of patients, although lower rates of vascular com-
plications can now be expected with reduced anticoagulation
and smaller sheath sizes (757-762). Major factors associated
with vascular complications include use of fibrinolytic or
platelet inhibitor therapy, coexisting peripheral vascular dis-
ease, female gender, prolonged heparin use with delayed
sheath removal, and older age (736,758,760-764). Although
most bleeding complications at the vascular access site are
obvious and readily managed, physicians and nurses should
remain alert for retroperitoneal hematoma, the signs and
symptoms of which may include hypotension, marked
suprainguinal tenderness, and severe back or lower-quadrant
abdominal pain (765). Post-PCI hematocrit should be moni-
tored for a decrease greater than absolute 5% to 6%.
Computed tomography can confirm the diagnosis of
retroperitoneal hematoma, and more than 80% of patients
can be treated conservatively with transfusions without sur-
gery (764). Pseudoaneurysms may be treated effectively with
ultrasound-directed compression in the majority of patients
who are not bleeding and do not require continued anticoag-
ulation (763,766,767). Arteriovenous fistulas, generally
occurring late after a procedure, are detected by a continuous
murmur over the puncture site and, in rare cases, may be
associated with high-output failure. In general, repeat use of
the access site should be avoided because of the possibility
of making the fistula larger, accessing the vein when attempt-
ing to access the artery, and increasing potential issues with
hemostasis. Both pseudoaneurysm and arteriovenous fistula
can occur secondary to cannulation of the superficial rather
than the common femoral artery (768). Arterial compression
systems and percutaneous vascular closure devices reduce
the incidence of vascular complications (753,756). A meta-
analysis involving 37 000 patients undergoing diagnostic
coronary arteriography and PCI compared manual compres-
sion with 3 closure devices (VasoSeal™, AngioSeal™, and
PerClose™). No difference was seen in access-related com-
plications between manual compression, PerClose™, and
AngioSeal™; however, there were more complications asso-
ciated with VasoSeal™ than with manual compression. The
complications evaluated included pseudoaneurysm requiring
ultrasound-guided compression or surgical repair; arteriove-
nous fistula; retroperitoneal hematoma causing hemodynam-
ic compromise and necessitating surgery, blood transfusion,
prolonged hospitalization, and/or death; femoral artery
thrombosis (vessel occlusion requiring surgery or thrombol-
ysis); surgical vascular repair; access-site infection necessi-
tating treatment with antibiotics or surgical drainage; and
blood transfusion. The study was performed with early gen-
erations of devices. Potential benefits of newer adjunctive
therapies are not well established (753,769). However, the
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Depending on the risk factors and contraindications pres-
ent, advice should include antithrombotic therapy (aspirin
and/or clopidogrel or ticlopidine), control of hypertension,
diabetic management, aggressive control of serum lipids,
maintenance of a low-density lipoprotein cholesterol level
substantially below 100 mg per dL (optional therapeutic tar-
get less than 70 mg per dL in very-high-risk patients [611]),
abstinence from tobacco use, weight control, regular exer-
cise, beta-blocker use, and inhibition of the renin-
angiotensin-aldosterone system as recommended in the
ACC/AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction (Table 26) (332,783).
Given the natural history and pathophysiology of CAD
among patients undergoing PCI, the clinically indicated sec-
ondary prevention measures (Table 26) (332,783), which
usually include aspirin, statin therapy, beta-blockers, and
inhibitors of the renin-angiotensin-aldosterone system,
should be continued indefinitely except in those patients
intolerant to these agents (242,783-792). Patients should
receive instructions on participation in cardiac rehabilitation
and the timing of return to full activities, be informed to con-
tact their physician or seek immediate medical attention if
symptoms recur, and have made plans for a follow-up visit to
assess compliance with secondary prevention therapies.
6.3.3. Exercise Testing After PCI
The published ACC/AHA practice guidelines for exercise
testing (793) provide an excellent summary of the available
information on exercise testing after PTCA. Although
restenosis remains the major limitation of PCI, symptom sta-
tus is an unreliable index to development of restenosis, with
25% of asymptomatic patients documented as having
ischemia on exercise testing (794). (See Section 5.1, Patients
With Asymptomatic Ischemia or CCS Class I or II Angina
for further information.)
To identify restenosis rather than predict the probability of
its occurrence, patients may be tested later (3 to 6 months
after PCI). Table 27 reviews the predictive value of exercise
testing for restenosis (794-802). Variability is attributed pre-
dominantly to differences in the populations studied and cri-
teria for restenosis. 
Because myocardial ischemia, whether painful or silent,
worsens prognosis (803), some authorities have advocated
routine testing. However, the ACC/AHA practice guidelines
for exercise testing favor selective evaluation in patients con-
sidered to be at particularly high risk (e.g., patients with
decreased LV function, multivessel CAD, proximal LAD
disease, previous sudden death, diabetes mellitus, left main
disease, hazardous occupations, and suboptimal PCI results)
(793). The exercise ECG is an insensitive predictor of
restenosis, with sensitivities ranging from 40% to 55%, sig-
nificantly less than those obtainable with single photon emis-
sion computed tomography (SPECT) (804,805) or exercise
echocardiography (806-808). This lower sensitivity of the
exercise ECG and its inability to localize disease limit its
usefulness in patient management both before and after PCI
(797,804,809). For these reasons, stress imaging is preferred
higher risk of death or subsequent MI are associated with
elevated cardiac biomarkers, increasing as a continuous
function with no obvious threshold effect. Both acute and
chronic complications are more common among patients
with elevated cardiac biomarkers. Even in patients with low-
level elevations of CK-MB in whom the in-hospital risk is
low, the intermediate- and long-term risks are also increased.
Postprocedural increases in CK and CK-MB are not specific
for a particular technique and have been reported after bal-
loon angioplasty, directional and rotablator atherectomy,
excimer laser angioplasty, and stent placement. Kong et al.
(782) found that increased levels of CK are a significant
independent predictor of cardiac mortality and subsequent
MI (56). Cardiac mortality after elective PCI was signifi-
cantly higher for patients with high (more than 3.0 times nor-
mal) and intermediate (1.5 to 3.0 times normal) CK com-
pared with those with low CK (more than 1.0 but less than
1.5 times normal) elevations and control patients (P equals
0.007). (See Section 3.2, Acute Outcome: Procedural
Complications.) 
CK and CK-MB measurements should be obtained in
patients with suspected ischemia (prolonged chest pain, side-
branch occlusion, recurrent ischemia, or hemodynamic insta-
bility) during PCI. Ideally, the European Society of
Cardiology and the ACC recommend that small infarcts may
and should be detected by serial blood sampling and analysis
before and after the procedure (6 to 8 h before and 24 h after,
respectively) (21). In patients in whom a clinically driven
CK-MB determination is made, a CK-MB index increase of
more than 5 times the upper limit of normal should be treat-
ed as signifying an MI, and the patient should be referred for
further observation. The results of CK-MB should be con-
sidered for the discharge management strategies for these
patients. 
The troponin isoforms I and T have a high level of sensi-
tivity and specificity for the diagnosis of acute MI. Troponin
T or I elevation occurs frequently after PCI. The timing of
the peak elevation after PCI is unclear (25). Minor elevations
do not appear to have prognostic value, whereas marked
(more than 5 times) elevations are associated with worsened
1-year outcome (26,27).
6.3.2. Risk Factor Modifications
All patients should be instructed about necessary behavior
and risk factor modification, and the appropriate medical
therapies should be initiated for the secondary prevention of
atherosclerosis before the patient leaves the hospital. The
interventional cardiologist should emphasize the importance
of these measures directly to the patient, because failure to
do so may suggest that secondary prevention therapies are
not necessary. The interventional cardiologist should interact
with the primary care physician to ensure that the necessary
secondary prevention therapies initiated during hospitaliza-
tion are maintained by patients after discharge from the hos-
pital. Secondary prevention measures are an essential part of
long-term therapy because they can reduce future morbidity
and mortality associated with the atherosclerotic process. 
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Table 26. Comprehensive Risk Reduction for Patients With Coronary and Other Vascular Disease After PCI
Goals Intervention Recommendations
Smoking: Ask about tobacco status at every visit. Strongly encourage patient and family to
Goal stop smoking and to avoid environmental tobacco smoke. Assess the tobacco
Complete cessation. No exposure to user’s willingness to quit. Assist by counseling and developing a plan for quitting.
environmental tobacco smoke Arrange follow-up, referral to special programs, orpharmacological therapy 
(including nicotine replacement and buproprion). Urge avoidance of exposure to
environmental tobacco smoke at work and home.
Blood pressure control:
Goal
Less than 140 over 90 mm Hg 
or
less than 130 over 80 mm Hg 
if chronic kidney disease or diabetes is present
Lipid management:
(TG less than 200 mg per dL)
Primary goal
LDL-C substantially less than 
100 mg per dL (optional target less 
than 70 mg per dL for very-high-risk patients)¶
Lipid management: If TG is greater than or equal to 150 mg per dL or HDL-C is less than 
(TG 200 mg per dL or greater) 40 mg per dL:
• Emphasize weight management and physical activity. Advise smoking 
cessation.
Primary goal If TG is 200-499 mg per dL: 
Non–HDL-C* substantially less • After LDL-C–lowering therapy†**, consider adding fibrate or niacin‡.
than 130 mg per dL
If TG is greater than or equal to 500 mg per dL:
• Consider fibrate or niacin‡ before LDL-C–lowering therapy.†**
• Consider omega-3 fatty acids as adjunct for high TG.
Physical activity: Assess risk, preferably with exercise test, to guide prescription.
Minimum goal Encourage minimum of 30 to 60 minutes of activity, preferably daily or at
30 minutes 5 days per week; least 5 times weekly (brisk walking, jogging, cycling, or other  aerobic 
optimal daily activity) supplemented by an increase in daily lifestyle activities (e.g., walking 
breaks at work, gardening, household work). Encourage resistance training 2 
days per week.
Cardiac rehabilitation programs are recommended, particularly for those patients 
with multiple modifiable risk factors and/or those moderate- to high-risk patients 
in whom supervised exercise training is warranted.
Continued on next page
If blood pressure is 120 over 80 mm Hg or greater:·
• Initiate or maintain lifestyle modification (weight control, increased
physical activity, alcohol moderation, moderate sodium restriction,
and emphasis on fruits, vegetables, and low-fat dairy products) 
in all patients.
If blood pressure is 140 over 90 mm Hg or greater (or 130 over 80 mm Hg or
greater for individuals with chronic kidney disease or diabetes):
• Add blood pressure medication, emphasizing the use of beta-blockers and
inhibitors of the renin-angiotensin-aldosterone system.
Start dietary therapy in all patients (less than 7% of total calories as saturated fat and less
than 200 mg of cholesterol per day). Promote physical activity and weight management.
Encourage increased consumption of omega-3 fatty acids in fish# or 1 g per day omega-3
fatty acids from supplements for risk reduction (for treatment of elevated TG, higher
doses are usually necessary for risk reduction). 
Assess fasting lipid profile in all patients, preferably within 24 h of an acute event. For
patients hospitalized, initiate lipid-lowering medication as recommended below before
discharge according to the following guide:
LDL-C less than 100 mg per dL LDL-C greater than or equal to 
(baseline or on-treatment): 100 mg per dL (baseline or on-
treatment):
• Statins preferred to lower LDL-C. • Initiate or intensify LDL-
C–lowering therapy with drug 
treatment. May require 
combination therapy with 
standard-dose ezetimide, bile 
acid sequestrant, or niacin‡.
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
e239
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
Circulation    February 21, 2006
ACC/AHA/SCAI Practice Guidelines
Table 26. Continued
Goals Intervention Recommendations
Weight management: Calculate BMI and measure waist circumference as part of evaluation. Monitor 
Goal response of BMI and waist circumference to therapy.
BMI 18.5 to 24.9 kg per m2
Start weight management and physical activity as appropriate. Desirable BMI 
Waist circumference: range: 18.5 to 24.9 kg per m2.
Women: Less than 35 inches
Men: Less than 40 inches If waist circumference is 35 inches or greater in women or 40 inches or greater
in men, initiate lifestyle changes and consider treatment strategies for metabolic 
syndrome.
Diabetes management: Appropriate glucose-lowering therapy to achieve near-normal fasting plasma 
Goal glucose as indicated by HbA1c.
HbA1c less than 7%
Treatment of other risk factors (e.g., physical 
activity, weight management, blood pressure cholesterol management).
Antiplatelet agents/ anticoagulants: For all post-PCI stented patients, aspirin 325 mg daily should be given for at least
1 month after bare metal stent implantation, 3 months after sirolimus stent, and 6
months after paclitaxel stent, after which daily chronic aspirin†† (75 to 162 mg per
day) should be continued indefinitely in all patients if not contraindicated. 
For post-PCI stented patients, clopidogrel 75 mg per day should be given for at 
least 1 month after bare metal stent implantation, 3 months after sirolimus stent, 
and 6 months after paclitaxel stent, after which clopidogrel should ideally be con-
tinued up to 12 months in all stented patients  who are not at high risk of bleeding. 
Use warfarin in combination with clopidogrel and low-dose aspirin with great 
caution and when INR is carefully regulated (2.0 to 3.0).
Manage warfarin to INR 2.5 to 3.5 for post-MI patients when clinically indicated or 
for those not able to take aspirin or clopidogrel.
Renin-angiotensin- Consider ACE inhibitors for all CHD patients indefinitely; start early after MI in 
aldosterone system blockers: stable high-risk patients (anterior MI, previous MI, Killip class greater than or equal
to II [S3 gallop, rales, radiographic HF]). 
Continue indefinitely in for all patients with LV dysfunction (ejection fraction less 
than or equal to 0.40) or symptoms of heart failure.
Use as needed to manage blood pressure or consider for chronic therapy in all 
other patients.
Use angiotensin receptor blockers in post-STEMI patients who are intolerant of ACE
inhibitors and who have either clinical or radiological signs of heart failure or LVEF
less than 0.40.
Aldosterone blockade in post-STEMI patients without significant renal dysfunction§
or hyperkalemia¦ who are already receiving therapeutic doses of an ACE inhibitor, 
have an LVEF less than or equal to 0.40, and have either diabetes or heart failure.
Beta-blockers: Start in all post-MI and acute patients (arrhythmia, LV dysfunction, inducible
ischemia). Continue for a minimum of 6 months; continue indefinitely in patients 
with STEMI. Observe usual contraindications. Use as needed to manage angina, 
rhythm, or blood pressure in all other patients.
ACE indicates angiotensin-converting enzyme; BMI, body mass index; HF, congestive heart failure; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; INR, interna-
tional normalized ratio; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary inter-
vention; STEMI, ST-elevation myocardial infarction; and TG, triglyceride.  
*Non–HDL-C equals total cholesterol minus HDL cholesterol.
†Treat to a goal of non–HDL-C substantially less than 130 mg per dL.
‡Dietary supplement niacin must not be used as a substitute for prescription niacin.
§Creatinine should be less than or equal to 2.5 mg per dL in men and less than or equal to 2.0 mg per dL in women.
¦Potassium should be less than or equal to 5.0 mEq per liter.
¶Patients with acute coronary syndromes and other very-high-risk patients (e.g., established CHD plus multiple major risk factors [especially diabetes] or severe and poorly controlled risk fac-
tors [especially continued cigarette smoking and/or metabolic syndrome]) should be considered for optional LDL-C goal less than 70 mg per dL.
#Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury.
**The use of resin is relatively contraindicated when TGs are greater than 200 mg per dL.
††Some recommend avoiding regular use of ibuprofen, which may limit the cardioprotective effects of aspirin. Use of cyclo-oxygenase-2 inhibitors may be associated with increased incidence
of cardiovascular events.
Modified with permission from Smith et al. Circulation 2001;104:1577-9 (810) (undergoing update with anticipated release in 2005) and Antman et al. J Am Coll Cardiol 2004;44:e1-e211 (362).
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surveillance angiography at 2 to 3 months for all patients
after ULM PCI. Studies from the DES era have reported the
performance of routine angiography 4 to 8 months after PCI
or earlier if clinically indicated by symptoms or documented
myocardial ischemia (159,160).
7. SPECIAL CONSIDERATIONS
7.1. Ad Hoc Angioplasty—PCI at the Time of 
Initial Cardiac Catheterization
Ad hoc coronary intervention is defined as PCI performed at
the same time as diagnostic cardiac catheterization. During
the past several years, in an effort to reduce hospital length
of stay and potentially reduce costs, PCI has increasingly
been performed immediately after the diagnostic coronary
angiographic procedure (811), with reported incidence rang-
ing from 52% to 83% (812-814). The indications for diag-
nostic catheterization and coronary angiography in different
catheterization laboratory settings are discussed in the
ACC/SCAI Expert Consensus Document on Catheterization
Laboratory Standards (Table 28) (309,815). 
Ad hoc angioplasty has several inherent advantages. It
expedites patient care, avoids a second invasive procedure
with its associated risks and recognized morbidity, and
reduces total X-ray exposure and therefore cost, but only in
settings in which intrinsic risks are low (813). However, ad
hoc intervention is associated with a higher procedural con-
trast use and should be avoided in situations where excessive
to evaluate symptomatic patients after PCI. If the patient’s
exertional capacity is significantly limited, coronary angiog-
raphy may be more efficacious to evaluate symptoms of typ-
ical angina. Exercise testing after discharge is helpful for
activity counseling and exercise training as part of cardiac
rehabilitation. Neither exercise testing nor radionuclide
imaging is indicated for the routine, periodic monitoring of
asymptomatic patients after PCI without specific indications.
6.3.4. Left Main CAD
Class IIa
It is reasonable that patients undergoing PCI to
unprotected left main coronary obstructions be fol-
lowed up with coronary angiography between 2 and 6
months after PCI. (Level of Evidence: C)
Careful postprocedure surveillance with coronary angiog-
raphy is needed to prevent fatal MI or sudden death that may
be associated with ISR with a large area of myocardium in
jeopardy; however, the frequency and best method of follow-
up is unknown (162). Early experience in the ULTIMA reg-
istry using BMS for ULM lesions suggested a high early
mortality (2% per month) after PCI, which led the study’s
authors to suggest routine surveillance angiography at 2 and
4 months after PCI (153). Others advocate routine stress test-
ing or cardiac catheterization at 3 and 6 months even in
asymptomatic patients (148,150). In view of these observa-
tions and suggestions, the Committee recommends routine
Table 28. Exclusion Criteria for Invasive Cardiac Procedures in Settings Without Full-Support Services
Type of 
Location Patient Diagnostic Procedures Therapeutic Procedures
Hospitals Adult Age greater than 75 years All valvuloplasty procedures, complex adult 
NYHA class III or IV heart failure congenital heart disease diagnostic or therapeutic
Acute, intermediate, or high-risk procedures
ischemic syndromes
Recent MI with postinfarction ischemia Diagnostic pericardiocentesis when the effusion is 
Pulmonary edema thought to be caused small or moderate in size and there is no 
by ischemia tamponade
Markedly abnormal noninvasive test
indicating a high likelihood of left main or Elective coronary intervention
severe multivessel coronary disease
Known left main coronary artery disease
Severe valvular dysfunction, especially in the
setting of depressed LV performance
Pediatric No procedures approved No procedures approved
Freestanding Adult All of the above plus high-risk patients by 
laboratories virtue of comorbid conditions, including need 
for anticoagulation, poorly controlled hyper-
tension or diabetes, contrast allergy, or renal 
insufficiency
Pediatric No procedures approved No procedures approved
LV indicates left ventricular, MI, myocardial infarction; and NYHA, New York Heart Association. 
Modified from Bashore et al. J Am Coll Cardiol 2001;37:2170-214.
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contrast has been used and when adequate pretreatment with
aspirin or antiplatelet agents has not been achieved (814). 
In contrast to ad hoc angioplasty, a staged approach also
has several advantages. It allows ample time to review the
angiogram and plan the procedural strategy; discuss the
risks, benefits, and alternatives with the patient and family;
and obtain consultation from cardiothoracic surgical col-
leagues. It is far more difficult to adequately inform the
patient of risks, benefits, and alternatives without knowledge
of the anatomy and the extent of coronary disease. A staged
approach also allows for optimal hydration and pretreatment
with oral antiplatelet agents. Explicit and clear informed con-
sent, especially for ad hoc PCI, should be discussed by the
interventional cardiologist with the patient and family. 
Studies evaluating the outcome of patients undergoing ad
hoc coronary intervention have reported that informed
patients with suitable anatomy have a shorter hospital stay,
less radiation exposure, and lower costs without an increase
in procedural complications compared with patients under-
going a staged approach (812,813,816,817). In a multicenter
cohort study of 35 700 patients undergoing elective coronary
angioplasty between 1992 and 1995, the risk of a major com-
plication (MI, emergency CABG, or death) from combined
(“ad hoc”) versus staged procedures was 2% and 1.6%,
respectively. After adjustment for clinical and angiographic
differences between groups, the risk from combined proce-
dures was not significantly different. However, patients with
multivessel disease, women, patients older than 65 years, and
patients undergoing multilesion coronary angioplasty were at
increased risk of an adverse outcome (818). In an analysis of
patients in the New York State PCI Registry, in-hospital mor-
tality was similar in patients undergoing ad hoc and staged
procedures, although patients with HF had a significantly
lower mortality when undergoing staged procedures. These
studies suggest that it is safe to perform PCI after diagnostic
catheterization in selected patients (819). 
Ad hoc coronary intervention is particularly suitable for
patients with clinical evidence of restenosis 6 to 12 months
after the initial procedure (820), patients undergoing primary
angioplasty for MI, and patients with refractory UA in need
of urgent revascularization (821). Before the procedure,
these patients should be treated with aspirin and clopidogrel
(822) only when PCI with stent placement is highly likely,
and they should give appropriate informed consent for antic-
ipated PCI. Ad hoc PCI should be performed only in a well-
informed patient, particularly in the setting of single-vessel
disease without morphologic features predictive of an
adverse outcome, when it is clear that this treatment strategy
is the best alternative. However, ad hoc percutaneous revas-
cularization should not be performed in patients in whom the
angiographic findings are unanticipated or in whom the indi-
cation, suitability, or preference for percutaneous revascular-
ization is unclear (823). Patient safety should be the para-
mount consideration when ad hoc intervention is being con-
sidered. This Committee endorses the recommendations
from the SCAI that ad hoc PCI be individualized and not be
a standard or required strategy for all patients (824). The
Writing Committee encourages future studies to further eval-
uate the outcomes associated with ad hoc angioplasty and its
cost effectiveness.
7.2. PCI in Cardiac Transplant Patients
Allograft atherosclerosis and vasculopathy are the main
cause of death in cardiac transplant recipients. Because no
medical therapy is known to prevent graft atherosclerosis,
and retransplantation is associated with decreased survival,
palliative therapy with PCI has been proposed and performed
(825). No single medical center has performed PCI in many
patients, and thus, the responses and outcomes of a large
cohort are unavailable for review. However, pooled informa-
tion from 11 medical centers retrospectively analyzing
results of coronary angioplasty in cardiac transplant patients
has been reported (826). These investigators concluded that
although high procedural success can be achieved and PCI
may be applied in a selected cardiac transplant population
with success and complication rates comparable to the rou-
tine patient population, it remains unknown whether PCI
prolongs allograft survival. 
Coronary stenting in cardiac allograft vascular disease has
been performed in small numbers of patients with favorable
results (827). Heublein et al. (828) compared angioplasty and
stenting in 27 patients who received 48 stents, 5.7 plus or
minus 2.9 years after heart transplantation. Coronary angio-
plasty resulted in a minimal increase in luminal dimensions
compared with stenting (2.04 plus or minus 0.36 mm for
angioplasty vs 2.53 plus or minus 0.38 mm for stenting).
There were no stent thromboses or bleeding complications.
At a mean follow-up period of 8 plus or minus 5 months
(range 2 weeks to 23 months), all patients were clinically
event-free. Six of 24 stented vessels in 16 patients had
restenosis greater than 50% by ultrasound or angiography 6
months after the procedure. These somewhat disappointing
results highlight the need for a better understanding of the
mechanism of graft vasculopathy and the development of
refined, specific PCI-related therapies with better outcomes.
The largest reported experience of PCI in cardiac transplant
recipients to date showed that PCI with stents is effective in
relieving focal stenoses in patients with allograft coronary
disease (829). Between 1990 and 2000, 62 patients (1.5 to 15
years after transplant) underwent 151 procedures that result-
ed in PCI of 219 lesions. Periprocedural mortality was low at
2% (4 of 151 procedures). Two-year freedom from allograft
coronary disease death or graft loss was 74% for 1-vessel
disease at first PCI, 75% for 2-vessel disease, and 27% for 3-
vessel disease (P equals 0.009). There were no incidences of
acute stent thrombosis. Freedom from repeat PCI of the same
vessel ranged from 75% at 6 months to 57% at 4 years.
Freedom from restenosis ranged from 95% at 1 month to
57% at 6 months. Multivariate predictors of freedom from
restenosis were the use of stents, higher antiproliferative
immunosuppressant dose, and an era effect (e.g., procedural
advances and widespread use of periprocedural GP IIb/IIIa
inhibitors and thienopyridines, among others). Long-term
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Long-term patency of the initial target lesion may be
achieved with repeated balloon dilatations. In a series of
1455 de novo lesions treated with PTCA, angiographic
restenosis requiring repeat PTCA developed in 32% (842).
Late patency was achieved in 93% of lesions with up to 3
PTCA procedures. Only 23 lesions (1.6%) required 4 or
more procedures (842). 
Although atheroablation devices have been developed in an
attempt to lower the second restenosis risk in patients, none
has shown an incremental benefit over PTCA. In a study of
1569 patients who underwent excimer laser coronary angio-
plasty for restenotic (n equals 620 patients) or de novo (n
equals 949) lesions (843), procedural success was higher in
restenotic patients (92% vs 88% in de novo patients; P less
than 0.001), although clinical recurrence was high in both
groups (49% in restenotic patients and 44% in de novo
patients, P equals NS) (843). 
Stent placement is superior to PTCA for the treatment of
restenotic lesions. In the REstenosis STent (REST) Study
(844), a randomized clinical trial, late clinical and angio-
graphic outcomes were compared in 351 patients undergoing
either PTCA or Palmaz-Schatz stent placement for restenot-
ic lesions. Stent-treated patients had lower rates of target-
lesion revascularization (10% vs 32% in balloon-treated
patients) and restenosis (18% vs 32% in balloon-treated
patients; P equals 0.03) (844). 
Given these findings, it is recommended that patients who
develop restenosis after an initially successful PTCA be con-
sidered for repeat PCI with stent placement. Factors that may
influence this decision include the technical difficulty of the
initial procedure, the potential for the lesion to be treated
successfully with a stent, and the severity and extent of the
restenotic process. If restenosis presents as a much longer
lesion than was originally present, additional procedures may
aggravate rather than relieve coronary narrowing. If repeat
intervention is performed, treatment with a stent appears to
be preferred. Each time restenosis recurs, consideration
should be given to alternate methods of revascularization,
particularly CABG surgery, as well as continued medical
therapy. Patients who have angiographic evidence of resteno-
sis but no symptoms or evidence for ischemia may be able to
continue with medical therapy alone. It is recommended that
patients who develop restenosis after PTCA or atheroablative
device therapy plus PTCA be candidates for repeat coronary
intervention with intracoronary stents if anatomy is appro-
priate. Patients who have no signs or symptoms of ischemia
and who have intermediate (50%) stenoses at the time of
clinical follow-up may not require PCI and, especially where
the anatomy is complex, may be followed up for evidence of
ischemia rather than subjected to PCI.
7.3.4. Background on Restenosis After BMS
Implantation
Although coronary stents have been shown to reduce the fre-
quency of restenosis compared with conventional balloon
angioplasty, lumen renarrowing due to intimal hyperplasia
within the stent may develop in 17% to 32% of patients
survival effects remain under examination (Table 29)
(826,830-833).
7.3. Clinical Restenosis: Background and
Management
7.3.1. Background on Restenosis After PTCA
Angiographic restenosis after PTCA has been reported to
occur in 32% to 40% of patients within 6 months after the
procedure (80,85). Initial procedural success rates after
PTCA of restenotic lesions appear similar to those after
PTCA for de novo lesions. The risk for repeat angiographic
restenosis after repeat PTCA for a single episode of resteno-
sis also appears similar to the restenosis risk for de novo
lesions (834,835). The risk of recurrent symptoms progres-
sively increases with the number of restenosis episodes,
approaching 50% to 53% for patients undergoing a fourth
PTCA for a third episode of restenosis (836,837).
7.3.2. Clinical and Angiographic Factors for
Restenosis After PTCA
A number of factors are associated with lesion recurrence
among patients undergoing a second PTCA for restenosis.
These factors include an interval less than 60 to 90 days
between the initial angioplasty and the treatment of resteno-
sis (834-838), LAD lesion location (837), multivessel versus
single-vessel redilations (838), the presence of diabetes mel-
litus (834,838), hypertension (834), UA (834), need for high-
er (7 atm) balloon inflation pressures (835), and multiple (3)
balloon inflations (835,836). Of these, the most important
factor is the time between the initial and subsequent PTCA
(839). In a series of 423 patients, restenosis was more com-
mon in those having repeat angioplasty less than 3 months
after a first angioplasty than in patients undergoing later redi-
lation (56% vs 37%, P equals 0.007) (839). 
Some studies have suggested that lesions become longer
and more severe after repeat PTCA of restenotic lesions
(840,841). In a serial angiographic study, the mean stenosis
length before the initial angioplasty was 7.0 mm but
increased to 8.7 mm at the time of the repeat procedure (an
increase of more than 1.7 mm, 95% CI 0.6 to 2.8 mm, P less
than 0.01) (841). A history of restenosis may also predict the
risk for subsequent restenosis after PTCA of a new lesion
(104). Multivariate analysis identified that prior restenosis (P
less than 0.02, OR equals 3.4), LAD location of stenosis (P
less than 0.04, OR equals 3.0), and severity of stenosis before
PTCA (P less than 0.02, OR equals 1.8) were independently
associated with restenosis after PTCA (104). 
7.3.3. Management Strategies for Restenosis 
After PTCA
Class IIa
It is reasonable to consider that patients who develop
restenosis after PTCA or PTCA with atheroablative
devices are candidates for repeat coronary interven-
tion with intracoronary stents if anatomic factors are
appropriate. (Level of Evidence: B)
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
e244
Smith et al. 2005
ACC/AHA/SCAI Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
Ta
bl
e 
29
.C
or
on
ar
y 
A
ng
io
pl
as
ty
 S
tu
di
es
 in
 H
ea
rt 
Tr
an
sp
la
nt
 P
at
ie
nt
s
Ti
m
e A
fte
r
Su
cc
es
s R
at
e,
 
M
ajo
r
Fi
rs
t A
ut
ho
r
Ye
a
r
R
ef
.
n
Pr
o
ce
du
re
s
Le
sio
ns
Tx
, m
o
%
C
om
pl
ex
H
al
le
19
92
(82
6)
35
51
95
45
 p
lu
s o
r m
in
us
 5
93
3
Sa
nd
hu
19
92
(83
0)
8
11
13
43
 p
lu
s o
r m
in
us
 1
9
85
N
A
Sw
an
19
93
(83
1)
13
31
N
A
N
A
N
A
N
A
Vo
n
 S
ch
ei
dt
19
95
(83
2)
14
38
62
41
 p
lu
s o
r m
in
us
 2
5
97
1
Pa
nd
e
19
96
(83
3)
8
N
A
11
N
A
91
1
R
es
te
no
sis
 R
at
e 
La
te
 D
ea
th
 o
r
M
in
or
a
t M
or
e 
Th
an
1-
Ye
a
r
Ev
en
t-
re
Tx
 a
t M
or
e 
C
om
pl
ex
6 
m
o,
 %
Fr
ee
 R
at
e,
 %
Th
an
 6
 m
o,
 n
3
N
A
60
7
1
N
A
38
4
N
A
10
0
N
A
N
A
N
A
61
60
5
1
N
A
50
3
m
o
 in
di
ca
te
s m
on
th
; n
, n
um
be
r o
f p
at
ie
nt
s; 
N
A
, n
ot
 a
pp
lic
ab
le
; R
ef
, r
ef
er
en
ce
; r
eT
X
, r
et
re
at
m
en
t; 
an
d 
Tx
, t
re
at
m
en
t.
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
e245
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
Circulation    February 21, 2006
ACC/AHA/SCAI Practice Guidelines
New coronary devices, including directional (857,858),
rotational (859,860), extraction (861-865), and pullback
(866) atherectomy, a cutting balloon, and excimer laser-
assisted angioplasty, have also been used for stent restenosis
before balloon dilation. Although some comparative registry
series have suggested an improved angiographic outcome
associated with the use of these ablative devices, no long-
term studies demonstrating clinical advantage have been
completed. 
When a significant residual stenosis exists after conven-
tional PTCA of stent restenosis fails to achieve an optimal
lumen diameter, additional stents have been used to improve
the initial angiographic result (867-869). Although prelimi-
nary results of clinical trials failed to demonstrate a benefit
using routine BMS placement for the treatment of stent
restenosis, favorable results have been shown with DES (see
Section 7.3.5 for further discussion) (116,870,871). 
Acute platelet inhibition with abciximab does not reduce
ISR, as demonstrated in the ERASER (Evaluation of ReoPro
And Stenting to Eliminate Restenosis) study (280). In a study
of 225 patients randomly allocated to placebo or abciximab
before intervention, 215 patients received a stent and the
study drug. Of the 191 patients who returned for follow-up
more than 4 months after evaluation, there was no difference
between tissue volume as measured by IVUS between the
placebo and treatment groups. Lack of abciximab benefit
was confirmed by quantitative angiography. The investiga-
tors concluded that potent platelet inhibition with abciximab
as administered in the ERASER study did not reduce ISR. 
Since the last (2001) revision of the ACC/AHA PCI guide-
line, the proportional use of stents in percutaneous interven-
tions has continued to increase. In part, this derives from ran-
domized trial data suggesting that routine stenting is more
effective than provisional stenting (636,872-874). In addi-
tion, stents are being used in a much wider spectrum of coro-
nary and even graft anatomies (875). Accordingly, ISR has
become increasingly important. Because stents prevent elas-
tic recoil and late negative remodeling, the predominant
mechanism of ISR is neointimal hyperplasia due to smooth
muscle cell proliferation and extracellular matrix production.
Two of the biggest changes since the 2001 revision have
been the expanding databases of 1) brachytherapy to treat
ISR and 2) DES to try to prevent ISR.
7.3.5. Drug-Eluting Stents
Class I
A drug-eluting stent (DES) should be considered as an
alternative to the bare-metal stent in subsets of
patients in whom trial data suggest efficacy. (Level of
Evidence: A)
Class IIb
A DES may be considered for use in anatomic settings
in which the usefulness, effectiveness, and safety have
not been fully documented in published trials. (Level
of Evidence: C)
(80,83,845). A number of factors have been associated with
the propensity to develop stent restenosis, including small
vessel size (846), smaller postprocedure minimum lumen
diameter (847), higher residual percent diameter stenosis
(848), lesions located in the LAD (83), stent length, and the
presence of diabetes mellitus (721,841,842,844,846-848). 
Stent restenosis may occur within the stent, due to intimal
hyperplasia, or at the stent margins, due to both intimal
hyperplasia and arterial remodeling (849). A serial IVUS
study performed in 115 lesions treated with the Palmaz-
Schatz stent demonstrated that tissue growth was uniformly
distributed throughout the stent at follow-up study, with a
slightly higher tendency for neointimal tissue accumulation
at the central articulation (850). The stent lumen tended to be
smallest at the articulation site, presumably owing to tissue
prolapse between the stent struts. For multiple stents, there
was no difference in the postintervention or follow-up lumen
when overlapped stents were compared with nonoverlapped
stents (850). In another series of patients treated with the
Palmaz-Schatz stent, 77 (26%) of 301 stent margins were
restenotic at follow-up (more than 50% late lumen loss)
(849). The dominant periprocedural predictor of stent margin
restenosis was the plaque burden of the contiguous reference
segment (849). 
Balloon angioplasty has been used frequently to treat
patients with stent restenosis (851-853). The mechanism of
lumen improvement after balloon angioplasty for stent
restenosis relates to further stent expansion (851) and extru-
sion of the tissue through the stent struts (851-854). In an
IVUS study of 64 restenotic Palmaz-Schatz stents, 56% plus
or minus 28% of the lumen enlargement was the result of
additional stent expansion and 44% plus or minus 28% was
the result of a decrease in neointimal tissue (851). Despite
the use of high-pressure balloon dilation, a relatively high
residual stenosis (18% plus or minus 12%) remained after
treatment with balloon angioplasty. 
The outcome after balloon angioplasty has been variable,
depending, in part, on the size of the stented segment and
length of the stent restenosis (855). In a consecutive series of
124 patients presenting with stent restenosis successfully
treated with repeat percutaneous intervention, clinical fol-
low-up was obtained at 27.4 plus or minus 14.7 months
(855). Recurrent clinical events occurred in 25 patients
(20%), including death (2%), MI (1%), and target-vessel
revascularization (11%) (855). Cumulative event-free sur-
vival at 12 and 24 months was 86.2% and 80.7%, respec-
tively (855). 
A number of factors have been related to the frequency of
clinical recurrence after balloon angioplasty for stent
restenosis (855), which include repeat intervention in SVGs,
multivessel disease, low ejection fraction, and a 3-month
interval between stent implantation and repeat intervention.
One preliminary report has shown target-lesion revascular-
ization was related to the length of the stent restenosis, rang-
ing from 10% for focal stent stenosis to 25% for intrastent
restenosis, 50% for diffuse stent restenosis, and 80% for stent
total occlusions (856). 
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ed stents, the long-term outcome depends on the response to
both stent and coating. For DES, the long-term healing
response depends on the response to the polymer and the
therapeutic agent, as well as the stent. As evidenced by the
trials of gold coating and the preliminary experiences (reg-
istry) with the QuaDS stent, actinomycin, and batimastat,
some combinations are potentially even more proliferative,
inflammatory, or thrombogenic than BMS.
Peer-reviewed publications of human DES implantation,
including consecutive case series and randomized trials, are
available for 3 polymer-based, drug-eluting, balloon-expand-
able stent systems (Table 30) (236,441,624,628,697,698,
879-888): the antiproliferative, antimigratory, anti-inflam-
matory macrolide antibiotic rapamycin (sirolimus) affixed to
a stent (Bx Velocity); the 7-hexanoyltaxol (QP2)-eluting
polymer stent system (QuaDS); and the microtubule
inhibitor paclitaxel (TAXUS) affixed to a stent. Each of these
systems had undergone rigorous testing in animal models
that demonstrated an intact endothelial layer and significant
reductions in neointimal hyperplasia and inflammation.
The first reported series of 45 patients who underwent SES
implantation in either Sao Paulo, Brazil, or Rotterdam,
Holland, demonstrated the virtual absence of intimal hyper-
plasia at 4 months (889). Subsequent studies of the same
cohort at 1 and 2 years continued to document sustained sup-
pression of neointimal hyperplasia as detected with both
IVUS and quantitative angiography (628,879). In the
Randomized Study With the Sirolimus-Eluting Bx Velocity
Balloon-Expandable Stent (RAVEL) trial, 238 patients were
randomly allocated between BMS and SES (624). At 6
months the binary restenosis rate was 26% for the bare metal
group versus 0% for the DES group, and there were no sub-
acute stent thromboses with a 2-month dual antiplatelet reg-
imen. In 1 year of follow-up, the bare metal group had a 29%
rate of MACE versus 5.8% for the sirolimus-eluting group;
this difference was driven entirely by target-vessel revascu-
larization.
A 3-year follow-up of the RAVEL trial (890), involving
114 patients from the SES arm and 113 in the BMS arm, doc-
umented target-vessel revascularization in 11.4% of the SES
group compared with 33.6% of the BMS group. These data
support the long-term durability of SES in reducing repeat
revascularization compared with BMS.
The SIRIUS (Sirolimus-Eluting Balloon Expandable Stent
in the Treatment of Patients With De Novo Native Coronary
Artery Lesions) investigators reported 1058 patients ran-
domly allocated at 1 of 53 centers between BMS and SES
(93). This cohort included diabetic patients (26%) and some-
what longer lesions (mean 14.4 mm) and smaller-diameter
vessels (mean 2.8 mm) than the RAVEL population. Again,
the sirolimus-eluting group had lower MACE at 270 days
than the BMS group (7.1% vs 18.9%), which was driven by
lower rates of target-vessel revascularization (4.1% vs
16.6%). Both quantitative angiography and IVUS were used
to document that the mechanism for this salutary effect was
decreased neointimal hyperplasia. SIRIUS was the pivotal
All PCI creates injury to the vessel wall, specifically tears
or dissection. Larger devices and higher pressures are asso-
ciated with tears at deeper levels of the vessel wall (media or
even adventitia, as opposed to intima and plaque boundary
only). All injuries tend to heal; specifically, injury to the ves-
sel wall is associated with re-establishment of an intact
endothelial layer. Failure to re-establish an intact, functional
endothelial layer is likely to be associated with continued
risk of arterial thrombosis and an abnormal balance between
vasoconstrictive and vasodilatory mechanisms. In general,
deeper injury is associated with more proliferative healing
(876-878). The demonstration, by quantitative angiography,
that late lumen diameter after balloon angioplasty follows a
“normal” or Gaussian distribution supports the concept that
restenosis is an exaggerated healing response rather than a
distinct biologic process, which occurs in a minority of indi-
viduals.
For balloon angioplasty, the healing response includes, on
the macroscopic level, negative (narrowing) and positive
(dilatation) remodeling, elastic recoil, and neointimal hyper-
plasia. Because stents block elastic recoil and negative
remodeling, ISR is predominantly due to neointimal hyper-
plasia. Neointimal hyperplasia is the name given to a com-
plex process of multifactorial causation, which leads to ves-
sel lumen encroachment. The causes of neointimal hyperpla-
sia appear to include, but are not limited to, the following
inflammatory response involving cells and molecular media-
tors; growth factors and cytokines; release of mediators and
upregulation of signaling systems that stimulate cellular
migration and proliferation; activation, adherence, and
aggregation of platelets; and thrombosis with release of clot-
ting factors. Neointimal hyperplasia may be distinct from
atherosclerosis and negative remodeling, but it shares many
of the same causative factors. Accordingly, investigators and
clinicians are inclined to try many of the same antithrombot-
ic, antiplatelet, anti-inflammatory, and antiproliferative
agents to try to modify atherosclerosis, neointimal hyperpla-
sia, and negative remodeling. Additionally, many therapeutic
agents affect multiple mechanisms.
To date, no systemically administered therapeutic agent has
consistently reduced restenosis after balloon angioplasty or
placement of BMS. Stents have reduced restenosis relative to
balloon angioplasty (albeit with increased late loss due to
increased neointimal proliferation), and locally delivered
radiation (brachytherapy) has reduced ISR. Taken together,
these observations and the early success of sirolimus- and
paclitaxel-eluting stents have supported the paradigm of
blocking elastic recoil and negative remodeling with a
mechanical stent and inhibiting neointimal hyperplasia with
a locally delivered (higher concentration than can be
achieved systemically) antiproliferative and anti-inflamma-
tory agent.
Local delivery of a therapeutic agent with stents has taken
2 forms: simple coating of the stent and adherence of the
therapeutic agent to a polymer, which allows for sustained
release over time. Diffusion of the therapeutic agent into the
tissues and into blood is an additional complexity. For coat-
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• Most of the follow-up is still relatively short-term (1 year
or less)
• Comparison of the 2 FDA-released systems is needed and
should provide clinically useful information. One such
trial that supplies information in this regard is ISAR-
DESIRE (Intracoronary Stenting and Angiographic
Results: Drug-Eluting Stents for In-Stent Restenosis),
which is discussed in Section 7.3.6.2.
• Preliminary results from randomized trials (REALITY,
SIRTAX) comparing SES and PES (CYPHER versus
TAXUS) have not shown large differences in clinical out-
comes [M.C. Morice, oral presentation, American College
of Cardiology Scientific Session, Orlando, Fla, March
2005; S. Windecker, oral presentation, American College
of Cardiology Scientific Session, Orlando, Fla, March
2005].
• Mandated angiographic follow-up applied in trials has
increased the reintervention rate, and therefore, the differ-
ence between DES and BMS in clinical practice may be
less.
The major trials of SES and PES, which were the basis for
FDA approval, involved patients with stable or unstable
ischemia with documented coronary artery narrowing of
51% to 99%, which stenoses were, for the most part, between
2.75 and 3.5 mm in diameter and 15 to 30 mm in length.
Specific clinical exclusions from these landmark trials
included the following: MI within 48 h; LV ejection fraction
less than 0.25; previous or planned use of brachytherapy;
previous PCI of the same lesion; coexisting medical condi-
tions likely to limit life expectancy; contraindications to
aspirin, thienopyridines, or stent substances; and severe renal
or hematologic comorbidity. Specific angiographic exclu-
sions from these landmark trials included the following:
ostial lesions; bifurcation lesions; ULM lesion; SVG lesion;
severe calcification; angiographic thrombus; severe tortuosi-
ty; and occluded vessel. Babapulle and coworkers have per-
formed a Bayesian meta-analysis of randomized clinical tri-
als of DES that incorporates the results of RAVEL, SIRIUS,
C-SIRIUS, and E-SIRIUS regarding rapamycin-eluting
stents and TAXUS, I, II, and IV regarding PES (234, 880,
881). These authors also included 4 trials of a nonpolymeric
formulation of paclitaxel, which has not been shown to be
effective in reducing restenosis or target-lesion or target-ves-
sel revascularization and which has not been released for
commercial use (234).
In an effort to extend the application of DES to most of the
other clinical angiographic subsets, unstudied in these land-
mark trials, Serruys and coworkers at Thoraxcenter
Rotterdam, the Netherlands, established the RESEARCH
Registry (882). In this experience, the rapamycin-eluting
stent has been used as the default strategy since it became
available, and consecutive prospective cases of particular
clinical and angiographic subsets have been compared with
trial for FDA release of the rapamycin, polymer, Bx Velocity
system.
Subsequent studies from the RESEARCH (Rapamycin-
Eluting and TAXUS Stent Evaluated At Rotterdam
Cardiology Hospital) registry experience at Thoraxcenter,
Rotterdam, Netherlands, have documented the short-term
safety of using these SES systems in patients with acute
coronary syndromes, including STEMI (882,891). An addi-
tional small registry experience from the Rotterdam group
suggests the potential applicability of the sirolimus DES sys-
tem to ISR. A consecutive case series of 368 patients with
735 lesions for which 841 SES were implanted documented
only 11 cases of restenosis (greater than 50% diameter), and
all of those occurred in a focal pattern (892). The operators
in that series, which included longer lesions (mean length of
lesion 17.48 plus or minus 12.19 mm) and more complex
anatomic subsets, learned from earlier studies of DES edge
lesions to fully cover diseased segments (mean stent length
27.59 plus or minus 14.02 mm) (892).
TAXUS-I was the first feasibility and safety study of the
paclitaxel, polymer, NIR stent system. There were 61
patients randomly allocated between a BMS and DES. At 12
months, the MACE rate was 3% (1 event) in the TAXUS
group and 10% in the BMS group (4 events in 3 patients),
and there were no subacute stent thromboses. Although these
differences were not statistically significantly different, the
continuous outcome of minimal lumen diameter was signifi-
cantly better in the TAXUS group (886). 
The ASPECT trial was a 3-center prospective, randomized
trial of 177 patients with short (less than 15 mm), favorable
(2.25 to 3.5 mm diameter) native vessel lesions who were
randomly allocated between bare-metal Cook Supra-G stents
and stents bonded with 1 of 2 doses of paclitaxel (885).
Interpretation of this trial was complicated by the use of 3
different antiplatelet regimens. Binary restenosis was 4% in
the high dose of paclitaxel, 12% in the low dose of paclitax-
el, and 27% in the BMS arm. Subsequent mechanistic stud-
ies with IVUS documented that the paclitaxel-coated stents
reduced neointimal hyperplasia (893).
TAXUS-IV was a prospective, randomized clinical trial of
the slow-release; polymer-based paclitaxel-NIR stent system
conducted at 73 US centers (94). A total of 1314 patients
with native coronary lesions 10 to 28 mm in length and 2.5
to 3.75 mm in diameter were randomly allocated between
BMS and the paclitaxel polymer system. At 9 months, angio-
graphic restenosis was reduced from 26.6% to 7.9% with
DES, albeit there were no differences in death, MI, or suba-
cute stent thrombosis (0.6% and 0.8%, respectively). It is pri-
marily on the basis of TAXUS-IV that the FDA released the
paclitaxel, polymer NIR stent system. TAXUS-III was a reg-
istry study that demonstrated the potential efficacy of this
DES system for ISR (888).
There is considerable promise and excitement surrounding
the release of DES; nevertheless, important reservations
remain, including the following:
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relates to further stent expansion (851) and extrusion of the
tissue through the stent struts (851-854). In an IVUS study of
64 restenotic Palmaz-Schatz stents, 56% plus or minus 28%
of the lumen enlargement was the result of additional stent
expansion, and 44% plus or minus 28% was the result of a
decrease in neointimal tissue (851). Despite the use of high-
pressure balloon dilation, a relatively high residual stenosis
(18% plus or minus 12%) remained after treatment with
PTCA.
The outcome after PTCA has been variable, depending in
part on the size of the stented segment and length of the stent
restenosis (855). In a consecutive series of 124 patients pre-
senting with stent restenosis successfully treated with repeat
PTCA, clinical follow-up was obtained at 27.4 plus or minus
14.7 months (855). Recurrent clinical events occurred in 25
patients (20%), including death (2%), MI (1%), and target-
vessel revascularization (11%) (855). Cumulative event-free
survival at 12 and 24 months was 86.2% and 80.7%, respec-
tively (855).
A number of factors have been related to the frequency of
clinical recurrence after PTCA for ISR (855), which include
repeat intervention in SVGs, multivessel disease, low ejec-
tion fraction, and a 3-month interval between stent implanta-
tion and repeat intervention. One report involving 245
patients receiving BMS in the pre-DES era has categorized
ISR into 4 classifications: focal, diffuse intrastent, diffuse
proliferative, and total occlusion. Pattern I contains 4 types
(A-D). Patterns II through IV are defined according to geo-
graphic position of ISR in relation to the previously implant-
ed stent. Target-lesion revascularization was related to the
length of the ISR, ranging from 10% for focal in-stent steno-
sis (class I) to 25% for intrastent restenosis (class II), 50%
for diffuse proliferative ISR (class III), and 80% for ISR with
total occlusion (class IV) (856). 
A broad array of catheter-based technologies, including
directional (857,858), rotational (859,860), extraction (861-
865), and pullback (866) atherectomy, a cutting balloon, and
excimer laser-assisted angioplasty, have been used to treat
ISR in association with PTCA. Although some comparative
registry series have suggested an improved angiographic out-
come associated with the use of these ablative devices, no
long-term studies demonstrating clinical advantage have
been completed. 
When a significant residual stenosis exists after conven-
tional PTCA for ISR, PCI with stenting has been used to
improve the initial angiographic result (867-869). Although
preliminary results of clinical trials failed to demonstrate a
benefit using routine BMS placement for the treatment of
ISR, favorable results have been shown with DES, as sum-
marized in the following section (116,870,871).
7.3.6.2. Drug-Eluting Stents
Class IIa
It is reasonable to perform repeat PCI for ISR with a
DES or a new DES for patients who develop ISR if
anatomic factors are appropriate. (Level of Evidence:
B)
the immediately prior experience at the same institution with
the particular subset (882).
Patients with acute coronary syndromes were considered
for SES in a RESEARCH registry comparison of 198 con-
secutive patients receiving the SES versus a prior consecu-
tive case series of 301 patients with acute coronary syn-
dromes treated with BMS (882). Major adverse cardiac
events including death (3.0% vs 3.0%), nonfatal MI (3.0% vs
1.0%), and target-vessel revascularization (1.0% vs 2.7%)
were comparable for SES and BMS (total 6.1% vs 6.6%).
Lemos and colleagues reported a series of 186 consecutive
STEMI patients treated with an SES and compared that
group with 183 patients treated with a BMS in terms of both
short- and long-term outcomes (441). MACE at 30 days
(7.5% vs 10.4%) and stent thrombosis (0% vs 1.6%) were
not significantly different for SES compared with BMS
patients. By 300 days, both target-vessel revascularization
(1.1% vs 8.2%) and MACE (9.4% vs 17.0%) were reduced
with SES versus BMS (441). A quantitative study reported
by Saia et al demonstrated a binary restenosis rate of 0% at 6
months in a subset of 96 STEMI patients, which document-
ed reduced late loss to a degree comparable to what was seen
in the landmark trials of more stable patients with less com-
plex anatomy (891).
Hoye and coauthors compared the outcomes of a consecu-
tive case cohort of 56 patients with chronic total occlusions
treated with SES and compared them with a prior consecu-
tive case series of 28 patients with chronic total occlusions
treated with BMS (883). By 12 months, MACE was 96.4%
with SES and 82.1% with BMS (P less than 0.05 by log-rank
testing) (883). A consecutive case series of 19 patients with
21 lesions of old SVGs treated with SES had 0% early revas-
cularization and a 1-year (average) MACE of 84% (894).
Unlike the other RESEARCH Registry series, this report
included no historic control group.
7.3.6. Management Strategies for ISR
Since the last (2001) revision of the ACC/AHA PCI guide-
line, the proportional use of stents in percutaneous interven-
tions has continued to increase. In part, this derives from ran-
domized trial data suggesting that routine stenting is more
effective than provisional stenting (636,872-874). In addi-
tion, stents are being used in a much wider spectrum of coro-
nary and even graft anatomies (875). Accordingly, ISR has
become increasingly important. Because stents prevent elas-
tic recoil and late negative remodeling, the predominant
mechanism of ISR is neointimal hyperplasia due to smooth
muscle cell proliferation and extracellular matrix production.
Two of the biggest changes since the 2001 revision have
been the expanding databases evaluating the use of 1) DES
to prevent ISR and 2) brachytherapy to treat ISR (discussed
in Sections 7.3.6.2 and 7.3.6.3, respectively).
7.3.6.1. PTCA
PTCA has been used to treat patients with ISR (851-853).
The mechanism of lumen improvement after PTCA for ISR
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with ISR (898-900). In the 2001 revision of the guideline, the
initial results of the SCRIPPS trial (Scripps Coronary
Radiation to Inhibit Proliferation Post Stenting) were sum-
marized (117). Since then, the 5-year results of the SCRIPPS
cohort have been published (901). The Ir-192–treated
patients continued to demonstrate improved event-free sur-
vival (freedom from death, MI, or target-lesion revascular-
ization) compared with placebo (61.5% vs 34.5%; P equals
0.02) (900). As shown in Table 31, this composite end point
derived from improvements in each of the 3 component end
points (92,116,117,658-660,901-903).
A number of reports of the GAMMA-1 trial have been pub-
lished since the 2001 revision (622,658,904,905). The initial
report of 9 months of follow-up demonstrated a statistically
significant reduction in target-lesion revascularization with
Ir-192 (42% vs 24 %; P less than 0.01). Death and MI were
insignificantly higher with radiation.
The WRIST (Washington Radiation for In-Stent Restenosis
Trial) investigators randomized 130 patients (65/65) with
ISR between placebo and 15 Gy Ir-192 (116). The SVG-
WRIST investigators randomized 120 patients (60/60)
between placebo and Ir-192 for the treatment of ISR in SVGs
(902). Again, the brachytherapy-treated cohort had lower
rates of binary restenosis (21% vs 44%; P equals 0.005) and
target-lesion revascularization (17% vs 57%; P less than
0.001).
Among the specific limitations of gamma radiation are the
need for long treatment times and the high radiation expo-
sure, which necessitate special shielding and removal of staff
from the treatment room during dwell times (906). Beta radi-
ation, in the form of electrons or particulate energy, has also
demonstrated effectiveness in randomized trials of ISR,
despite its more limited tissue penetration (92,659,660).
Taken together, these data support the effectiveness of radia-
tion in reducing restenosis after treatment of ISR. Further
investigation into the causes of late stent thrombosis (907)
have led to recommendations that 1) new stents not be
implanted at the time of brachytherapy unless necessary and
2) antiplatelet therapy with both aspirin and a thienopyridine
be continued for at least 6 to 12 months after brachytherapy
(898-900,906). 
Brachytherapy dosing for ISR is prescribed so as to achieve
adequate radiation in the vessel wall to block cellular prolif-
eration. The manufacturer’s recommended dosing for the
beta radiation source is 18.4 Gy at 2 mm from the source
center for vessels from 2.7 to 3.35 mm in diameter and 23 Gy
for vessels 3.35 to 4.0 mm in diameter. It is also recom-
mended that radiation be delivered over the entire segment
injured by balloon dilation and that at least a 5-mm margin
be allowed on each side of the injured segment (908). 
To date, the following potential limitations have been
observed with the use of brachytherapy to treat ISR: edge
stenoses or geographic miss; acute thrombosis; late throm-
bosis and occlusion (up to 14%); persistent dissections; late
stent malapposition; increased plaque burden outside the
stent; IVUS echolucent areas or black holes (898-900,906);
In-stent restenosis represents a clinical challenge of great
interest for DES technology. Sousa and coworkers treated 25
consecutive cases of ISR with SES (870). They demonstrat-
ed minimal intimal hyperplasia and no delayed malapposi-
tion by intracoronary ultrasound (870). Clinically, they
reported a remarkable 0 repeat revascularizations, stent
thromboses, or deaths (870). Degertekin and colleagues
reported a group of 26 consecutive ISR patients treated with
SES (871). They also used 3-dimensional ultrasound to doc-
ument minimal neointimal formation by 4 months (871).
This more complex cohort included 1 patient with transplant
vasculopathy and 4 with prior brachytherapy, which provid-
ed support not only for the effectiveness of SES but also of
the need for prolonged antiplatelet therapy and risk factor
modification in patients with diffuse coronary disease (871).
Saia and coworkers reported a series of 12 patients with ISR
refractory to brachytherapy who received SES; 4 of 10
patients who were followed up long-term developed resteno-
sis (895). 
The ISAR-DESIRE trial compared the use of balloon
angioplasty SES and PES treatment of ISR in 300 patients
(896). Angiography at 6 months in 92% of the patients (n
equals 275) demonstrated angiographic restenosis in 44.6%
(41 of 92) of the balloon-alone group; 14.3% (13 of 91) of
the SES group; and 21.7% (20 of 92) of the PES group. Both
DES were superior to balloon alone, reducing the incidence
of target-vessel revascularization (33% for balloon alone vs
8% for SES and 19% for PES). There was a trend toward
superiority of SES over PES in angiographic restenosis that
was marginally significant (P equals 0.19) and significance
for target-vessel revascularization (P equals 0.02). These
data support the use of either approved DES for the treatment
of ISR over a BMS. Additional data for DES and ISR have
been reported in the TReatment Of Patients with an In-
STENT REstenotic Coronary Artery Lesion (TROPICAL)
Study, which assessed outcomes in 155 patients with ISR
receiving an SES. In-lesion late loss of 0.08 plus or minus
0.49 and a binary restenosis rate of 9.7% was reported at 6-
month follow-up, with a reintervention rate of 7.4% (897).
Furthermore, preliminary data suggest that in patients receiv-
ing SES for ISR (TROPICAL group), late lesion loss and
binary restenosis at 6 months were significantly reduced
compared with a historical group receiving brachytherapy
for ISR in the GAMMA I and II studies [F.J. Neumann, oral
presentation, EuroPCR, Paris, France, May 2004]. The
potential benefit of SES compared with brachytherapy
remains to be delineated in ongoing randomized trials.
7.3.6.3. Radiation 
Class IIa
Brachytherapy can be useful as a safe and effective
treatment for ISR. (Level of Evidence: A)
Both gamma energy (photons), and beta energy (electrons)
have been used in randomized clinical trials and prospective
registries to reduce the neointimal proliferation associated
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ized comparative trials of DES versus BMS: acute coronary
syndromes; STEMI, chronic total occlusions; SVGs; and
ISR. Most of the data currently available regarding the use of
DES for ostial lesions, bifurcation lesions, ULM arteries, and
extremely long segments are in the form of uncontrolled case
reports or series. Nonetheless, given the promising results in
reducing late target-lesion and target-vessel revasculariza-
tion in nearly every group, it is to be expected that registry
and randomized trial data will continue to accumulate at a
rapid pace.
7.4. Cost-Effectiveness Analysis for PCI
Among all diseases worldwide, ischemic heart disease cur-
rently ranks fifth in disability burden and is projected to rank
first by the year 2020 (911). As healthcare delivery systems
in countries with established economic markets continue to
incorporate new and expensive technologies, the costs of
medical care have seemingly escalated beyond the revenue
historically allotted to health care. Given limited healthcare
resources, a cost-effectiveness analysis is appropriate to
evaluate percutaneous coronary revascularization strategies
(912). The results of cost-effectiveness analyses for any
comparable treatment are reported in terms of the incremen-
tal cost per unit of health gained, such as 1 year of life adjust-
ed to perfect health (quality-adjusted life year, QALY) com-
pared with the standard of care (913). By modeling different
treatments, different patient subsets, and different levels of
disease, a series of cost-effectiveness ratios may be con-
structed to show the tradeoffs associated with choosing
among competing interventions. 
Although there is no established cost-effectiveness ratio
threshold, cost-effectiveness ratios of less than $20 000 per
QALY (such as seen in the treatment of severe diastolic
hypertension or with cholesterol lowering in patients with
ischemic heart disease) are considered highly favorable and
consistent with well-accepted therapies. Incremental cost-
effectiveness ratios that range between $20 000 and $60 000
per QALY may be viewed as reasonably cost-effective and
thus acceptable in most countries, whereas ratios greater than
$60000 to $80000 may be considered too expensive for most
healthcare systems. The Committee defines useful and effi-
cacious treatments, in terms of cost-effectiveness, as treat-
ments with acceptable or favorable cost-effectiveness ratios.
Cost-effectiveness analysis is not by itself sufficient to incor-
porate all factors necessary for medical decision making on
an individual patient basis, nor is it sufficient to dictate the
broad allocation of societal resources for health care. Rather,
cost-effectiveness analysis aims to serve mainly as an aid to
medical decision making on the basis of comparison with
other evaluated therapies. 
The results of cost-effectiveness analysis in the field of per-
cutaneous revascularization for ischemic heart disease have
been derived from decision models that incorporate litera-
ture-based procedure-related morbidity and mortality, coro-
nary disease–related mortality, and estimates of the benefit of
selected revascularization procedures. When available,
and very late catch-up phenomenon (in studies with more
than 1 year of follow-up).
7.3.6.4. Medical Therapy
Acute platelet inhibition with abciximab does not reduce
ISR, as demonstrated in the ERASER study (280). In a study
of 225 patients randomly allocated to placebo or abciximab
before intervention, 215 patients received a stent and the
study drug. Of the 191 patients who returned for follow-up
more than 4 months after evaluation, there was no difference
between tissue volume, as measured by IVUS, between the
placebo and treatment groups. Lack of abciximab benefit
was confirmed by quantitative angiography. The investiga-
tors concluded that potent platelet inhibition with abciximab
as administered in the ERASER study did not reduce ISR. In
the Oral Sirolimus to Inhibit Recurrent In-Stent Restenosis
(OSIRUS) trial, 300 patients were randomly assigned to
receive a cumulative loading dose of either placebo (0 mg),
usual-dose (8 mg) oral sirolimus, or high-dose (24 mg) oral
sirolimus 2 days before and the day of repeat PCI, followed
by maintenance therapy of 2 mg per day for 7 days (909).
Restenosis was significantly reduced from 42.2% to 36.8%
and 22.1% in the placebo, usual-dose, and high-dose groups,
respectively (P equals 0.005). The need for target-vessel
revascularization was reduced from 25.5% to 24.2% and
15.2%, respectively, although this was not statistically sig-
nificant (P equals 0.08). Blood concentration of oral
sirolimus was significantly correlated with late lumen loss at
follow-up (P less than 0.001). The investigators concluded
that oral adjunctive sirolimus treatment for treatment of ISR
resulted in significant improvement in the angiographic
parameters of restenosis. Further elucidation of optimal dos-
ing, need for pretreatment, and duration of oral sirolimus, as
well as long-term follow-up, are needed.
7.3.7. Subacute Stent Thrombosis
The issues of subacute stent thrombosis and technical issues
with the PES balloon-delivery system were early causes for
concern (910). After many more data have been accumulat-
ed, as exemplified by the above-cited registry data, there
does not appear to be an increased incidence of early throm-
bosis with either SES or PES. As reported in the FDA edito-
rial (910), Boston Scientific has recalled a number of
TAXUS stent systems because of reports of balloon deflation
or retrieval problems and is working closely with the FDA to
monitor the situation. 
7.3.8. Drug-Eluting Stents: Areas Requiring
Further Investigation 
Both small vessels (less than 2.75 mm) and long lesions
(greater than 18 mm) have been included in the C-SIRIUS
and E-SIRIUS trials (880,881). In addition, there are increas-
ing numbers of patients entered into prospective registries
and compared retrospectively with the following clinical and
angiographic subsets, which were not included in random-
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The use of DES is affecting the cost-effectiveness of PCI.
In the SIRIUS trial (93), there were 21 fewer repeat revascu-
larization procedures per 100 patients treated with the
sirolimus stent. Although the DES group’s hospital costs
were $2800 more, much of that was negated in follow-up by
the high reintervention rate in the BMS group (920).
However, the number of repeat procedures in such trials with
routine angiographic follow-up is inflated compared with
registries of BMS, which suggests only 6 to 7 repeat proce-
dures are avoided by routinely using DES (882). The ulti-
mate cost effectiveness of drug-eluting stenting will depend
on the cost of the stents, how many are implanted per patient,
and how many repeat procedures are avoided.
Because cost-effectiveness analysis research is new in the
field of PCI, its results are limited. The Committee under-
scores the need for cost containment and careful decision
making regarding the use of PCI strategies.
8. FUTURE DIRECTIONS 
The field of coronary intervention has expanded dramatical-
ly over the past decade and will continue to evolve over the
next several years. New directions will focus on strategies
that will further improve procedural safety, reduce the recur-
rence rate after PCI, and expand the procedure to more com-
plex anatomic subsets. Clinical acceptance of these tech-
nologies will be based on demonstration of safety and effica-
cy over conventional therapies in randomized clinical stud-
ies. Several novel strategies are summarized below. 
Because the widespread use of stent implantation has less-
ened the risk of need for emergency bypass, future clinical
research will focus on remaining obstacles that decrease pro-
cedural success or increase risk. Chronic total occlusion
remains a stubborn problem. New devices such as the
Frontrunner catheter and new ultrastiff guidewires show
some promise in improving procedural success; however,
new approaches are needed.
Degenerated vein graft disease remains a high-risk subset.
The SAFER trial (255) has demonstrated that distal protec-
tion with a balloon occlusive device with intraprocedural
aspiration decreases procedural risk. Similarly, a number of
distal filter devices are undergoing active testing (254). The
results of one such multicenter trial comparing a filter-based
catheter with a balloon occlusive and aspiration device
showed similar results for MACE at 30 days (254). In spite
of these approaches, these procedures are still associated
with MACE event rates of 8% to10%. More research is still
needed in this area. The use of distal protection devices in
settings other than degenerative vein graft disease requires
further study. For example, initial studies in primary PCI
suggested a benefit with the FilterWire™; however, subse-
quent trials with the GuideWire have failed to show any ben-
efit, instead showing poor outcomes in this setting. Thus, fur-
ther research is needed before this technology is adopted for
use beyond degenerative vein graft disease. 
Dramatic advances have been made in the treatment of
restenosis. Although the oral agents tranilast (921) and folic
results from randomized trials (levels of evidence A and B)
are used to estimate the outcomes of each decision tree
branch within the decision-analytical model, for example,
using data estimating the restenosis rate after uncomplicated
coronary stenting of a single, simple lesion. Cost-effective-
ness analyses have been used to compare medical therapy
with PTCA with CABG (914), balloon angioplasty with
coronary stenting (915,916), and routine coronary angiogra-
phy after acute MI with symptom-driven coronary angiogra-
phy (917). 
In patients with severe angina, normal LV function, and
single-vessel disease of the LAD, the cost-effectiveness ratio
for PTCA, directional coronary atherectomy, or coronary
stenting that can be expected to provide a more than 90%
success rate with a less than 3% major acute complication
rate is very favorable (less than $20 000 per QALY) com-
pared with medical therapy (914). The rating also applies to
patients with symptomatic angina or documented ischemia
and 2-vessel coronary disease, in whom percutaneous coro-
nary revascularization can be expected to provide a more
than 90% success rate with a less than 3% major acute com-
plication rate. In patients with 3-vessel coronary disease who
have comorbidities that increase the operative risk for CABG
surgery, PCI that is believed to be safe and feasible is rea-
sonably acceptable ($20 000 to $60 000 per QALY). In
patients in the post-MI setting, a strategy of routine,
non–symptom-driven coronary angiography and PCI per-
formed for critical (greater than 70% diameter stenosis) cul-
prit coronary lesions amenable to balloon angioplasty or
stenting has been proposed to be reasonably cost-effective in
many subgroups (917). 
In patients with symptomatic angina or documented
ischemia and 3-vessel coronary disease, for which bypass
surgery can be expected to provide full revascularization and
an acute complication rate of less than 5%, the cost-effec-
tiveness of PCI is not well established. Although PTCA for
2- and 3-vessel coronary disease appears to be as safe as but
initially less expensive than CABG surgery, the costs of
PTCA converge toward the higher costs of bypass surgery
after 3 to 5 years (918,919). Thus, whereas PTCA or CABG
surgery has been shown to be cost-effective compared with
medical therapy, there is no evidence for incremental cost-
effectiveness of PTCA over bypass surgery for 2- or 3-vessel
coronary disease in patients who are considered good candi-
dates for both procedures. For patients with 1- or 2-vessel
coronary disease who are asymptomatic or have only mild
angina, without documented left main disease, the estimated
cost-effectiveness ratios for PCI are greater than $80 000 per
QALY compared with medical therapy and are thus consid-
ered less favorable. 
The initial mean cost of angioplasty was 65% that of sur-
gery, but the need for repeat interventions increased medical
expenses so that after 5 years, the total medical cost of PTCA
was 95% that of surgery ($56 225 vs $58 889), a significant
difference of $2664 (P equals 0.047). Compared with CABG,
PTCA appeared less costly for patients with 2-vessel disease
but not for patients with 3-vessel disease. 
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rial infusion of marrow-derived stem cells (926) and direct
injection of skeletal muscle–derived myoblasts (927) for
myogenesis. Studies to date were performed in patients with
severe angina; thus, it is uncertain how this technology might
apply to other subsets of patients with coronary disease (e.g.,
acute coronary syndromes, ischemic cardiomyopathy), and
rigorous, blinded evaluation of these approaches must occur.
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acid have proven unsuccessful, other catheter-based strate-
gies have dramatically decreased restenosis risk.
Brachytherapy (for ISR), rapamycin-eluting stents, and PES
have been extremely effective. Subgroups such as diffuse
ISR and insulin-dependent diabetes mellitus will require fur-
ther study. Other therapies, such as photodynamic therapy,
cryotherapy, and therapeutic ultrasound, remain interesting
but unproven approaches to treat restenosis.
In patients with refractory angina who have no vessels suit-
ed for revascularization, a number of new therapies are being
tested. Enhanced external counterpulsation appears to
decrease symptoms (922). Treatment with fibroblast growth
factor by an intracoronary approach also shows promise
(923). Percutaneous laser transmyocardial revascularization
has shown mixed results. The PACIFIC trial (Potential Class
Improvement From Intramyocardial Channels) putatively
demonstrated some benefit of percutaneous laser transmy-
ocardial revascularization, but the major limitation of that
study was that it was not placebo-controlled; thus, after its
failure to address potential concerns, general consensus
attributes the results in PACIFIC to a placebo effect. Also, in
PACIFIC, diverse outcomes tended to be higher with laser
therapy (924). Although the randomized, double-blind
BELIEF trial (Blinded Evaluation of Laser PMR
Intervention Electively For angina pectoris) of 82 patients
appeared to show some benefit of percutaneous laser trans-
myocardial revascularization versus sham procedure on
angina class and quality-of-life measures, the results were
inconclusive given the small size of the study (925). To date,
data are insufficient for FDA approval of percutaneous laser
therapy. A new frontier has been opened with the intra-arte-
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